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anxiety: definition, diagnosis, epidemiology,  
and current treatment status
Anxiety is a commonly occurring negative human emotional state and is character-
ized by subjective feelings of worry and fear. By definition, worry or apprehension 
refers to thoughts and expectations about future events while fear is an acute 
reaction to perceived imminent danger. Subjective phenomena are usually accom-
panied by physical symptoms such as increased heart rate, shakiness, fatigue, and 
muscle tension, as well as cognitive, and behavioral manifestations. Anxiety can be 
adaptive that occurs in response to a threat and prepares to cope with the environ-
ment. However, anxiety becomes pathological when it causes significant personal 
distress and impairs everyday functioning. In order to be diagnosed with an anxiety 
disorder, individuals have to experience a certain number of symptoms that are 
disproportionate to either actual or imagined environmental threat for at least six 
months [1,2]. 
Anxiety disorders are chronic, disabling conditions that impose enormous costs 
both on individuals and on society [3-6]. These disorders are prevalent in Western 
countries. According to a recent 3-year multi-method study covering 30 European 
countries, 14% of the total population (i.e., 514 million people) were suffering from 
anxiety disorders [4]. In the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (dsm 5) [1], seven anxiety syndromes are classified, including panic 
disorder, agoraphobia, social anxiety disorder (sad), generalized anxiety disorder 
(gad), specific phobias, separation anxiety disorder and selective mutism. The eti-
ology of anxiety disorders is multifactorial and includes genetic liability to a certain 
extent for some syndromes. In addition, drug withdrawal, substance/medication 
(e.g. alcohol, caffeine, and benzodiazepines) abuse and dependence, occupation-
al exposure to organic solvents, and life stresses have been related to the etiology 
of anxiety disordersm while psychiatric complications of endocrine disorders like 
pheochromocytoma and hyperthyroidism have been demonstrated to mimic 
anxiety disorders. Taken together, the phenomenologically-based diagnostic clas-
sification and the multifactorial nature of anxiety disorders are expected to affected 
efficacy of anxiolytic cns active drugs that have been discovered in the past decades. 
Current treatment modalities for anxiety disorders can be categorized into psy-
chological treatments (e.g., exposure therapy, cognitive therapy and cognitive 
behavioral therapy) and pharmacological interventions [2]. The pharmacological 
interventions can be further divided to chronic or maintenance treatments and 
short-term treatments inducing acute anxiolysis. Monoamine modulating drugs 
such as the selective serotonin reuptake inhibitors (ssris) and serotonin-noradren-
aline reuptake inhibitors (snris) are considered the first-line drugs for anxiety 
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disorders. This is mainly due to their ‘broad spectrum’ anxiolytic efficacy in both 
short-term and long-term therapy and the relatively good tolerability in terms of 
side effects and treatment adherence [2]. However, since it is not unusual for treat-
ment response to be reached only after 12 weeks of treatment at a therapeutic dose, 
the delayed onset of action of ssris and snris remains a major disadvantage. In 
addition, when patients do not respond to or are intolerant of ssri/snri treatment, 
alternative classes of psychotropic drugs, such as other antidepressant drugs (e.g., 
tricyclic antidepressants [tcas], irreversible monoamine oxidase inhibitor [maoi] 
phenelzine), anticonvulsant drug pregabalin, antipsychotic drugs (e.g., queti-
apine), and anti-histamine drug hydroxyzine, are considered. Nonetheless, even 
after treatment with multiple anxiolytic drugs, up to 40% of patients with anxiety 
disorders do not respond to such drugs at all or only respond partially [7]. Given the 
rapid-onset effectiveness of benzodiazepines (bzds) in many patients with anxi-
ety disorders, especially in panic disorder, gad and sad patients, these drugs are 
generally reserved for the treatment of patients who have failed to respond to at 
least three previous treatments (such as after non-response to an ssri, an snri and 
a psychological intervention). The use of bzds should however be minimalized and 
preferably be reserved for short-term treatments to mitigate the risks of trouble-
some sedation, cognitive impairment and discontinuation symptoms after abrupt 
withdrawal [8] in both short-term and long-term treatment, and to avoid develop-
ment of tolerance and dependence with prolonged use. Taken together, an obvious 
unmet clinical need in the pharmacological treatment of anxiety disorders opens 
an opportunity for novel pharmacological approaches that demonstrate rapid anx-
iolytic efficacy that is superior to existing treatments and lacks tolerance induction, 
abuse liability and withdrawal symptoms. 
the brain circuitry involved in anxiety and the role  
of gamma-aminobutyric acid a (gaba) in the amygdala 
On a neurobiological level, anxiety disorders arise from disruption of the highly 
interconnected circuits normally serving to process the stream of potentially threat-
ening stimuli detected by the human brain from the outside world. Perturbations 
anywhere in these circuits cause imbalance in the entire system, resulting in a 
fundamental misinterpretation of neural sensory information as threatening and 
leading to the inappropriate emotional- and thereby behavioral-responses seen in 
anxiety disorders [9].
Briefly speaking, anxiety is linked to compromised interactions between the amyg-
dala and the dorsal and ventral medial prefrontal cortex (mpfc). Tract-tracing 
studies in rats show that axons originating in the infra-limbic cortex of the mpfc 
terminate most densely in the ventromedial lateral nucleus, the rostral part of the 
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accessory basal amygdala, lateral capsular subdivision of the central nucleus and 
the superficial nuclei (lateral olfactory tract, periamygdaloid cortex and cortical 
nuclei) [10-12]. Neurons in the more caudal areas of the infra-limbic sub-region also 
project to the medial and intermediate subdivisions of the central nucleus [11,13]. 
The pre-limbic cortex of the mpfc is located dorsally adjacent to the infra-limbic 
sub-region and it has a different pattern of connectivity with the amygdala. Pre-
limbic cortex neurons target the basal nucleus of the amygdala (ba), primarily 
the dorso-medial part [11,14], while caudal pre-limbic cortex neurons concentrate 
inputs in the medial parvicellular basal nucleus [15]. 
Fear extinction is defined as a decline in conditioned fear responses following 
repeated exposure to a feared conditioned stimulus (e.g., a tone in both animals 
and humans) in the absence of the unconditioned stimulus (usually a footshock in 
animals) with which it was previously paired [16]. Extincted fear can be recovered 
with time or change of the experimental context, suggesting that fear extinction 
reflects a learning process. The fear reduction is associated with inhibition rather 
than erasure of the original fear memory. Given that fear extinction has a close 
therapeutic analogue in the form of exposure therapy for patients with anxiety dis-
orders, it has been implicated in many preclinical studies to investigate drugs acting 
as adjuncts to strengthen extinction and reduce intrusive fear memories in ptsd 
and specific phobias [17]. The acquisition, consolidation and retrieval of extinction 
therefore are separable processes that are controlled by different brain regions and 
neural systems [18]. 
In both experimental animal and human functional imaging studies, the amygdala 
and the mpfc has been demonstrated to be associated with the regulation of neg-
ative emotion, such as anxiety or worry and apprehension. Neuroimaging studies 
consistently show that higher levels of anxiety are associated with both attenuated 
ventral medial prefrontal cortex (vmpfc) activity and exaggerated dorsal medial 
prefrontal cortex (dmpfc) activity [19,20] in the presence of threatening stimuli. 
In the absence of threatening stimuli (i.e., at rest) Kim and colleagues [21] report-
ed that the negative connectivity normally seen between the amygdala and the 
dmpfc at rest was attenuated in high anxious subjects, whereas the positive con-
nectivity normally observed between the amygdala and vmpfc at rest, manifested 
as negative connectivity in high anxious subjects. Interestingly, the mpfc-amyg-
dala coupling is inversely correlated with self-reported measures of anxiety or 
anxious temperament, indicating that the mpfc functions to actively regulate the 
amygdala and impaired connection between the two neural structures may lead 
to inadequate response to threatening stimuli. On the other hand, the amygdala 
– nuclei situated in the median temporal lobes – appears to play a crucial role in 
the regulation of negative affect and therefore anxiety-related symptomatology. 
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Emerging evidence from functional magnetic resonance imaging supports that 
amygdala is the key brain region of activity in response to negative emotional stim-
uli in healthy volunteers [22-24]. Besides, patients with anxiety disorders are prone 
to amygdala activation in response to a given threatening stimulus more than the 
non-anxious controls [25]. Moreover, successful treatment of anxiety disorders 
with cognitive behavioral therapy leads to extinction of this hyperactivation in the 
amygdala [26]. Taken together, mpfc functions to regulate amygdala function by 
actively suppressing activity, and so deficiency in the top-down regulation of mpfc 
and hyperactivation of the amegdela have been implicated in the pathophysiology 
of anxiety-related disorders.
In the amygdela, two groups of nuclei should be noted, namely the basolateral 
amygdala complex (bla) and the centromedial amygdala complex, in particular 
the central nucleus (cea) [27,28]. The bla receives afferent information on poten-
tially negative emotional signals from the thalamus and the sensory association 
cortex. The bla activates the cea either directly through an excitatory glutamater-
gic pathway or indirectly by activating a relay of inhibitory gabaergic interneurons 
that lie between the bla and the cea and exert an inhibitory influence upon the lat-
ter [29,30]. The cea is the principal efferent pathway from the amygdala. Inhibitory 
gabaergic neurons project from the cea to the hypothalamus and brainstem; the 
activation of these neurons leads to the somatic manifestations of anxiety [31]. 
Projections to other basal forebrain nuclei such as the ventrotegmental area and 
the locus ceruleus may be involved in the subjective effects that are related to anx-
iety, such as apprehension and dysphoria [32]. In addition, neurons from the bla 
also activate cells in the adjacent bed nucleus of the stria terminalis, which project 
to the same areas as the cea and apparently play a similar role [28,32]. 
The knowledge about the neurobiology underlining anxiety disorders serves as the 
basis for the search of novel anxiolytic agents. Compounds that manipulate this 
potential pathway may provide new options for the treatment of anxiety disorders. 
Moreover, neuroimaging and neurophysiological measurements that address the 
corresponding processes may be used to assess human responses to drug-mediat-
ed target modulation. 
the involvement of gaba system in the pathophysiology 
ofanxiety and anxiety disorders
Mounting evidence has suggested the pathogenesis of human anxiety disorders is 
related to a dysfunction of central top-down inhibitory mechanisms. By providing 
the major source of inhibitory neurotransmission in the mpfc and amygdala, gaba 
exerts a powerful influence on a range of fear- and anxiety-related behaviours, 
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including fear extinction [33-37]. Temporary inactivation induced by gaba(a) 
receptor agonists has been implicated to establish necessary contribution of the 
infralimbic subregion or basolateral amygdala (bla) (but not prelimbic cortex) to 
fear extinction [38,39]. Infusions of gaba or gaba receptor agonists into the amyg-
dala were found reducing measures of fear and anxiety (possibly related to effects 
on memory reconsolidation) in several animal species [40,41]. On the other hand, 
infusion of the gaba antagonist bicuculline was found to block chlordiazepoxide-in-
duced anxiolytic-like activity in rats, whereas injecting bicuculline methiodide to 
the anterior basolateral amygdala of rats elicited anxiogenic-like effects in both 
the social interaction paradigm and the conflict paradigm. Microinjection of bicu-
culline methiodide into the central nucleus of the amygdala elicited no change in 
experimental anxiety [42].
In humans, administration of benzodiazepines is translated to anxiolytic effect by 
attenuating amygdala activation in response to negative emotional stimuli [43,44]. 
To the contrary, Nutt et al. [45] performed an interesting study, in which they 
injected the benzodiazepine-antagonist flumazenil to 10 patients with panic disor-
der and 10 control subjects. Subjective anxiety responses after flumazenil infusion 
were significantly higher in patients with panic disorder than in the controls, and 
panic attacks were successfully induced in eight patients with panic disorder but 
no panic attack occurred in the controls.   Although such findings have not been 
replicated [46], they are regarded as a potential signal for the possible shift of 
the ‘‘receptor set-point’’ [45]. Nikolaus et al reviewed 14 nuclear neuroimaging 
(Positron emission tomography [pet] and Single-Photon Emission Computed 
Tomography [spect]) studies conducted in patients with anxiety disorders (160 
patients [mostly gad patients] vs. 172 healthy controls). They identified a wide-
spread decline of gaba(a)  receptor  binding sites and reduced binding extent in 
the whole mesolimbocortical system in patients suffering from anxiety disorders, 
suggesting attenuation of physiological central depression. The disturbances of the 
downstream dopaminergic and serotonergic neurotransmission are thought to, at 
least partly, result from the diminished tone of gabaergic neurotransmission [47]. 
A decrease of cortical gaba neurons and reduction of gaba levels were reported in 
patients with major depressive disorder (mdd) using proton magnetic resonance 
spectroscopy [48]. Considering the frequent comorbidity of mdd with anxiety 
states, a shared underlying pathology that emphasizes the causal contribution of 
gabaergic deficit is proposed for both anxiety disorders and depression [49-51]. 
Similar gaba(a) receptors reduction is also seen in patients with panic anxiety 
or post-trauma stress disorder (ptsd). Noteworthy, the extent of gaba(a) recep-
tor deficit is significantly correlated to the clinical severity of these two disorders 
[52-56], suggesting an ‘exposure’-response relationship and hence reinforcing the 
contribution of gabaergic deficit to anxiety status.
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In summary, all aforementioned research findings suggest gabaergic neurotrans-
mission in the mpfc-amygdala coupling is a promising target for modulation of 
anxiety-related responses. 
gaba(a) receptor structure, function, and its implication  
in the pharmacotherapy of anxiety disorders 
The discovery of the gaba(a) receptor in the 1970s, originally called benzodiazepine 
receptor, was essential for elaborating the mechanism of action of benzodiazepines, 
it was the recognition of benzodiazepine-sensitive gaba(a) receptor subtypes that 
opened up a new gaba pharmacology [57]. 
gaba(a) receptors belong to the class of ligand-gated ion channels [58]. The gab-
a(a) receptors are hetero-pentamers traversing the neuronal membrane. To date, a 
large number of gaba(a) receptor subtypes have been identified: α 1-6, ß 1-3, γ 1-3, 
∆, δ 1-3, θ, π [59]. The majority of gaba(a) receptors in the brain are comprised of two 
α subunits, two ß subunits, and a γ sub-unit. These subunits construct a cylinder. 
Activation of the receptor by gaba leads to a conformational change in the protein 
subunits and results in transient opening of a pore along the axis of the cylinder, 
allowing the flow of chloride ions from one side of the membrane to another [60]. 
The pharmacological interaction between benzodiazepines and gaba(a) receptors 
occurs at a different site independent from the gaba binding site on the gaba(a) 
receptor. gaba binds within the two interfaces between the α and ß subunits on 
the gaba(a) receptor. Benzodiazepines bind within the interface between the α 
and γ sub-units, thereby potentiating gaba-related activation of the chloride con-
ductance through allosteric modulation [61]. Nevertheless, such benzodiazepine 
recognition site does not exist in all α and γ2 subunit combinations. Therefore, 
although gaba(a) receptors containing ß, γ2 plus either α1, α2, α3, or α5 subunits pos-
sess a binding site for classical benzodiazepines, analogous receptors containing α4 
or α6 subunits do not. The research by Seeburg et al has attributed the benzodiaze-
pine-sensitivity of α1, α2, α3, and α5 subunits to the histidine residue in a homologous 
position in their N-terminal extracellular region, which switches to an arginine res-
idue in the benzodiazepine-insensitive α4 and α6 subunits [62].
Given the evolutional preservation of the gaba(a)/Gly receptor-like (grl) gene 
sequences in the vertebrates [63], the function of each gaba(a) receptor subunit 
was initially investigated through a gene knock-out approach. Thanks to the gained 
experience in gene targeting techniques that enables introduction of specific point 
mutations, and the recognition that a single amino acid residue in the α subunit 
determines the sensitivity of a gaba(a) receptor to diazepam, point mutation 
of the histidine to an arginine in the α1, α2, α3, and α5 subunits was employed in in 
vivo animal studies to convey the interaction between benzodiazepines and the 
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α1,2,3,5-containing gaba(a) receptors from agonism to inverse agonism [64]. This 
knock-in approach was used to investigate the underlying pharmacological action 
of the manipulated receptor subunit. 
Based on various experimental knock-in and knock-out mice models, α1-containing 
gaba(a) receptors are linked to sedative effect [65-68], while spinal α2/α3 gaba(a) 
receptors are found to mediate analgesia [69-71] and α5-containing gaba(a) recep-
tors, which relatively specifically express in the hippocampus (the central domain 
for learning and memory), are associated with cognition [72-77]. The gaba(a) sub-
type responsible for the anxiolytic effects of benzodiazepines are less clear. The 
involvement of α2 gaba(a) receptors in anxiolysis is anticipated given their high 
expression in human amygdala-prefrontal circuitry [78,79]. Most studies suggest 
that the α2 rather than the α3 subtype is related to the benzodiazepines-induced 
anxiolysis [80,81], while pharmacological studies using either an α3-selective 
inverse agonist [82] or an α3-selective agonist [83] implicates the α3 subtype. Despite 
of the controversies, the affinity and efficacy of current investigational compounds 
acting at the α2 and α3 subtypes are mostly similar at the α2- and α3- subunits con-
taining gaba(a) receptors [84].
novel α2,3-subtype selective compounds for anxiolysis
In contrast to other areas of pharmacology, in the field of gabaergic receptor 
modulator, it has been particularly difficult for medicinal chemists to develop sub-
type-selective ligands [85], mainly because the high flexibility of gaba(a) receptors 
and the existence of multiple drug-binding sites. In addition, the distinct subunit 
composition among the gaba(a)  receptor subtypes, the contribution of distinct 
subunit sequences to binding sites of different receptor subtypes, as well as the 
fact that even subunits not directly connected to a binding site are able to influ-
ence affinity and efficacy of drugs, contribute to a unique pharmacology of each 
gaba(a) receptor subtype [86].
The binding and efficacy profiles of candidate α2,3 subtype-selective drugs can 
be classified to either binding-selectivity or efficacy-selectivity. A compound 
with binding-selectivity is expected to have higher affinity for α2 and/or α3 sub-
types in vitro and hence specific receptor occupancy and cns distribution in vivo. 
Even though the compound may have comparable efficacy at the four benzodi-
azepine-sensitive gaba(a) receptor subtypes, its pharmacological selectivity is 
determined in vivo by preferential occupancy. As for efficacy-selectivity, an ideal 
compound should have opposite pharmacological interactions at different sub-
types. In other words, it should exert agonism at the α2,3 subtypes whereas present 
antagonism or inverse agonsim at the α1 and α5 subtypes. Between these two 
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extreme conditions, there could be multiple permutations, including a compound 
behaves as a full agonist or a relatively high partial agonist at α2 and/or α3 subtypes 
but has weak or none activity at the α1 and α5 subtypes. 
Based on these principles, a number of conceptually gaba(a) α2,3 subtype-selec-
tive compounds have been identified through in vitro studies using recombinant 
human gaba(a) receptors and carried forward into clinical development. Because 
of their pharmacological selectivity, these compounds are expected to have favor-
able therapeutic effect with less sedating or cognition impairing effect. Table 1 
listed the in vitro pharmacological properties of these novel gabaergic compounds.
Table 1 • In vitro pharmacological properties of the gabaergic compounds

















tpa0233 0.27 0# 0.31 11 0.19 21 0.41 5 
mk-03433 0.22 18 0.40 23 0.21 45 0.23 18 
sl65.14984 17 45 73 115 80 83 215 48 
Zolpidem 20 755 400 (d) 785 400 (d) 805 5000(d) 95 
azd73256 0.5 0 0.3 18 1.3 15 230 8
azd62807 0.5 0 21 32 31 34 1680 7
ns118218 1.6 4 9.7 17 3.8 40 2.5 41 
1. Ki = constant of receptor-subtype binding / 2. Relative efficacy is defined as the extent of the potentiation of 
gaba(a) ec20-equivalent current produced by the compound compared to that produced by a nonselective 
full agonist (chlordiazepoxide/diazepam) / 3. Mean values of 3 experiments in Xenopus oocytes with human 
recombinant αß3γ2 receptors; efficacy relative to chlordiazepoxide [86,89] / 4. Mean values of 3 experiments in 
hek293 cells with recombinant rat receptors αß2γ2; efficacy relative to chlordiazepoxide [97] / 5. Mean values 
of 3 experiments in Xenopus oocytes with human recombinant αß2γ2 receptor; efficacy relative to diazepam 
[98,99] / 6. Data adapted from [100] / 7. Data adapted from [101] / 8. Data adapted from [102].
evaluation of human pharmacology
bzds exert their cns actions in a concentration-dependent manner [87]. The 
anxiolytic, hypnotic, muscle relaxant, and amnesic effects of benzodiazepines 
generally appear concomitantly, and the onset and duration of action correlate 
closely with the pharmacokinetic profiles of these compounds. Based on non-
clinical investigations using in vitro assays and animal models of anxiety, the 
human pharmacology of novel gabaergic agents is approached through clinical 
pharmacology studies investigating pharmacokinetics, receptor occupancy, and 
pharmacodynamics (pd) in healthy volunteers. Direct links have been proposed 
between plasma drug concentration and gaba receptor occupancy [84], as well as 
between plasma drug concentration and the pharmacodynamic measurements 
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[88-91]. Such pharmacokinetic/pharmacodynamic (pk/pd) relationships warrant 
the use of surrogate biomarkers in healthy volunteers treated with single-dose 
administration of selective novel gabaergic compound(s).
More than 170 pharmacodynamic tests or test variants have been developed to 
assess the cns effects of benzodiazepines. De Visser et al. [87] analyzed the inter-
study consistency, sensitivity, and pharmacological specificity of the frequently 
used biomarkers. Saccadic peak velocity (spv) and visual analogue scale of alertness 
(vasalertness) were identified as the most sensitive parameters for benzodiazepines. 
Both measurements showed consistently dose-dependent responses to a variety 
of benzodiazepines. Based on these finding, the Centre for Human Drug Research 
(chdr) has established a selection of computerized cns-pharmacodynamic tests 
called the Neurocart battery [92]. The components of this battery target a variety of 
neurophysiological and/or neuropsychological domains (Table 2). 
Table 2 • Component tests of the Neurocart battery and the related cns domains
Neurocart test Targeted function Related cns domains
Saccadic eye movement Neurophysiologic function Superior colliculus, substantia nigra, amygdala
Smooth pursuit Neurophysiologic function Midbrain
Adaptive tracking Visuo-motor coordination Neocortex, basal nuclei, brain stem, cerebellum
Body sway Balance Cerebellum, brain stem
Visual verbal learning test (vvlt) Memory Hippocampus
vas Bond and Lader Alertness, mood, calmness Cortex, prefrontal cortex
vas Bowdle Feeling high, internal and 
external perception
Cortex, prefrontal cortex, amygdala
Of this battery, adaptive tracking, saccadic eye movements, and body sway were 
proven sensitive to the sedating effects of sleep deprivation [93], as well as to the 
effects of benzodiazepines and other gabaergic hypnotic drugs [89,91]. In the 
recent years, the Neurocart battery was used in a series of phase I studies to assess 
cns pharmacodynamics of partial α2,3 subtype selective gaba(a) agonists. Both 
nonselective and/or selective gaba(a) agonists were administered as single oral 
dose to healthy volunteers. Clear distinctions were observed between the effect 
profile of non-subtype-selective full gaba(a) agonist and that of selective partial 
gaba(a) agonist in these trials [88-90], probably because the subtype specificity 
of the pharmacodynamic measurements for the pharmacological modulation of 
gaba(a)-ergic compounds. Unfortunately, none of the novel receptor subtype-se-
lective compounds have reached the market: the development of gaba(a) receptor 
α2 and α3 subunit agonist sl65.1498 [90], was discontinued owing to unexpect-
ed amnestic effects, while the phase 2 studies of another compound of this drug 
class, tpa023, were terminated prematurally due to preclinical toxicity (cataract 
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formation) in long-term dosing studies [94], despite exhibiting anxioselective 
activity in gad; mk-0343 also displayed an anxioselective profile in animal models 
but produced sedation in humans at low levels of receptor occupancy (<10%) [95]. 
In summary, these reports indicate that the human pharmacodynamic approach 
with sensitive and cns-domain specific neuropsychological and neurophysiologi-
cal measures is useful in predicting the drug’s clinical effect on the central nervous 
system. Inter-species difference is also noted between human and rodents or pri-
mates: although a low in vitro efficacy at the α1-containing gaba(a) receptors may 
not lead to an overtly sedative effect in the experimental animals, it apparently 
causes sedation in humans at comparable exposure levels. The following questions 
remain to be answered: 1) is reduction of saccadic peak velocity a promising surro-
gate marker for clinical anxiolysis? 2) can we also differentiate partial agonism from 
the full agonism of benzodiazepines via this pharmacodynamic package? 3) is such 
selective cns-pharmacodynamic effect profile characteristic for the family of gab-
a(a) α2,3-subtype receptor agonists? 
conclusion and aim of thesis 
Anxiety disorders are highly prevalent psychiatric disorders and have high personal 
and societal costs. The transition from ‘‘normal’’ negative affect or anxiety to an anx-
iety disorder is implemented by the interplay between psychosocial stressors and 
a wide array of neurobiological alterations which lead to subjective suffering and 
functional impairment. Monoamine modulating treatments are widely applied to 
treat anxiety disorders but are not effective in a large proportion of patients. As the 
predominant inhibitory neurotransmitter system in the human brain, the gabaer-
gic system in general and its α2,3 subunit-containing gaba(a) receptor subtypes in 
particular, have been implicated in the pathophysiology of anxiety disorders. Novel 
pharmacological treatments selectively targeting the anxiolysis-mediating gab-
a(a) receptor subtypes are currently emerging. These range from affinity-selective 
agents to efficacy-selective agents and represent potentially useful future pharma-
cological treatments for anxiety disorders [95]. 
In this thesis, we report several human pharmacology studies that were performed 
to identify the pharmacologically active doses/exposure levels of several novel 
compounds with potential anxiolytic effects (Chapter 2, 3, 4). Because of their 
pharmacological selectivity at the α2,3 gaba(a) receptor subtypes, the novel drugs 
were expected to elicit clinical anxiolysis and less sedating effects. An overview of 
the performance of the selected and validated pharmacodynamic measurements 
is composed to summarize the utility of these neurophysiological and neuropsy-
chological biomarkers in early clinical development of novel anxiolytic drugs 
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(Chapter 5). However, the difficulty of evaluating therapeutic anxiolytic drug 
effects in healthy volunteers has led to further explorations on the neuroendocrine 
biomarkers (Chapter 6) and the integration of a stress-challenging procedure into 
the evaluations (Chapter 7).
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abstract
Aims: azd7325 is a novel α2,3-subtype-selective partial gaba-a-receptor modulator. 
This study investigated the pharmacodynamics of single-oral-dose azd7325 2 mg 
and 10 mg on the central nervous system (cns) compared to placebo and lorazepam 
2 mg. Methods: This double-blind, randomized, 4-way-crossover study enrolled 
sixteen healthy males and administered two validated cns-test-batteries to mea-
sure drug effects on cognitive, neurophysiologic and psychomotor function, and 
subjective feelings. The pharmacological selectivity of azd7325 was compared to 
lorazepam by plotting saccadic peak velocity change from baseline (∆spv) against 
body sway (∆sway) and visual analogue scale for alertness (∆vasalertness). This 
analysis has previously been used to identify α2,3-subtype-selectivity. Results: In 
contrast with the robust impairment caused by lorazepam (all p<0.05 vs. placebo), 
neither dose of azd7325 induced statistically significant effects on any pharmaco-
dynamic measurements. Lorazepam-induced spv-reduction was linearly related to 
changes in other neurophysiologic biomarkers. In contrast, the slopes of the regres-
sion lines were flatter for azd7325, particularly for the ∆Log(Sway)-∆spv relation 
(estimate slope, azd7325 10 mg vs. lorazepam, difference [95% confidence inter-
val], p-value: -0.00036 vs. -0.00206, 0.001704 [0.000639, 0.002768], p=0.0018) 
and the ∆vasalertness-∆spv relationship (0.01855 vs. 0.08216,-0.06360 [-0.1046, 
-0.02257]; p=0.0024). azd7325 10 mg and lorazepam induced different response 
patterns on vas ‘feeling high’ and electro-encephalography. Conclusion: The 
characteristic ∆spv-relative effect profiles of azd7325 versus lorazepam suggests 
anxio-selectivity related to α2,3-selective gaba-a agonism. However, exploration of 
higher doses may be warranted. The paucity of effects on most cns-pd parameters 
also indicates a mitigated side-effect pattern, with potentially lower cognitive and 
neurophysiological side-effect burden than non-selective benzodiazepines.
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introduction
Benzodiazepines (bzds) are widely used in the treatment of anxiety disorders and 
for symptomatic relief of various anxiety states related to diverse psychiatric dis-
orders, including mood-, psychotic- and personality disorders. However, concerns 
have been raised regarding the untoward effects of these drugs, which include 
movement/balance disorders, cognitive impairment, as well as problems with tol-
erance and abuse liability. All these facts limit the usefulness of bzds as a long-term 
therapy in vulnerable patient populations. 
Benzodiazepines elicit their pharmacological effects through allosteric modu-
lation of gaba-a receptors. These compounds have non-selective binding affinities 
and present full in vitro efficacy at the gaba-a receptors that contain subunits α1, 
α2, α3 or α5. A collection of loss-of-function studies were performed to compare the 
bzd-mediated behavior between wild-type animals and knock-in animals [1] and 
the pharmacological role of each gaba-a subtype. These studies in experimental 
animals have suggested that the gaba α1 subtype is associated with sedation [2,3]; 
α2/α3 receptors are responsible for the anxiolytic properties of bzds [4,5], where α2 
is found more correlated to anxiolysis than α3 [1]; and the α5 subunit is related to 
modification of memory and cognition [6,7]. Based on these findings, the adverse 
effects of benzodiazepines are attributed to the pharmacological effects of these 
compounds on gaba-a receptors other than the α2,3 subtype. Compounds with 
relatively high efficacy at the α2,3 subunits but reduced efficacy at the α1 and/or 
α5 subunits are classified as subtype-selective gabaergic compounds and expected 
to be potential anxioselective treatments with reduced sedation and no impact on 
cognition and psychomotor performance. 
azd7325, 4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propyl-cinnoline-3-car-
boxamide [8], is a novel partial subtype-selective gaba-a α2,3 receptor modulator, 
which is in development for anxiety disorders. In vitro azd7325 demonstrated func-
tional specificity for the gaba-a α2 and gaba-a α3 receptor subtypes. azd7325 exerts 
neutral antagonism at the α1-subunit and partial efficacy at the α2,3-subunits over 
the α5-subunit (α2~α3 vs. α5: 18%~15% vs. 8%, percentage compared to maximal 
diazepam response). Meanwhile, the compound has much higher binding affini-
ty (mean Ki [nm], α1~α2~α3 vs. α5: 0.3~1.3 vs. 230) and larger relative efficacy at the 
α2,3-subunits over the α5-subunit (AstraZeneca data on file). Selective in vitro prop-
erties have also been confirmed in preclinical biomarker studies using eeg and pet 
imaging in rodents and primates, which revealed that exposures that result in 50% 
occupancy produce robust anxiolytic effects without benzodiazepine-like side 
effects (AstraZeneca data on file). However, translation of the effects of gaba(a) 
α1modulation from pre-clinical studies into human has been unpredictable, with 
some weak partial gaba(a) α1 modulator showing persistence of sedative prop-
erties [9], whereas some non-subtype selective gaba-a-ergic compounds, such 
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as ocinaplon [10] and alpidem [11,12], were found anxiolytic but less sedating or 
less psychomotor- and cognition-impairing in the clinic [13]. In addition, the ideal 
degree of modulation at each of the two preferred subtypes is not known since 
the behavior of non-sedating benzodiazepines has not been extensively inves-
tigated in clinical settings. Since preclinical data that have been obtained on the 
pharmacology, pharmacokinetics and toxicology of azd7325 support the conduct 
of clinical studies in humans, the current phase I trial was designed to provide an 
initial assessment of the side-effect profile of azd7325.
The present study aimed to investigate the pharmacodynamic (pd) effects and 
evaluate the safety and tolerability of single oral doses of azd7325 in healthy sub-
jects, in comparison with placebo and lorazepam. Lorazepam is clinically effective 
as an anxiolytic at a dose of 2 mg. Single oral doses of lorazepam 2 mg have demon-
strated robust effects on saccadic peak velocity (spv), smooth pursuit, body sway, 
and visual analogue scale (vas) of alertness in healthy volunteers [14,15,16]. These 
effects reflect the typical effect profile of benzodiazepines on different central 
nervous system (cns) functions [17]. More importantly, spv is very sensitive to the 
effect of bzds, and the drug-induced changes of spv seem to reflect the anxiolytic 
potency of different anxiolytic compounds [17]. For this study, the doses of azd7325 
were determined at 2 mg and 10 mg. A previous single-ascending-dose (sad) study 
in healthy volunteers indicated that azd7325 has an acceptable safety profile in oral 
doses up to 100 mg (AstraZeneca data on file). pet study using [11C]-flumazenil sug-
gested that azd7325 2 mg is associated with approximately 50% occupancy of the 
gaba-a receptors and 10 mg causes maximal (>80%) displacement of flumazenil at 
peak concentration of the compound in occipital cortex (AstraZeneca data on file). 
Compared to the low receptor occupancy of lorazepam 1 mg [18] as well as the in 
vitro α2,3-subtype modulation of azd7325, azd7325 2 mg and 10 mg are expected to 
fall within the anticipated clinical therapeutic window of this compound.
methods
design
The trial was designed as a randomized, double-blind, double-dummy, placebo- 
and comparator- controlled study in sixteen male healthy volunteers, where the 
positive control was used to benchmark the effects of the investigational product.
subjects
Following the approval of the Medical Ethics Review Board of Leiden University 
Medical Centre (lumc), subjects who provided written informed consents received 
medical screening at the Centre for Human Drug Research (chdr). The eligibilities 
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of sixteen healthy male subjects were confirmed before their entry into the trial. 
These subjects should be aged between 18 and 55 years, with a body mass index 
(bmi) of 18 to 30 kg/m2. All subjects were required to refrain from alcoholic beverag-
es, smoking and caffeine-containing products during study days. A normal diurnal 
rhythm was advised from minimally two weeks before the first study day until the 
last visit. 
sample size determination
Based on power calculations using data from previous studies [14], a sample size of 
16 was determined to have equal to or greater than 80% power to detect the mean 
differences of 1.24 mm in vasalertness and 20.6 degree/second in spv, respectively, 
assuming standard deviations of 1.66 mm (vas alertness) and 27.4 degree/sec-
ond (spv) between placebo and lorazepam 2 mg using a paired t-test with a 0.050 
two-sided significance level.
treatments
The study treatments were randomly allocated based on a 4×4 William’s Latin 
Square. The treatment sequence was unique for each subject. Each subject received 
1) azd7325 2 mg (two capsules of azd7325 1 mg and two tablets of lorazepam pla-
cebo), 2) azd7325 10 mg (one capsule of azd7325 10 mg, one capsule of azd7325 
placebo and two tablets of lorazepam placebo), 3) lorazepam 2 mg (two capsules 
of azd7325 placebo and two tablets of lorazepam 1 mg), or 4) placebo (two capsules 
of azd7325 placebo and two tablets of lorazepam placebo) on the morning of each 
study day. A washout period of at least 7 days was arranged between treatments. 
pharmacodynamic measurements
A standard Neurocart battery of neurophysiologic and neuropsychological 
tests included the following validated pharmacodynamic assessments: body sway, 
visual analogue scale (vas) of Bond & Lader, vas Bowdle, saccadic eye movements, 
smooth pursuit eye movements, adaptive tracking and  electro-encephalo-
grams (eeg).  The repeatable measurements were presented to the subjects during 
a pre-dose visit in order to familiarize subjects with the cns tests and prevent 
potential learning effects during the post-dose measurements. In each study peri-
od, the Neurocart battery was performed twice at baseline and at 0.5, 1, 1.5, 2, 2.5, 3, 
3.5, 4, 4.5, 6, 8, and 12 hours post-dose. In the meantime, the CogState Early Phase 
Battery (described below) was carried out thrice pre-dose and four times (i.e. at 1.25, 
2.25, 3.25, and 4.25 hours) post-dose. Moreover, subjects completed the Cogstate 
International Shopping List task, which required them to memorize a shopping 
304_Connie_Proefschrift_19.indd   27 12-09-17   17:55
human pharmacology of current and novel gaba(a)-ergic treatments for anxiety
28
list of 16 words at 1.75 hours post-dose and recall these items both immediately 
and at 21 hours post-dose without being read the words again.  All assessments 




Saccadic eye movements were evaluated using a computer-based system com-
posed of 1) stimulus display and signal collection (Nihon Kohden Corporation, 
Tokyo, Japan), 2) signal amplification (Grass-Telefactor, Astro-Med, Inc., Braintree, 
usa), 3) data recording (Cambridge Electronics Design, Cambridge, uk), 4) dis-
posable silver-silver chloride electrodes (Medicotest N-oo-S, Olstykke, Denmark), 
as well as 5) the sampling and analysis scripts developed by chdr (Leiden, the 
Netherlands). The parameters of this test were the average values of saccadic peak 
velocity (spv, degree/sec), latency (i.e. reaction time, sec) and inaccuracy (%) of all 
artefact-free saccades that were calculated on each session. Saccadic peak velocity 
appears to be the most sensitive measure for the sedative effect of benzodiazepines 
[17], which has been found to be related to the anxiolytic component of benzodi-
azepines [17] and to be selectively affected by some newly developed gabaergic 
compounds with potential anxiolytic effects [14,15,16].
body sway
Body sway was measured with an apparatus similar to the Wright ataxia meter, 
which integrates the amplitude of unidirectional body sway. Two-minute measure-
ments were made in the antero-posterior direction with eyes closed. The subject 
was asked to stand comfortably on a stable floor with his/her feet slightly apart. 
Body sway measures postural (in)stability. It has demonstrated considerable sensi-
tivity to the effect of benzodiazepines [19]. 
visual analogue scales (vas) of bond & lader and bowdle
Visual analogue scales as originally described by Norris have often been used 
previously to quantify subjective effects of a variety of sedative agents [20]. Dutch 
versions of the scales have been frequently employed at the chdr, for a variety of 
sedative agents [21] and circumstances [22]. During the test, the subject indicated 
(with a mouse click on the computer screen) on horizontal visual analogue scales 
how he/she feels. From the sixteen measurements of vas Bond & Lader, three 
main factors are the calculated [23] for subjective alertness, contentedness, and 
calmness. 
The Bowdle Psychotomimetic Effects Scores have been developed to quantify 
the psychotomimimetic effects of ketamine [24]. A translated Dutch version of the 
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original scales has been computerized and used at the chdr to study the effects 
of cannabinoids [25] and zolpidem [26], among others. This scale has thirteen 10 
cm visual analogue lines ranging from 0 (‘not at all) to 100 mm (‘extremely’) [27], 
addressing various abnormal states of mind. From the thirteen measurements 
of vas Bowdle, three distinct total sum scores are calculated: internal perception 
(reflects inner feelings that do not correspond with reality, including mistrustful 
feelings), external perception (reflects a misperception of an external stimulus or a 
change in the awareness of the subject’s surroundings) and feeling high [28]. 
smooth pursuit eye movements
The same system as used for saccadic eye movements was also used for measure-
ment of smooth pursuit. For smooth pursuit eye movements, the target moved 
sinusoidally at frequencies ranging from 0.3 to 1.1 Hz, by steps of 0.1 Hz. The 
amplitude of target displacement corresponded to 22.5 degrees eyeball rotation 
to both sides. Four cycles were recorded for each stimulus frequency. The meth-
od has been validated at the chdr by van Steveninck et al. [21,28] based on the 
work of Bittencourt et al. [29] and the original description of Baloh et al. [30]. The 
time in which the eyes were in smooth pursuit of the target were calculated for 
each frequency and expressed as a percentage of stimulus duration. The average 
percentage of smooth pursuit for all stimulus frequencies were used as the test 
parameter. Smooth pursuit is a measure of neurophysiological function and has 
been shown sensitivity to the effects of bzds [16], zolpidem [31], and some α2,3-sub-
type selective gaba-a receptor modulators [16]. 
adaptive tracking
Adaptive tracking is a pursuit-tracking task that measures drug effect on visuo-mo-
tor coordination. The adaptive tracking test was performed as originally described 
by Borland and Nicholson [32], using customised equipment and software. After a 
0.5-minute run-in time without data-recording, the average performance over 3.0 
minutes was scored and was used as the test parameter. The subject was required 
to operate a joystick and try to keep a dot inside a circle moving randomly on the 
computer screen. If he/she succeeded, the speed of the moving circle increased, or 
vice versa. 
eeg
Pharmaco-electroencephalography (Pharmaco-eeg) was used to monitor any drug 
effects, which can be interpreted as evidence of penetration and activity in the 
brain [33]. eeg recordings were made using gold electrodes, fixed with ec2 paste 
(Astromed) and using standard pharmaco-eeg lead placement, with the same 
common ground electrode as for the eye movement registration (international 
10/20 system). The electrode resistances were kept below 5 kOhm. The signals were 
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amplified with a Grass 15lt series Amplifier Systems, using a time constant of 0.3 
seconds and a low pass filter at 100 Hz. Data collection and analysis were performed 
using customized ced and Spike2 for Windows software (Cambridge Electronics 
Design, Cambridge, uk). Per session eight consecutive blocks of eight seconds 
were recorded. The signal was ad-converted using a ced 1401 Power (Cambridge 
Electronics Design, Cambridge, uk) and stored on hard disk for subsequent analy-
sis. Data blocks containing artifacts were identified by visual inspection and these 
were excluded from analysis. For each lead, fast Fourier transform analysis was 
performed to obtain the sum of amplitudes in the delta- (0.5-3.5 Hz), theta- (3.5-7.5 
Hz), alpha- (7.5-11.5 Hz), beta- (11.5-30 Hz) frequency ranges. Frequency band above 
30 Hz was also recorded for exploratory pharmaco-eeg analyses, in order to test 
whether the findings of an effect of azd7325 on gamma-frequency band (> 30 Hz) 
in animals translate to humans. 
cogstate battery
The CogState Early Phase Battery is a computer administered cognitive test battery 
that takes about 12 minutes to perform. It is designed to provide objective infor-
mation regarding possible drug effects on cognitive function [34]. The CogState 
Early Phase Battery consists of the following tests that address pharmacodynamic 
effects on different cognitive domains [35]. The tests were presented in the order 
listed below. In addition, the 16-word CogState International Shopping List Task 
and its delayed recall session were presented once per dosing period, respectively 
[36].
groton maze learning task (gmlt)
A 28-step pathway was hidden among the 100 possible locations of a 10 x 10 grid of 
tiles showing on a computer touch screen. Subjects were instructed to move from 
the start location (top left), one tile at a time, toward the end (bottom right). The 
entire 28-step pathway could be figured out based on the computer’s feedbacks. 
Once completed, subjects returned to the start location and repeated the task for 4 
more times. Twenty well-matched alternate forms of this task were cycled among 
measurements so that subjects would not take a same trial during one dosing peri-
od. The gmlt is a measure of executive functioning. During a ‘timed chase’ part of 
the test, the subject was asked to quickly follow a moving tile around in a 10 x 10 
grid of tiles on a computer touch screen with a stylus pen for 30 seconds. This test 
measures attention and psychomotor function.
detection task
During the test, a playing card was presented in the center of the screen. Subjects 
were required to press the ‘Yes’ key whenever the card flipped over and faced up. 
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Subjects were encouraged to work as quickly and accurately as they could, but 
try not to press the ‘Yes’ key before a card flips over. If subjects did this or did not 
respond to a card that had flipped over, they would hear an error sound. After a 
short period for practice, the real test began. The test measures attention and psy-
chomotor function.
identification task
A playing card was presented in the center of the screen and flipped over from time 
to time. When the card faced up, the subject should press ‘Yes’ for a red card but 
‘No’ for a non-red one. An error sound would appear when the subject pressed a key 
before a card flipped over or made a mistake. The real test began after practice. The 
test measures speed of mental processing and attention.
one card learning task
Subjects were asked to identify whether the playing card presented on the screen 
had been shown during the current test trial. They responded by pressing the ‘Yes’ 
or ‘No’ key. An error noise would appear when there was an incorrect or missing 
response. The real test began after practice. The test measures spatial learning. 
international shopping list task (islt)
At 1.75 h post-dose, the test supervisor read a shopping list of 16 words forthe sub-
ject as they appear on the computer screen at a rate of one word every two seconds. 
Subjects were instructed to memorize and recall as many words as possible, while 
the test supervisor clicked / touched the appropriate button on the screen with the 
stylus or mouse. As such, the entire word list reading session (in the same order) 
and the immediate recall session were repeated for another two times. The task 
measures verbal learning ability. At 21 h post-dose, subjects were required to recall 
the previous shopping list without being read them again, while the test supervisor 
clicked / touched the appropriate button on the screen with the stylus or mouse. 
Performance on this test reflects long term storage, memory consolidation and 
retrieval. 
safety
Safety and tolerability were evaluated using clinical laboratory tests, 12-lead elec-
trocardiograms (ecgs), and records of adverse events and vital signs. Twelve-Lead 
ecg recordings were assessed with Cardiofax V (Nihon Kohden, Tokyo, Japan) or 
Marquette 5000/5500. After a 5-minute rest in supine position, blood pressures 
and pulses were taken with a semi-automatic blood pressure recording device (a 
Nihon-Kohden bsm-1101K monitor or a Colin Pressmate bp 8800 or a Dash 4000) 
at supine and, 2 minutes later, at standing position. The Central Clinical Chemistry 
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and Haematology Laboratories of lumc were responsible for the safety laboratory 
assays on blood or urine samples.
pharmacokinetic measurements
In order to acquire the plasma concentrations of azd7325 or lorazepam, venous 
blood samples (6 mL) were collected at pre-dose and 0.5, 1, 1.25, 1.5, 2, 2.5, 3.25, 4, 
4.5, 6, 8, 12, and 21 hours post-dose into ethylenediamine tetra-acetic acid (edta K2) 
spray-dried tubes. These tubes were immediately ice-bathed and centrifuged for 10 
minutes at 2°C to 8°C at a relative centrifugal force of 2000g within 30 minutes from 
collection. Thereafter, the plasma was transferred to two 2 mL Sarstedt tubes and 
immediately frozen upright at or below -70°C within 15 minutes of plasma prepara-
tion and stored at this condition until bioassay. 
statistical analysis
The pharmacodynamic parameters (short names are written in parentheses) of 
the Neurocart consist of amplitude of body sway (Sway), saccadic peak velocity 
(spv), percentage of smooth pursuit (Smooth), performance of adaptive tracking 
(Tracking), visual analogue scale for alertness (vasalertness), feeling high (vashigh), 
internal perception (vasinternal ), and external perception (vasexternal), power of 
various eeg bands (delta, theta, alpha, beta, gamma bands in the frontal-central 
[Fz-Cz] and the parietal-occipital [Pz-Oz] areas, respectively). eeg parameters, body 
sway and vas Bowdle sub-scales were log-transformed prior to analysis and thus 
corrected for the expected log-normal distribution of the data. Safety variables 
were frequency and incidence of adverse events (aes) and related information, vital 
signs (blood pressure, heart rate, respiratory rate and auricular temperature), lab-
oratory parameters, and ecg outputs. All statistical analyses were performed with 
sas (version 9.1). 
analysis of the spv change from baseline 
(∆spv)-relative effect profiles
Previous studies suggested good sensitivity of spv to the effect of bzds [17] and α2,3 
subtype-selective gaba-a receptor modulators [14,15,16]. Based on these results, 
spv is hypothesized as a biomarker indicative of clinical anxiolysis associated with 
gaba α2,3 activation, and the predictability of spv was supported by early clinical 
findings with tpa023 [6]. bzds also affected body sway and vasalertness, suggesting 
balance impairment and subjective sedation, respectively [14,15,16,17]. Given the 
clinical relevance of these pharmacodynamic parameters, the spv-relative effect 
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profiles of both body sway and vasalertness have been shown to differentiate the 
pharmacological selectivity of α2,3 subtype-selective gaba-a receptor modulators 
from the non-selective gaba-a agonism with bzds [37]. As such, we performed a 
regression analysis to demonstrate the relationship of individual changes from 
baseline on body sway (∆sway) and vas alertness (∆vasalertness) against the change 
from baseline of spv (∆spv). The slopes of these regression lines are thought to cor-
respond with the relation between off-target sedating effects and anxiolysis [37]. 
A mixed effect model was used, where the fixed factors were treatment and treat-
ment by spv, whereas the random factors were subject, slope and intercept. The 
estimates of the slopes of the regression lines of these ∆spv-relative effect profiles 
were compared between each dose of azd7325 and lorazepam.
Repeated pharmacodynamic measurements were also compared with a 
mixed model analysis of variance with fixed factors of treatment, period, time and 
treatment by time, and random factors subject, subject by treatment and subject 
by time, and the average pre-value (average over all measurements at or before 
time=0) as covariate. The least square means (lsms) of the measurements up to 8h 
post-dose were calculated within the statistical model. Contrasts of placebo vs each 
active treatment and between each two active treatments were reported along 
with 95% confidence intervals. The log-transformed parameters were back-trans-
formed after analysis, where the results were interpreted as percentage change. 
Moreover, the ∆spv-relative effect profiles of adaptive tracking (∆tracking) and 
smooth pursuit (∆smooth) were explored to gain further insights about the phar-
macological selectivity of azd7325. 
The pharmacokinetic analysis was performed at Clinical Pharmacology, Astra-
Zeneca Wilmington, de, usa using the WinNonlin program (Pharsight Corporation, 
MountainView, California, usa) using non-compartmental analysis. The resultant 
pk parameters were summarized with descriptive statistics by treatment. The 
frequency and incidence of adverse events were summarized based on preferred 
terms by system organ class (soc) and treatment. Parameters of vital signs, 12-lead 
ecgs and safety laboratories, along with their changes from baseline, were summa-
rized using descriptive statistics by treatment.
results
subjects
Eighteen healthy male subjects, aged 24.6±7.6 years, were eligible for the trial. Two 
subjects withdrew their informed consents for personal reasons after completion 
of the first treatment period and were replaced by another two male subjects who 
received the same sequences of treatments. Sixteen subjects completed the study 
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per protocol. The mean (standard deviation, sd) body weight and body mass index 
(bmi) of the completers were 74.3 (7.2) kg and 22.6 (2.4) kg/m2, respectively. Safety 
analyses were performed on data from all treated subjects. Valid data from sub-
jects who completed at least one dosing period per protocol were included into the 
pharmacokinetic and pharmacodynamic analyses.
pharmacodynamic (pd) results 
The profiles of various pharmacodynamic parameters were obtained with each 
study treatment and graphically presented in Figure 1-4. In general, the maximal 
effect of lorazepam 2 mg appeared around 3 hours post-dose, which was slightly 
behind the time to peak plasma concentration, whereas the eeg effects of loraze-
pam and azd7325 reached their peak level around tmax.
An overview of the regression analyses for the slopes of effects relative to spv is 
plotted in Figure 5, in combination with the calculated population regression lines 
(Table 1). In figure 5, each dot represents the average change from baseline of the 
y-axis pd parameter versus that of the x-axis pd parameter (i.e. ∆spv) of 17 subjects 
at a certain time point. There are in total 12 dots per treatment arm in each graph 
panel. Each dot refers to one post-dose time-point pre-scheduled in the study. The 
connecting lines represent the time line, which suggest there was no obvious time-
shift between the effect on spv and any of the other cns-pd effects. The straight 
lines indicate the regression lines for the ∆pd-∆spv relations. These regression lines 
are not based on the average dots but on the underlying individual values that are 
not shown in the graphs. 
As is can be seen the figure, the slopes of the regression lines are generally flat-
ter for either dose of azd7325 than for lorazepam. 10 mg demonstrated statistically 
significant difference from lorazepam 2 mg in most ∆spv-relative relations, except 
the ∆smooth-∆spv relation. The effects of azd7325 2mg were too small for a reli-
able determination of effect slopes.
The effects of azd7325 10 mg also failed to reach statistical significance for 
vasalertness, spv, body sway, smooth pursuit, or adaptive tracking. In contrast, 
lorazepam 2 mg induced robust and significantly larger effects on these pharmaco-
dynamic parameters compared to either dose of azd7325 or placebo. 
There was a trend towards a short-lasting small increase in vashigh after 
azd7325 10 mg, without significant alteration in either internal (vasinternal ) 
or external (vasexternal ) perceptions. The only statistically significant effect of 
azd7325 10 mg was an eeg power reduction in the delta (2-4 Hz) and theta (4-7.5 
Hz) bands of the frontal-central area. These eeg profiles of azd7325 differed from 
the characteristic benzodiazepine eeg signature induced by lorazepam, which was 
associated with increased power in delta, beta (13.5-35 Hz) and gamma (35-48 Hz) 
bands, as well as reductions in theta and alpha (7.5-13.5 Hz). The pharmacodynamic 
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(pd) effects of each active treatment and the results of statistical comparisons are 
summarized and tabulated in Table 2 and Table 3.
Results of the CogState Early Phase Battery are presented in Figure 4. As expect-
ed, repeated exposure to the test paradigms resulted in no significant learning 
effects in the placebo group. Neither dose of azd7325 showed statistically signif-
icant effects on any individual CogState variable. In contrast, lorazepam induced 
statistically significant impairments on the following cognitive parameters com-
pared to placebo (lorazepam vs. placebo, [unit], p-value): reaction time of correct 
responses in the detection task (2.59 vs. 2.52 [log(msec)], p<0.0001), reaction time 
of correct responses in the identification task (2.78 vs. 2.70 [log(msec)], p<0.0001), 
response accuracy in the one card learning task (0.70 vs. 0.86 [arc(%)], p<0.0001), 
moves per second (mps) in the chase test (1.58 vs. 1.84 [mps], p<0.0001), and the 
sum of errors in gmlt (62.0 vs. 33.1, p=0.0003), as well as reduced the number of 
words recalled in both the islt and the isl delayed-recall task.
safety
Single oral dose of azd7325 2 mg, azd7325 10 mg or lorazepam 2 mg were generally 
safe and well-tolerated in the eighteen selected healthy male participants. A major-
ity of subjects reported adverse events after administration of lorazepam 2 mg (ae 
frequency, incidence%: 14, 87.5%), whereas the high dose of azd7325 was associ-
ated with relatively fewer adverse events (12, 70.6%), and even lower incidences of 
aes were observed after azd7325 2 mg (4, 23.5%) and placebo (9, 56.3%). As was 
observed with lorazepam 2 mg (14, 87.5%), most aes that occurred in subjects 
receiving azd7325 10 mg (11, 64.7%) were classified as ‘nervous system disorders’, 
but fewer subjective somnolence (azd7235 10 mg: 7, 41.2%; azd7325 2 mg: 2, 11.8%) 
and dizziness (azd7235 10 mg: 3, 17.6%; azd7325 2 mg: 1, 5.9%) were reported with 
either dose of azd7325 than with lorazepam (somnolence: 9, 56.3%; dizziness: 5, 
31.3%). On the other hand, the incidence of somnolence and dizziness was higher 
with azd7325 10 mg than with placebo (3, 18.8%). The frequency of gastrointestinal 
events was also less with azd7325 10 mg (2, 11.8%) than with lorazepam (6, 37.5%). 
No changes or individual abnormalities of vital signs or laboratory or ecg results 
were judged clinically important by the investigator.
pharmacokinetic (pk) results 
Both azd7325 2 mg and azd7325 10 mg were quickly absorbed after oral admin-
istration, with a short lag time of maximally 0.5 hours. Mean (sd) peak plasma 
concentration (cmax) arrived at 14.2 (5.36) ng/ml between 1 hours and 3.25 hours 
after azd7325 2 mg, and at 67.4 (33.5) ng/ml between 0.5 hours and 3.25 hours 
after azd7325 10 mg, with a median time to cmax (tmax) of 1.75 hours and 2 hours, 
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respectively. The area under the concentration-time curve from zero to the last 
detectable concentration (auc0-t) was 51.9 (18.9) h·ng/mL for azd7325 2 mg and 259 
(77.6) h·ng/ml for azd7325 10 mg. As is shown in Figure 6, drug elimination seemed 
to exhibit roughly three phases after tmax. The mean elimination half-life was 8.5 
to 9.0 hours for both doses of azd7325 (ranging from 5.09 to 15.4 hr). The apparent 
oral clearance (cl/f) of azd7325 was 38.3 L/hr on average (ranging from 9.87 to 89.9 
L/hr). No statistically significant differences were found between azd7325 2 mg and 
azd7325 10 mg with respect to tmax, t1/2, or cl/f (p>0.05). In comparison, lorazepam 
reached a mean (sd) cmax of 20.7 (4.86) ng/ml in a longer median tmax of 2.50 hr 
(range 0.50-6.00 hr) and was eliminated with a mean t1/2 of 14.6 hr (range 8.31-25.1 
hr). The auc0-t for lorazepam was 233 (35.8) h·ng/mL. The average levels of auc and 
cmax increased in a dose proportional manner with similar dose-normalized values 
of cmax and auc0-t between azd7325 2 mg and azd7325 10 mg.
discussion
In vitro, azd7325 exhibits relatively potent positive modulation at the α2,3 subunits 
together with neutral α1-antagonism and weak α5-affinity. Based on these prop-
erties, the compound was expected to have a rapid onset of anxiolysis with less 
untoward effects at its therapeutic dose(s) in healthy volunteers. Prior to initiating 
phase ii trials, the present study aimed to provide support for the pharmacological 
selectivity of azd7325 in healthy volunteers by comparing its pharmacodynamic 
profile to the non-selective gaba-a receptor modulator, lorazepam.
Compared with lorazepam, both doses of azd7325 demonstrated smaller 
absolute slopes of the regression lines in the ∆spv-∆Log(Sway) relation and the 
∆spv-∆vasalertness relation. Thus, azd7325 is associated with a ∆spv-dominant 
response profile, whereas the pharmacodynamic responses to lorazepam are 
more comparable and balanced among the same set of cns parameters. This has 
also been observed with other subtype-selective gaba-a α2,3 receptor modulators 
[14,16]. Since spv was found sensitive [17] and functionally specific to the effect 
of anxiolytic drugs acting on the gabaergic system [37], the distinction between 
azd7325 and lorazepam suggests that the α2,3-selective agonist may cause less 
sedation than the benzodiazepine, at doses with a similar anxiolytic effect.
An alternative explanation for the non-significant spv effects of azd7235 could 
be that the doses of this compound may have been too low to be pharmacologically 
equipotent to lorazepam 2 mg. In the human pet study with [11C]flumazenil, a 50% 
receptor occupancy was linked to a free plasma concentration of approximately 4 
ng/ml [AstraZeneca data on file] which corresponded to estimated maximal con-
centrations achieved after azd7325 1.3 mg orally. Doses greater than 5 mg were 
linked with high levels of occupancy (> 70%). In the present study, the 10 mg dose 
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resulted in average peak plasma concentration of 67.4 ng/ml and average plasma 
concentration of 12.3 ng/mL over 21 hours, which are expected to produce gaba-a 
occupancy levels accounting for 80-90% and 60-70%, respectively, of the maximal 
occupancy level. It remains unknown whether higher doses of azd7325 would have 
more profound effects on spv. As another member of the family of gaba-a α2,3 sub-
type-selective partial agonist, tpa023 also produced average receptor occupancies 
over 70% at a dose of either 3 mg in immediate-release (im) formulation or 8-12 mg 
in a controlled release (gem) formulation [1]. However, a relatively small single dose 
of tpa023 (im 1.5 mg) is required to produce comparable spv reduction as lorazepam 
2 mg in healthy volunteers [14]. The development of tpa023 was discontinued due 
to toxicity findings in rodents following long-term administration. Nevertheless, 
limited clinical efficacy data that were accumulated before termination suggest an 
anxiolytic-like effect of tpa023 with flexible-doses (1.5-4.5mg b.i.d. or 3-8mg b.i.d.) 
of the extended-release (gem) formulation of tpa023 [1]. In vitro, tpa023 exerts 11% 
and 21% modulation at the α2 and α3 subunits relative to chlordiazepoxide [38], 
whereas the α2- and α3-agonism of azd7325 are equivalent to 18% and 15% of the 
full efficacy of diazepam, respectively. The combination of these information sug-
gests that relative to the doses of azd7235 used in this study, either stronger partial 
agonism at the α2 or α3 subunits or higher exposure (with larger or repeated dosing) 
are necessary for clinical anxiolysis.
Subsequent to the current study, two double-blind placebo-controlled proof-
of-concept studies were performed in patients with gad. azd7325 doses 2 mg bid, 
5 mg bid, or 10 mg qd were investigated in study nct00808249 (register identifier 
in ClinicalTrial.gov) [39] and doses 5 mg bid or 15 mg bid and lorazepam 2 mg bid 
were investigated in study nct00807937 [40]. Both studies were of 28 days dura-
tion. These studies were designed when the results of this study were available. 
Given that the azd7325 10 mg dose was well tolerated in the present study and the 
spv-effects of azd7325 10 mg were not equipotent with the lorazepam effects, it 
was decided that a higher dose of az7325 could be tested in the gad study (i.e. 15 mg 
bid). Since the incidence of cns side-effects appeared to be dose-dependent in the 
current study and the use of spv as a benchmark for anxiolytic efficacy is still experi-
mental, the dose of azd7325 15 mg bid was selected as the highest dose to be tested 
with predicted positive benefit to risk ratio. Although azd7325 demonstrated some 
anxiolytic activity in selected secondary end-points in these two studies, none of 
the azd7325 doses met the statistical significance for the primary end-point of 
improvement in Hamilton Rating scale for Anxiety (ham-a) at 4 weeks. Lorazepam 
2mg bid was shown to be marginally anxiolytic at 4 weeks based on the improve-
ment in ham-a (mean change from baseline ± standard error: -10.8 ± 0.88 vs. -9.5 
± 0.88 [with placebo] vs. -10.4 ± 0.89 [with azd7325 15mg bid]) [40]. In line with our 
observations described here, lower incidence of ‘fatigue’, ‘somnolence’ and ‘seda-
tion’ occurred in the azd7325-treated groups compared with lorazepam 2 mg bid. 
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azd7325 up to doses of 15 mg bid was generally well tolerated in gad patients. The 
most common adverse event associated with azd7325 was dizziness. In addition, 
more adverse events of euphoric mood were seen with azd7325 in comparison to 
placebo. 
The high dose of azd7325 elicited a transient increase of vashigh, with the 
maximal back-transformed amplitude (2.01 mm) similar to that after lorazepam 
(1.71 mm). In contrast to azd7325, however, lorazepam also caused concomitant 
enhancement of vas internal (vasinternal ) and external (vasexternal) perception. 
This is in line with the findings in the phase-ii studies, in which adverse event 
‘euphoric mood’ was more frequently reported by gad patients dosed with azd7325 
than those taking placebo [39,40] or lorazepam [40]. 
The main pharmacodynamic effects of azd7325 were on eeg parameters, which 
were distinct from the eeg effects of lorazepam. The decrease in delta-activity 
contrasts with the increase in delta-power seen with lorazepam and is consistent 
with the lack of effect of azd7325 on measures of sedation and alertness. A reduc-
tion of theta activity was seen with both azd7325 and lorazepam and may relate 
to a common effect independent of sedation. Whatever their physiological or 
clinical meaning, these findings demonstrate a central pharmacodynamic effect 
of azd7325. The eeg effects exhibited dose-response relationships and a close 
temporal link to the plasma concentrations. tmax was short and associated with a 
rapid peak effect, which may reflect a potential of quick-onset clinical effect after 
azd7325.
In conclusion, the pharmacodynamic profile of azd7325 differed from that of a 
typical benzodiazepine. At doses up to 10 mg, azd7235’s spv-effects were non-sig-
nificant by themselves, but showed preference over other cns-effects. Since the 
doses of azd7325 were not equivalent to lorazepam 2 mg, the lack of effects on sub-
jective alertness, visuo-motor coordination, postural balance, and psychomotor 
and cognitive functions cannot be directly extrapolated as reduced clinical side-ef-
fects. Therefore, further clinical evaluations with higher doses are warranted, but 
the dose-dependent side-effects on the central nervous system should be consid-
ered to balance dose selection. The effects of azd7325 10 mg on eeg spectrum and 
vashigh suggest entry of the compound into the central nervous system and a rapid 
onset of pharmacodynamic effect. 
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Table 1 • Results of the linear model for the Δlog(Sway)-Δspv, Δvasalertness-Δspv, ΔTracking-Δspv, 
and Δsmooth-Δspv relations
Slope azd7325 azd7325 Lora azd-2mg vs. Lorazepam azd-10mg vs. Lorazepam
2 mg 10 mg 2mg Estimate of 
difference [95% CI]
































Table 2 • Summary of pharmacodynamic (pd) effect of single doses of lorazepam 2 mg, azd7325  
10 mg, and azd7325 2 mg, compared to placebo as estimated difference (95% confidence interval)
pd Parameter Lorazepam-2mg azd7325-2mg azd7325-10mg
vs. Placebo
vasalertness (mm) -7.9(-11.0, -4.7) -1.6(-4.8, 1.6) -1.6(-4.7, 1.6)
p<0.0001 p=0.3111 p=0.3225
vascalmness (mm) 3.5 (0.6, 6.4) -1.7 (-4.6, 1.2) 1.1 (-1.8, 4.0)
p=0.0195 p=0.2417 p=0.4452
vasmood (mm) 0.2 (-2.9, 3.2) -2.0 (-5.0, 1.1) -1.4 (-4.5, 1.7)
p=0.9146 p=0.2012 p=0.3593
Sway (%) 89.13(60.99,122.2) 1.03(-13.9,18.50) -10.1(-23.4,5.52)
p<0.0001 p=0.8968 p=0.1869
spv (deg/sec) -40.4 (-58.6, -22.1) -14.1 (-32.2, 4.1) -15.2 (-33.3, 2.9)
p<0.0001 p=0.1240 p=0.0974
SacInacc (%) 1.1 (0.5, 1.6) 0.3 (-0.3, 0.8) -0.1 (-0.6, 0.4)
p=0.0002 p=0.3385 p=0.6511
Sac rt (sec) 0.014 (0.001,0.026) -0.009 (-0.021, 0.003) -0.009 (-0.021, 0.003)
p=0.0305 p=0.1337 p=0.1389
Smooth (%) -10.5 (-14.3, -6.7) -3.2 ( -7.0, 0.6) -1.9 (-5.7, 1.9)
p<0.0001 p=0.0997 p=0.3094
Tracking (%) -7.26 (-8.98, -5.54) -0.59 (-2.32, 1.13) -0.15 (-1.91, 1.61)
p<0.0001 p=0.4890 p=0.8648
vasexternal log(mm) 0.13 (0.06, 0.19) 0.01 (-0.05, 0.08) 0.04 (-0.03, 0.10)
p=0.0003 p=0.6941 p=0.2242
vasinternal log(mm) 0.06 ( 0.03, 0.10) 0.00 (-0.04, 0.04) 0.02 (-0.02, 0.06)
p=0.0009 p=0.9964 p=0.2613
vashigh log(mm) 0.25 (0.09, 0.41) 0.00 (-0.16, 0.16) 0.16 (-0.00, 0.32)
p=0.0028 p=0.9889 p=0.0570
vas=visual analogue scale; Smooth=Smooth pursuit; Tracking=Adaptive Tracking; spv=saccadic peak velocity; 
Sacrt=saccadic reaction time; SacInacc=saccadic inaccuracy
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Table 3 • Summary of electroencephalogram (eeg) effect of single doses of lorazepam 2 mg,  
azd7325 10 mg, and azd7325 2 mg, compared to placebo as estimated difference 
(95% confidence interval)
eeg Parameters(%) Lorazepan-2mg azd-2mg azd-10mg
vs. Placebo
Alpha Fz-Cz -19.5(-27.2, -11.0)  2.89(-6.96, 13.80)  0.19(-9.40, 10.80)
p<0.0001 p=0.5700 p=0.9696
Alpha Pz-Oz -41.4(-51.4, -29.4)  0.31(-16.8, 20.97) 10.33(-8.58, 33.15)
p<0.0001 p=0.9732 p=0.2937
Beta Fz-Cz 12.15( 3.94, 21.00) -0.84(-8.11, 7.00)  2.14(-5.32, 10.19)
p=0.0040 p=0.8240 p=0.5760
Beta Pz-Oz -12.9(-22.3, -2.34) -4.26(-14.7, 7.43)  3.09(-8.21, 15.79)
p=0.0194 p=0.4487 p=0.5987
Delta Fz-Cz 10.21(2.42, 18.58) -3.66(-10.5, 3.67) -18.7(-24.5, -12.4)
p=0.0108 p=0.3087 p<0.0001
Delta Pz-Oz  7.64(-2.54, 18.88)  1.16(-8.39, 11.70) -15.9(-23.8, -7.11)
p=0.1421 p=0.8157 p=0.0011
Gamma Fz-Cz  8.57(2.39, 15.13) -0.68(-6.52, 5.52)  1.73(-4.09, 7.90)
p=0.0073 p=0.8207 p=0.5593
Gamma Pz-Oz  1.02(-12.6, 16.75) -8.20(-20.8, 6.34) -1.80(-15.2, 13.65)
p=0.8885 p=0.2469 p=0.8033
Theta Fz-Cz -7.75(-13.8, -1.33) -2.45(-8.81, 4.36) -13.5(-19.1, -7.43)
p=0.0200 p=0.4624 p<0.0001
Theta Pz-Oz -15.0(-24.2, -4.80)  1.55(-9.43, 13.86) -10.3(-19.9, 0.53)
p=0.0062 p=0.7874 p=0.0610
Fz-Cz=Frontal-central area; Pz-Oz=Parietal-occipital area.
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Figure 1 • Least square means of change-from-baseline profiles of subjective  
pharmacodynamic paramters (i.e. visual analogue sub-scales) after the treatments of placebo, 
lorazepam 2 mg, azd7325 2 mg, and azd7325 10 mg
With 95% ci error bars; vas=visual analogue scale 
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Figure 2 • Least square means of change-from-baseline profiles of objective pharmacodynamic 
parameters after the treatments of placebo, lorazepam 2 mg, azd7325 2 mg, and azd7325 10 mg 
With 95% ci error bars ; Smooth=Smooth pursuit; Tracking=Adaptive Tracking; 
Sac Inacc=Saccadic Inaccuracy;Sacrt=Saccadic Reaction Time; spv=Saccadic Peak Velocity.
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Figure 3 • Least square means of change-from-baseline profiles of electroencephalogram 
parameters after the treatments of placebo, lorazepam 2 mg, azd7325 2 mg, and azd7325 10 mg 
With 95% ci error bars 
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Figure 4 • Least square means of change-from-baseline profiles of CogState parameters after 
the treatments of placebo, lorazepam 2 mg, azd7325 2 mg, and azd7325 10 mg (Panel a);  
mean number of correct responses in the International Shopping List Test (islt) and 
the delayed recall islt (Panel b).  
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With 95% ci error bars ; rt=Reaction Time; gmlt= Groton Maze Learning Task; 
islt=International Shopping List Task.
b
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Figure 5 • The ∆vasalertness (mm)-∆spv (deg/sec), ∆sway(logmm)-∆spv (deg/sec), ∆smooth(%)- 
∆spv (deg/sec), and ∆tracking(%)-∆spv(deg/sec) relation profiles of azd7325 2 mg and  
azd7325 10 mg vs. lorazepam 2 mg, respectively. 
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The azd7325 2 mg at time=30 min does not have an error bar down, because the value of the average - error bar 
reaches a below zero value (avg=3.53, sd=4.169) and cannot be shown on a log based axis.
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Figure 6 • Mean concentration-time profiles of azd7325 2 mg, azd7325 10 mg and  
lorazepam with standard deviation as error bars linear (Panel a) and semi-logarithmic  
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azd6280, a novel partial y-aminobutyric 
acid a receptor modulator, demonstrates 
a pharmacodynamically selective effect 
profile in healthy male volunteers
J Clin Psychopharmacol 2015; 35(1): 22-33.
Chen X1’2, Jacobs G2’3, de Kam ML2, Jaeger J1’2, Lappalainen J1’2, Maruff P1’2, Smith MA1’2, 
Cross AJ4, Cohen A2, van Gerven J2
1.Phase I Unit, Clinical Pharmacology Research Center (cprc), Peking Union Medical 
College Hospital, Beijing, China | 2. Centre for Human Drug Research, Leiden |  
3. vu University Medical Centre, Amsterdam, the Netherlands | 4. AstraZeneca,  
r&d, Wilmington, de | 5. Cogstate, Melbourne, Australia |  
6. Teva Pharmaceuticals, Frazer, pa
304_Connie_Proefschrift_19.indd   51 12-09-17   17:55
human pharmacology of current and novel gaba(a)-ergic treatments for anxiety
52
abstract
Objective: azd6280 is a novel gaba-a receptor modulator with higher in vitro effica-
cy at the α2,3-subtypes as compared to the α1- and α5-subtypes. This study compared 
the pharmacodynamic effects of single-oral-dose azd6280 10 mg and 40 mg on 
the central nervous system (cns) with lorazepam 2 mg. Methods: Sixteen healthy 
males were enrolled into the double-blind, randomized, 4-way crossover study. 
Two validated cns test-batteries, Neurocart and CogState, were administered to 
measure drug effects on cognition, neurophysiologic function, psychomotor and 
subjective feelings. Statistical analysis was performed using mixed model analysis 
of variance, with fixed factors of treatment, period, time and treatment by time, and 
random factors of subject, subject by treatment and subject by time and the average 
pre-value as covariate. Results: Most pharmacodynamic parameters were affected 
by lorazepam. azd6280 induced dose-dependent smaller-than-lorazepam effects 
on saccadic peak velocity (spv) (azd6280 10 mg vs. azd6280 40 mg vs. lorazepam 
[degree/second, deg/sec]: -22.6 vs. -50.0 vs. -62.9, p<0.001), while the impacts on 
adaptive-tracking, body-sway, smooth-pursuit and the one-card-learning tests 
were significant but much smaller than lorazepam. Thus the slopes of regression 
lines for the ∆Log(Sway)-∆spv, ∆tracking-∆spv, and ∆smooth-∆spv relations were 
flatter with azd6280 than with lorazepam. azd6280 caused a distinct electro-en-
cephalography signature from that of lorazepam. Conclusion: The spv responses 
to azd6280 suggest potential concentration-related anxiolytic effects, while the 
smaller spv-normalized effects of azd6280 on various non-spv pharmacodynamic 
parameters suggest a more favorable side-effect profile compared to lorazepam. 
Overall, the pharmacodynamic profile of azd6280 matches the pharmacological 
specificity and selectivity of this compound at the α2,3 gaba-a receptor subtypes. 
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introduction
The different anxiety disorders together constitute one of the most prevalent 
groups of psychiatric disorders [1]. Evidence supports the use of the selective sero-
tonin reuptake inhibitors (ssris) and the tricyclic antidepressant drugs (tcas) in 
the pharmacological treatment of virtually all anxiety disorders. In addition, the 
non-selective gaba-a receptor potentiating benzodiazepines (bzds) are partic-
ularly effective in the management of acute forms of anxiety due to their robust 
anxiolytic effects and rapid onset of action. However, patients frequently discontin-
ue ssris and tcas prematurely due to a delayed onset of action and unacceptable 
side effects, and the widespread application of bzds is restricted by untoward 
effects such as day-time sedation, fatigue, deleterious effects on cognition, memo-
ry impairment, tolerance and concerns regarding dependence liability [2,3]. These 
limitations of existing anxiolytic drugs underlie the pressing need for the develop-
ment of efficacious innovative anxiolytic agents with more favorable side-effect 
profiles.
It is well-established that bzds act through modulation of gaba-a receptors. A 
range of gaba-a receptor subtypes, defined by their subunit composition, medi-
ate these effects. The use of knock-out and knock-in techniques in rodents has 
helped to characterize the physiological role of various gaba-a receptor subtypes 
as candidates for mediating the clinical effects of bzds [4]: gaba-a receptor sub-
types that contain gaba-a α2 and α3 subunits may mediate anxiolytic effects [5,6], 
while gaba-a α1 and α5 subunits account for sedation and cognitive impairment 
[4,7,8,9,10], respectively. 
azd6280 (4-Amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxa-
mi de) [11,12] is a novel, subtype-selective gaba-a receptor modulator, which in 
contrast to bzds, exerts minimal efficacy at α1-subunit containing gaba-a receptors. 
Although azd6280 has relatively high (±standard deviation, sd) binding affinity to 
the α1 (Ki=0.5±0.2 nM), α2 (Ki=21±5 nM), and α3 (Ki=31±17 nM) gaba-a subunits, its 
affinity for the α5 subunit is much lower (Ki=1680±650 nM). On the other hand, the 
in vitro efficacy of azd6280 at the gaba-a α2 (32%) or α3 (34%) receptor subtypes is 
4-5-fold higher than that at the gaba-a α1 (8%) or α5 (7%) receptor subtypes relative 
to the corresponding maximal responses to diazepam. This profile is distinct from 
previously characterized α2,3 preferring compounds tpa-023 and azd7325 in that 
azd6280 has greater intrinsic activity at α2,3 subunits. Clinical relevance of these 
pharmacological characteristics has been tested in several pre-clinical animal mod-
els, where the compound demonstrated potential anxiolysis with reduced motor 
and cognitive side effects. 
The objectives of this study were to investigate the pharmacodynamic (pd) 
effects of single oral doses of azd6280 on the central nervous system (cns), and 
compare those effects to lorazepam, a commonly used bzd. 
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azd6280 10 mg and azd6280 40 mg were selected as the investigational doses. 
In the azd6280-ascending-dose study single doses up to 60 mg were tested. This 
dose was associated with increased rate of sedation and one event of transient 
depersonalization. The 10 mg and 40 mg doses were predicted to lead to peak 
plasma concentrations above minimally efficacious concentrations in animal 
models of anxiety, and provide gaba-a receptor occupancy levels 50% or higher of 
the maximal displaceable binding as determined by [11C]flumazenil. These data 
demonstrate that azd6280 crosses the blood brain barrier, interacts with the tar-
get, and has the potential to produce anxiolytic activity in humans.
For the current study, the Neurocart cns test battery [13] and the CogState 
cognitive test battery were used. Components of these two batteries provide bio-
markers for cns function(s) that have been shown to be sensitive to the effects of 
bzds and/or α2,3-selective gaba-a agonists [13,14,15,16]. Recent studies have sug-
gested that partial selective α2,3 gaba-a agonists exhibit distinct effect profile in the 
central nervous system, which is characterized by a preserved effect on the saccadic 
peak velocity (spv) but relatively reduced impairment of subjective alertness, pos-
tural balance and memory, compared to bzds [13,14,15,16].
methods
design
This was a single-center, four-way crossover, randomized, double blind, double- 
dummy, placebo-controlled study in 16 healthy male volunteers. 
subjects
Healthy male volunteers, aged 18 to 55 years, with a body mass index (bmi) between 
18 and 30 kg/m2, were medically screened after provision of written inform con-
sent. Eligible subjects were advised not to use alcoholic beverages from 24 hours 
preceding each study day and refrain from smoking and using caffeine-containing 
products from 22:00 prior to each study day. Keeping a normal diurnal pattern was 
also required from two weeks before the first study day until the last study day. 
treatments
All subjects arrived in the research unit at around 08:00hr on the dosing day of each 
study period. Study medication was administered orally between 09:00 and 11:00hr 
in the morning, when all pre-dose assessments were completed. Either capsules 
containing azd6280 or placebo, or tablets containing lorazepam (identical to the 
clinically available formulation of lorazepam) or placebo were orally administered. 
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On each study day, subjects received one of the four treatments according to a 
randomly allocated treatment schedule: azd6280 10 mg, azd6280 40 mg, loraz-
epam 2 mg, and placebo. The study days were separated by washout periods of 7 
days minimum. The order of the treatments was defined by a Williams Latin Square 
design that led to sixteen completely different sequences of four treatments.
safety
Safety and tolerability were assessed by the incidence and severity of adverse 
events, abnormalities in vital sign assessments, clinical laboratory parameters, and 
electrocardiograms (ecg). Twelve-Lead ecg recordings were made, using Cardiofax 
V equipped with ecaps12 analysis program (Nihon Kohden, Tokyo, Japan) or 
Marquette 5000/5500. Supine blood pressure and pulse were measured using 
a semi-automatic blood pressure recording device (a Nihon-Kohden bsm-1101K 
monitor or a Colin Pressmate bp 8800 or a Dash 4000). Subjects were required to 
rest in a supine position for at least 5 minutes prior to these measurements. Safety 
laboratory tests on blood or urine samples were assayed in the Central Clinical 
Laboratories of Leiden University Medical Centre.
pharmacokinetic measurements
Venous blood samples (6 mL) for determination of azd6280 or lorazepam in plasma 
were collected at pre-dose and 0.5, 1, 1.25, 1.5, 2, 2.5, 3.25, 4, 4.5, 6, 8, 12, and 21 hours 
post-dose. The plasma concentrations of azd6280 and lorazepam were measured 
using two validated methods at Bioanalytical Systems, Inc.,  West Lafayette, in, usa.
Plasma concentrations of azd6280 was determined with a solid-phase extraction / 
liquid chromatography coupled with tandem mass spectrometry [(spe)/lc-ms/ms] 
method and lorazepam was measured using a liquid/liquid extraction/lc-ms/ms 
method. In brief, the plasma samples of azd6280 were pre-purified by solid-phase 
extraction (spe) and analyzed using gradient chromatographic separation on an 
Atlantis T3 column with a gradient mobile phase, while the plasma samples of lora-
zepam were pre-purified by liquid/liquid extraction and analyzed using gradient 
chromatographic separation on an xbridge C18 column with a formic acid/aceto-
nitrile/water mobile phase. The bioassay method for azd6280 was validated over 
the concentration range of 0.150 to 120 ng/mL. The lower limit of quantification 
(lloq) was 0.150 ng/mL, utilizing a 50.0 μL sample aliquot with a validated dilution 
of 50-fold with human plasma. The bioassay method for lorazepam was validated 
over the concentration range of 0.300 to 100 ng/mL. The lower limit of quantifi-
cation (lloq) was 0.300 ng/mL, utilizing a 150 μL sample aliquot with a validated 
dilution of 20-fold with human plasma. Inter- and intra- batch precision of both 
methods were less than 15% and the accuracy was within 85-115%. A matrix-effect 
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test indicated that the determination was not affected by the matrix. In addition, 
azd6280 and lorazepam in plasma were proven to be stable under the storage con-
dition of -80 °C for at least 205 days and 144 days, respectively.
pharmacodynamic measurements
A collection of computerized neurophysiologic and neuropsychological tests was 
performed during the study. Most of these assessments were given during the 
cns training session to familiarize subjects with the tests and reduce learning 
effects. The Neurocart battery was performed in the following chronological order: 
body sway, visual analogue scale (vas) Bond & Lader, vas Bowdle, saccadic eye 
movements, smooth pursuit eye movements, adaptive tracking and electro-en-
cephalogram (eeg). In each treatment period, this battery was assessed at pre-dose 
(twice) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 8, and 12 hours post-dose. The CogState 
early phase battery was carried out before dosing (three times) and at 1.25, 2.25, 
3.25, and 4.25 hours post-dose. This cognitive test battery contains the Groton 
Maze Learning Task (gmlt), Detection task (det), Identification Task, and One Card 
Learning Task [17,18]. Each abovementioned Neurocart or Cogstate test lasted 1 to 5 
minutes, thus the total duration of these pharmacodynamic assessments was 15-30 
minutes at different time points. At 1.75 hours post-dose subjects also completed 
the International Shopping List Task, a word verbal list learning test presented 
three times, each time followed by an immediate recall trial. Delayed recall was 
tested 21 hours later. At each of these assessments, one subject at a time was tested 
in a quiet room with ambient illumination.
neurocart
body sway
Body sway was measured with an apparatus similar to the Wright ataxiameter [19], 
which integrates the amplitude of unidirectional body sway. Two-minute measure-
ments were made in the anterio-posterior direction with eyes closed. The subject 
was asked to stand comfortably on a floor with his/her feet slightly apart. Body sway 
measures postural (in)stability. It has demonstrated considerable sensitivity to the 
effect of benzodiazepines [20]. 
visual analogue scales of bond & lader (vas b&l) and bowdle
Visual analogue scales as originally described by Norris have often been used pre-
viously to quantify subjective effects of a variety of sedative agents [21,22]. Dutch 
versions of the scales have been frequently employed at the Centre for Human 
Drug Research (chdr), for a variety of sedative agents [23] and circumstances [24]. 
During the test, the subjects indicated (with a mouse click on the computer screen) 
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on horizontal visual analogue scales how he/she feels. From the sixteen measure-
ments of vas Bond & Lader, three main factors are the calculated [25] for subjective 
alertness, contentedness, and calmness. 
The Bowdle Psychotomimetic Effects Scores have been used to quantify the psy-
chotomimimetic effects of ketamine [26]. A translated Dutch version of the scale 
originally developed by Bowdle et al. has been computerized and used at the chdr 
to study glutamatergic drug effects. This scale has thirteen 10 cm visual analogue 
lines ranging from 0 (‘not at all’) to 100 mm (‘extremely’) [27], addressing various 
abnormal states of mind. 
saccadic eye movements
Saccadic eye movements were evaluated using a computer-based system com-
posed of 1) stimulus display and signal collection (Nihon Kohden Corporation, 
Tokyo, Japan), 2) signal amplification (Grass-Telefactor, An Astro-Med, Inc. 
Product Group, Braintree, usa), 3) data recording (Cambridge Electronics Design, 
Cambridge, uk), 4) disposable silver-silver chloride electrodes (Medicotest N-oo-S, 
Olstykke, Denmark), as well as 5) the sampling and analysis scripts developed by 
chdr (Leiden, the Netherlands). The parameters of this test were the average values 
of saccadic peak velocity (spv, deg/sec), latency (i.e. reaction time, msec) and inaccu-
racy (%) of all artefact-free saccades that were calculated on each session. Saccadic 
peak velocity appears to be the most sensitive measure for the effect of benzodiaz-
epines [22] and has been found to be closely related to the anxiolytic component of 
benzodiazepines and some newly developed compounds with potential anxiolytic 
effect [14,15,16]. 
smooth pursuit eye movements
The same system as used for saccadic eye movements was also used for measure-
ment of smooth pursuit. For smooth pursuit eye movements, the target moved 
sinusoidally at frequencies ranging from 0.3 to 1.1 Hz, by step of 0.1 Hz. The ampli-
tude of target displacement corresponded to 22.5 degrees eyeball rotation to both 
sides. Four cycles were recorded for each stimulus frequency. The method has been 
validated in healthy volunteers dosed with benzodiazepines at the chdr by van 
Steveninck et al. [23] based on the work of Bittencourt et al. [28] and the original 
description of Baloh et al. [29]. The time in which the eyes were in smooth pursuit 
of the target were calculated for each frequency and expressed as a percentage of 
stimulus duration. The average percentage of smooth pursuit for all stimulus fre-
quencies were used as the parameter.
adaptive tracking
The adaptive tracking test was performed as originally described by Borland and 
Nicholson [30], using customised equipment and software. After a 0.5-minute 
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run-in time without data-recording, the average performance over the rest 3.0 
minutes was scored and was used as the test parameter. Adaptive tracking is a pur-
suit-tracking task. The subject was required to operate a joystick and try to keep a 
dot inside a circle moving randomly on the computer screen. If he/she succeeded, 
the speed of the moving circle increases, and vice versa. 
electroencephalography
Pharmaco-electroencephalography (pharmaco-eeg) was used to monitor any 
drug effects, which can be interpreted as evidence of penetration across the blood 
brain barrier and changes in the activity of the brain [31,32]. eeg provides non-spe-
cific measures of cns functions. eeg recordings were made using gold electrodes, 
fixed with ec2 paste (Astromed) and using standard pharmacoeeg lead placement, 
with the same common ground electrode as for the eye movement registration 
(international 10/20 system for eeg electrode placement [33]). The electrode resis-
tances were kept below 5 kOhm. The signals were amplified by use of a Grass 15lt 
series Amplifier Systems with a time constant of 0.3 seconds and a low pass filter 
at 100 Hz. Data collection and analysis were performed using customized ced and 
Spike2 for Windows software (Cambridge Electronics Design, Cambridge, uk). Per 
session eight consecutive blocks of eight seconds were recorded. The signal was 
ad-converted using a ced 1401 Power (Cambridge Electronics Design, Cambridge, 
uk) and stored on hard disk for subsequent analysis. Data blocks containing arti-
facts were identified by visual inspection and these were excluded from analysis. 
For each lead, fast Fourier transform analysis was performed to obtain the sum of 
amplitudes in the delta- (0.5-3.5 Hz), theta (3.5-7.5 Hz), alpha- (7.5-11.5 Hz), beta- 
(11.5-30 Hz) frequency ranges. Frequency band above 30 Hz was also recorded for 
exploratory pharmacoeeg analyses in order to test whether the findings of an effect 
of azd6280 on gamma-frequency band (> 30 Hz) in animals translate to humans. 
cognition measures
The computerized CogState Early phase Battery, consists of four tasks with demon-
strated sensitivity to cognitive change associated with drug effects [34]. These tests 
are listed below, in order of administration. In addition Cogstate’s International 
Shopping List Task immediate and 21 hour delayed recall were administered once 
per dosing period.
groton maze learning task (gmlt)
This is an executive problem solving and spatial learning task which requires the 
subject to find a 28-step pathway that is hidden under a 10 x 10 grid of tiles displayed 
on a computer touch screen. Subjects were instructed to move from the start loca-
tion (top left), one tile at a time, toward the end (bottom right) while adhering to 
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several rules (no diagnonals, no skipping, no retracing movements). Once complet-
ed, subjects returned to the start location and repeated the task for 4 more times. 
Twenty well-matched alternate forms of this task were cycled among measure-
ments so that subjects would not take a same trial during one dosing period. During 
a ‘timed chase’ part of the test, the subject was asked to quickly follow a moving tile 
around in a 10 x 10 grid of tiles on a computer touch screen with a stylus pen for 30 
seconds. This aspect of the task measures attention and psychomotor function.
detection task
During the test, a playing card was presented in the center of the screen. Subjects 
were required to press the ‘Yes’ key whenever the card flipped over and faced up. 
Subjects were encouraged to work as quickly and accurately as possible. If subjects 
responded before the card flipped over or did not respond to a card that had flipped 
over, an error sound was emitted. After a brief practice test, the real test began. The 
test measures attention and psychomotor function.
identification task
A playing card was presented face down in the center of the screen and flipped over 
from time to time. When the card faced up, the subject should press ‘Yes’ for a red 
card but ‘No’ for a non-red (black) one. An error sound would appear when the sub-
ject pressed a key before a card flipped over or made a mistake. The real test began 
after practice. The test measures speed of mental processing and attention.
one card learning task
Subjects were asked to identify whether the playing card presented on the screen 
had been shown during the current test trial. They responded by pressing the ‘Yes’ 
or ‘No’ key. An error noise would appear when there was an incorrect or missing 
response. The real test began after practice. The test measures working memory 
and learning ability.
international shopping list task (islt)
At 1.75h post-dose, the test supervisor read a shopping list of 16 words to the subject 
as they appeared on the computer screen at a rate of one word every two seconds. 
Subjects were instructed to memorize and recall as many words as possible, while 
the test supervisor clicked / touched the appropriate button on the screen with the 
stylus or mouse. The list was read (in the same order) and the immediate recall 
session were repeated two more times for a total of three trials. The task measures 
verbal learning ability. At 21h post-dose, subjects were required to recall the shop-
ping list without being read them again, while the test supervisor clicked / touched 
the appropriate button on the screen with the stylus or mouse. This part of the islt 
task measures long term memory and retrieval (delayed recall). 
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statistical analysis
Statistical analysis was carried out using sas (version 9.1.3). The primary variables 
for pharmacodynamic evaluation were outcome parameters from vas assess-
ments for alertness, CogState battery and tests about other cns functions. The 
secondary variables for safety and tolerability evaluation were adverse events (aes), 
vital signs assessments (blood pressure, heart rate, respiratory rate and [auricular] 
temperature), laboratory parameters, and ecgs. The variables for pharmacokinetic 
evaluation were cmax, tmax, auc0-t, t1/2λz, and cl/f.
The pharmacokinetic analyses were performed by Clinical Pharmacology, 
AstraZeneca Wilmington, de, usa using the WinNonlin program (Pharsight 
Corporation, MountainView, California, usa) and descriptive statistics of the pk 
parameters were summarized by treatment. 
In total, twenty-nine pharmacodynamic (pd) parameters and their change 
from baseline were analyzed by mixed model analyses of variance (using sas proc 
mixed) with treatment, period, time and treatment by time as fixed effects, with 
subject, subject by time and subject by treatment as random effects, and with 
the baseline value as covariate, where baseline was defined as the average of the 
available values obtained prior to dosing. Treatment effects were reported as the 
contrasts of each active treatment vs. placebo, each dose of azd6280 vs. lorazepam, 
as well as azd6280 40 mg vs. azd6280 10 mg. No multiplicity adjustment was used 
for this study. The least square means (lsms) of the measurements up to 8h post-
dose were calculated within the statistical model. Contrasts were reported along 
with 95% confidence intervals. The eeg, body sway, and vas Bowdle subscales were 
analyzed after log-transformation, while the other parameters were analyzed 
without transformation. Log-transformed parameters were back-transformed 
after analysis where the results were interpreted as percentage change.
Adverse events were listed and summarized by system organ class and treat-
ment. Vital sign assessments, parameters of the 12-lead ecg recordings and 
safety laboratories, along with their changes from baseline, were summarized 
using descriptive statistics for each scheduled measurement by treatment. 
Previous studies demonstrated good sensitivity of spv to the effect of bzds 
[13,22] and α2,3 subtype-selective gaba-a agonists [13,14,15,16]. As α2,3 subunits 
are the common pharmacological targets shared by these compounds, spv is 
hypothesized to be a biomarker for gaba-a α2,3 subunit modulation. Moreover, 
early clinical findings with tpa023 [4] also link the pharmacodynamics effect on 
spv to therapeutic anxiolysis. Body sway, tracking, vasalertness, and smooth pursuit, 
on the other hand, are thought to reflect the sedative and adverse properties of 
gaba-ergic compounds. As such, we performed a regression analysis to explore the 
relationship of individual changes from baseline in body sway (∆sway), tracking 
(∆tracking), vas alertness (∆vasalertness), and smooth pursuit (∆smooth), relative 
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to the changes from baseline in spv (∆spv). The slopes of these regression lines are 
thought to reflect the relations between drug-induced anxiolysis and cns-depres-
sion. A mixed effect model was used, where the fixed factors were treatment and 
treatment by spv, whereas the random factors were subject and subject by spv. The 
estimate of the slopes of the regression lines of these ∆spv-relative effect profiles 
were compared between each dose of azd6280 and lorazepam. 
The pharmacodynamic effects (i.e., the changes from baseline) on spv were 
listed with plasma drug concentrations obtained at the same post-dose time 
points with azd6280 and lorazepam, respectively. Based on the effect profile of spv 
(Figure 2), the median effect size was summarized from all negative values, that 
is, the same direction of effect as the maximal effect of lorazepam and azd6280. 
Plasma drug concentrations of azd6280 and lorazepam that correspond to 40% 
to 60% percentile of the overall pd effect size were summarized. The two resultant 
geometric mean concentrations, termed as ‘pharmacodynamically equivalent 
concentrations’ in this case, were used to normalize the actual concentration mea-
surements of each compound. Subsequently, the post-dose pd effect values were 
plotted with the normalized drug concentrations. 
results
subjects
A total of seventeen male healthy volunteers participated in the study. Sixteen 
subjects completed the study. One subject was withdrawn from the study due to 
positive thc result in urine drug screen test on his 2nd treatment period. This drop-
out was replaced by a subject receiving the same order of study treatments. Subjects 
had an average age of 31.7±12.6 years, and bmi of 23.4±2.0 kg/m2. Data from all treat-
ed subjects were used in the analyses of safety and pharmacokinetics. Subjects who 
completed the study per protocol were included in the pharmacodynamic analysis.
pharmacokinetics (pk) 
As demonstrated in Figure 1, both azd6280 10 mg and azd6280 40 mg were rapidly 
absorbed after oral administration with no absorption lag time. The median time 
to maximum plasma-concentrations (tmax) was 1.50 hr (range 0.50 hr-3.23 hr) with 
azd6280 10 mg and 1.38 hr (range 0.50 hr-4.00 hr) with azd6280 40 mg. The mean 
termination half-life (t1/2) was comparable between the two dose levels of azd6280 
(7.10 hr for 40 mg and 6.65 hr for 10 mg) Lorazepam 2 mg had similar tmax (median 
1.50 hr, range 1.00 hr-4.50 hr) but longer t1/2 (mean 12.9 hr, range 8.28 hr-18.4 hr) 
when compared to azd6280. The dose-normalized pk parameters appeared to be 
independent from the dose of azd6280 (see Table 1). 
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pharmacodynamics
Table 2 summarizes the pharmacodynamic (pd) effects of each active treatment 
compared to placebo. vasalertness, was not significantly impaired by either azd6280 
10 mg or azd6280 40 mg compared to placebo (Table 2). However, alertness was 
significantly decreased after lorazepam 2 mg. Sedation caused by lorazepam was 
significantly larger than that of azd6280 10 mg (mean change from baseline: -5.9 
mm vs. -0.8 mm, p=0.0051), but was marginally distinguishable from the effect of 
azd6280 40 mg (-5.9 mm vs. -3.1 mm, p=0.1055). 
Saccadic peak velocity (spv) was significantly reduced by the three active 
treatments (Table 2), respectively, compared to placebo (Figure 2). spv reductions 
differed between lorazepam and azd6280 [estimated difference in spv, p-value] 
(lorazepam vs. azd6280 10 mg: -40.3 deg/sec, p<0.0001; lorazepam vs. azd6280 
40 mg: -12.9 deg/sec, p=0.0367) and were dose-dependent (azd6280 40 mg vs. 
azd6280 10 mg: -27.3 deg/sec, p<0.0001).
Body sway, smooth pursuit, tracking and vas ‘feeling high’ were significantly 
affected by lorazepam 2 mg and azd6280 40 mg, compared to both placebo and 
azd6280 10mg. The effects of lorazepam 2 mg on body sway, smooth pursuit, and 
tracking were significantly larger than those of azd6280 40 mg (Sway: 89.04% 
vs. 21.12%, p<0.0001; Smooth: -10.8% vs. -4.0%, p=0.0003; Tracking: -9.53% vs. 
-2.65%, p<0.0001). vas ‘feeling high’ [estimated difference between two treat-
ments, 95% cis, p-value] was significantly increased by azd6280 40 mg and 
lorazepam 2 mg (Table 2). Although the effect size of azd6280 40 mg was compa-
rable to that of lorazepam 2 mg (0.02 [log(mm)], [0.08, -0.12], p=0.6282), the effect 
lasted considerably shorter with azd6280 40 mg (Figure 3). Moreover, lorazepam 
also significantly distorted internal and external perceptions compared to placebo, 
but the effects of azd6280 did not differ from placebo (Table 2). 
The three active treatments had a different spectrum of pharmaco-eeg effects. 
All frequencies of eeg bands were statistically significantly affected by lorazepam 
2 mg. In comparison, azd6280 40 mg induced lower effects on alpha bands, no 
effect on gamma band, opposite effects on delta band (estimated difference versus 
placebo, 95% confidence interval, p-value: azd6280 40 mg: -6.7% (-12.3%, -0.6%), 
p=0.0325; lorazepam 2 mg: 8.6% (1.9%, 15.8%), p=0.0129) and affected only the 
theta and beta bands in the Fz-Cz (i.e. frontal-central) leads. azd6280 10 mg only 
induced changes in theta and alpha bands and the extent and distribution of these 
effects were similar to those of azd6280 40 mg. 
Results of the CogState early battery are presented in Figure 4. Neither dose 
of azd6280 affected the individual CogState variables, except for the statistically 
significant effect of azd6280 40 mg associated with worse performance on one-
card learning accuracy compared to placebo (azd6280 40 mg vs. placebo: -0.09 vs. 
-0.02, [acr(%)], p=0.0018). However, the effect size of azd6280 was significantly 
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less than that of lorazepam 2 mg (lorazepam vs. placebo: -0.14 vs. -0.02, [acr(%)], 
p<0.0001). Moreover, lorazepam was also associated with extensive impairments 
on the other CogState cognitive parameters compared to placebo (lorazepam vs. 
placebo, [unit], p-value): reaction time of correct responses in the detection task 
(0.12 vs. 0.03, [log(msec)], p<0.0001), reaction time of correct responses in the iden-
tification task (0.08 vs. 0.02, [log(msec)], p<0.0001), moves per second (mps) in the 
chase test (-0.20 vs. 0.03, [mps], p<0.0001), and the sum of errors in gmlt (22.2 vs. 
4.5, p=0.0003). Lorazepam also reduced the number of words recalled in both the 
islt immediate-recall (lorazepam vs. placebo: 25.2 vs. 35.3, p<0.001) and the islt 
delayed-recall (lorazepam vs. placebo: 4.8 vs. 10.1, p<0.001). 
Several cns effects of the different compounds are plotted against their impact 
on spv. The regression analyses for ∆Log(Sway)-∆spv and ∆tracking-∆spv are plot-
ted in Figure 5, in combination with the calculated population regression lines. The 
absolute slopes of the regression lines were significantly smaller for the relations 
of ∆Log(Sway)-∆spv (azd6280 10 mg vs. lorazepam 2 mg: -0.00056 vs. -0.00157, 
p=0.0099; azd6280 40 mg vs. lorazepam 2 mg: -0.00080 vs. -0.00157, p=0.0135), 
∆tracking-∆spv (azd6280 10 mg vs. lorazepam 2 mg: 0.03474 vs. 0.06453, 
p=0.0168; azd6280 40 mg vs. lorazepam 2 mg: 0.03080 vs. 0.06453, p=0.0006), and 
∆smooth-∆spv (azd6280 10 mg vs. lorazepam 2 mg: 0.06146 vs. 0.01083, p=0.0232; 
azd6280 40 mg vs. lorazepam 2 mg: 0.06106 vs. 0.01083, p<0.0001) for either dose 
of azd6280 than for lorazepam 2 mg, but the relations of ∆vasalertness-∆spv are 
comparable between azd6280 and lorazepam.
As is shown in Figure 6, the effect size on spv generally grows with the increase 
of concentration with either azd6280 or lorazepam. The range of effect size is gen-
erally comparable between lorazepam and azd6280 on spv. However, when the 
effect size is higher than 30 deg/sec (i.e. spv reduction > 30 deg/sec), the correspond-
ing range of normalized drug concentration is much larger with azd6280 than that 
with lorazepam. Moreover, lorazepam produces a relatively sharp decline of spv 
with concentration elevation, while the concentration-effect profile of azd6280 is 
less steep. The same concentration-effect profile also applies to the profiles of body 
sway and vas alertness, except that azd6280 had much lower maximal effect on 
the two pd parameters within the observed range of plasma concentrations (Figure 
6). These findings indicate that azd6280 is pharmacologically less potent than 
lorazepam, and that higher concentrations of the new compound are needed to 
reach the same effect as the benzodiazepine. 
safety
The administration of single dose azd6280 10 mg or 40 mg were safe and well 
tolerated in the 17 healthy male subjects. In general, Treatment-emergent aes (fre-
quency [incidence]) occurred more frequently with azd6280 40 mg (25 [75.0%]) 
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than with azd6280 10 mg (7 [43.8%]), but were milder and less frequent than with 
lorazepam 2 mg (39 [93.8%]). The frequency and severity of aes with low dose (10 
mg) azd6280 were comparable to those with placebo (8 [47.1%]). Compared to 
lorazepam 2 mg, azd6280 40 mg (lorazepam vs. azd6280 40mg) caused fewer 
gastrointestinal (2 [12.5%] vs. 1 [6.3%]) and less frequent and less intensive neu-
rological events (particularly indicative of sedation) (14 [87.5%] vs. 11 [68.8%]). No 
clinically significant abnormalities in vital signs, laboratory or ecg results were 
identified during the study.
discussion
The current study compared the cns effects of azd6280, a novel α2,3 subtype-specif-
ic gaba-a receptor modulator intended for anxiolytic use, with those of lorazepam. 
A comprehensive selection of neurophysiological and neuropsychological tests 
was employed to address the pharmacodynamic effects of the two gaba-ergic 
compounds on various brain domains. As a positive control, therapeutic dose of 
lorazepam was designed to benchmark the effect of clinically relevant gaba-a ago-
nism on each pharmacodynamic measure. 
Single doses of azd6280 10 mg, azd6280 40 mg, and lorazepam presented 
distinct pharmacodynamic effect profiles on the central nervous system. These 
effect profiles are likely to result from differences in selectivity and potency of the 
compounds to modulate the subtypes of the gaba-a receptor complex (azd6280 
vs. lorazepam) as well as from differences in exposure levels of the same drug 
(azd6280 10 mg vs. 40 mg). The highest dose of azd6280 in this study caused spv 
reductions that on average were somewhat smaller than those of lorazepam. This 
indicates that the treatments might not be fully equipotent. spv has been suggest-
ed as a pharmacodynamic biomarker for clinical anxiolysis of benzodiazepines 
and novel α2,3-subtype selective gaba-a receptor agonists [4,13,22]. The concen-
tration-effect profiles of lorazepam and azd6280 on spv provide a better approach 
for the evaluation of dose equivalence, because they show the entire range of 
drug plasma levels and effects. Noteworthy, the range of effect size is comparable 
between lorazepam 2 mg and azd6280 40 mg on spv, although fewer individual 
spv measurements reach the level that is regularly attained after lorazepam. Also, 
a larger range of azd6280 concentrations was linked to significant effect on spv (i.e. 
>30 deg/sec spv reduction) compared with lorazepam (Figure 6). These findings 
and the known relevance of spv effect suggest that the anxiolytic effect of peak 
concentrations of azd6280 40 mg may be similar to the effects of lorazepam 2 mg. 
Moreover, the spv effects of azd6280 diminish at relatively high plasma levels, 
which are compatible with partial agonism, with a maximum effect that seems to 
be smaller than with high doses of the full agonist lorazepam. 
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The cns-pd parameters other than spv are linked to various clinical side-effects of 
benzodiazepines, including postural instability, visuo-motor coordination, hyp-
notic effects and cognitive impairments. In Figure 6, the ranges of azd6280 and 
lorazepam concentrations are identical to the concentration-effect plots delineat-
ed for spv; however, larger relative differences are seen in the maximally attainable 
effect on sway between lorazepam and azd6280, versus the difference seen in peak 
spv effects. The smaller maximum effect of azd6280 on body sway indicates less 
impairment of postural stability despite of equal or even higher normalized con-
centrations of the new compound compared to lorazepam. These findings can 
be interpreted by the superior pharmacological selectivity of azd6280 over the 
non-selective gaba-a agonism of lorazepam. 
Moreover, the relations between drug-induced spv reduction and the drug 
effects on these side-effect-related cns-pd parameters were proposed to quanti-
tatively compare the pharmacodynamic selectivity of a gaba-a-ergic drug with 
benzodiazepine, regardless of dose or dose equivalence. In this study, azd6280 
demonstrated relatively flat regression lines in the scatter graphs for body sway, 
tracking or smooth pursuit against spv. The slopes for these regression lines were 
significantly different from those observed after lorazepam. Such a spv-dominant 
effect profile is distinguishable from that of benzodiazepines and is consistent with 
our previous reports regarding other gaba α2,3-selective partial agonists [13]. On 
the other hand, the similar slopes of the regression lines between the two doses of 
azd6280 support that such spv-relative indices are independent from dose or dose 
equivalence. 
In line with their distinct pharmacodynamic profile, lorazepam and azd6280 
differed considerably in their profiles of cns depression. Fewer treatment-emer-
gent adverse events, mostly ‘neurological disorders’ as defined in Meddra-ergic, 
occurred with the highest dose of azd6280 than with lorazepam. Lorazepam 
caused remarkable concentration-dependent response profiles on adaptive track-
ing, body sway, smooth pursuit, visual analogue scales for alertness, ‘feeling high’, 
external and internal perceptions, and various cognitive functions. The effects 
of azd6280 40 mg on these parameters were smaller and often not statistically 
significant. All these findings suggest that lorazepam induces substantial impair-
ments in a wide range of cns domains, but the effects of azd6280 40 mg were less 
extensive. These results are consistent with those reported in previous single-dose 
studies with lorazepam and other α2,3-selective gaba-a partial agonists [14,15,16]. 
Thus the abovementioned pharmacodynamic effect profiles probably reflect the 
characteristics of the entire family of α2,3-selective gaba-a partial agonists, which 
may translate into a reduced propensity to cause sedative side effects. 
azd6280 and lorazepam also showed different effects on the eeg power spec-
trum. The effect of azd6280 40 mg on eeg Delta band was opposite to that of 
lorazepam and may relate to differences in the sedative effects of the compounds. In 
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the eeg bands between 4 Hz and 35 Hz, the eeg responses to azd6280 were general-
ly consistent with but smaller than those to lorazepam. Lorazepam was associated 
with an increase in eeg power in the Gamma band, while the effect of azd6280 was 
negligible with either dose. The similarities of eeg signatures between azd6280 
and lorazepam in the medium frequency bands, as well as those between the two 
doses of azd6280, may reflect common pharmacological properties underlying 
an anxiolytic action. Furthermore, the relatively low effects of azd6280 on the eeg 
parameters may be explained by the partial gaba-a modulation of this new com-
pound, compared with the full agonism of lorazepam. 
In conclusion, the spv responses to azd6280 suggest potential anxiolytic effect 
of the compound, while the absent or smaller effects of azd6280 on subjective 
alertness, visuo-motor coordination, postural balance, psychomotor and cognitive 
functions indicates a more favorable and concentration-related side-effect profile 
compared to that of lorazepam. Overall, the pharmacodynamic profile of azd6280 
is consistent with the specificity and selectivity of this compound at the α2,3 gaba-a 
receptor subtypes. This pharmacodynamic profile, combined with a good toler-
ability profile, support further clinical development of azd6280 as a potential 
fast-onset anxiolytic at doses around 10 to 40 mg.
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Table 1• Mean (sd) of the dose-normalized pharmacokinetic parameters after administration  







Cmax,norm* ng/mL/mg 9.9 (2.4) 8.2 (2.4) nc
auc0-t,norm h·ng/mL/mg 41.0(8.6) 37.9 (10.0) nc
auc0-∞,norm h·ng/mL/mg 46.0 (10.8) 42.2 (11.9) nc
cmax ng/mL/mg 98.5(24.3) 328(97.5) 21.9(4.67)
auc0-t h·ng/mL/mg 397(100) 1515(400) 235(47.8)
auc0-∞ h·ng/mL/mg 444(125) 1686(477) 360(103)
auc1/2 h 7.0(1.2) 6.7(0.9) 13.0(2.6)
cl/f L/hr 24.9(9.55) 25.8(8.09) 5.96(1.56)
nc=not calculated; * ‘norm’ indicates dose-normalized pharmacokinetic parameter
Table 2 • Treatment contrasts as Estimated difference for the pd parameters
Parameters Lorazepam 2mg azd6280 10mg azd6280 40mg
vs. Placebo
spv (deg/sec) -62.9 (-75.2, -50.6) -22.6 (-34.6, -10.6) -50.0 (-62.1, -37.8)
p<0.0001 p=0.0005 p<0.0001
SacInacc (%) 0.7 (0.1, 1.3) -0.4 ( -0.9,0.2) -0.4 (-1.0, 0.2)
p=0.0206 p=0.2191 p=0.1590
Sacrt (sec) 0.029 (0.023, 0.035) 0.003 (-0.003, 0.009) 0.004 (-0.002, 0.010)
p<0.0001 p=0.2964 p=0.1548
Sway (%) 89.0%(62.8%, 119.6%) -1.0%(-14.8%, 15.1%) 21.1%(4.3%, 40.7%)
p<0.0001 p=0.8965 p=0.0134
Smooth (%) -10.8 (-14.2, -7.3) -1.1 ( -4.6, 2.3) -4.0 (-7.5, -0.6)
p<0.0001 p=0.5103 p=0.0238
Tracker (%) -9.53 (-11.9, -7.21) -0.63 (-2.95, 1.69) -2.65 (-4.97, -0.33)
p<0.0001 p=0.5806 p=0.0266
vasalertness (mm) -5.6 (-9.1,-2.1) -0.5 (-3.9, 2.9) -2.7(-6.1, 0.7)
p1=0.0024 p=0.7691 p=0.1178
vascalmness (mm) 2.2(-0.8, 5.3) 1.4 ( -1.6, 4.5) 1.2 (-1.8, 4.3)
p=0.1429 p=0.3402 p=0.4114
vasmood (mm) -0.7 (-2.5, 1.2) 0.5 ( -1.4, 2.4) 0.0 (-1.8, 1.9)
p=0.4733 p=0.5847 p=0.9723
vasexternal log(mm) 0.10 ( 0.05, 0.16) 0.01 (-0.04,0.07) 0.05 (-0.00, 0.10)
p=0.0004 p=0.5931 p=0.0719
vasinternal log(mm) 0.07 ( 0.03, 0.11) 0.01 (-0.02,0.05) 0.01 (-0.03, 0.05)
p=0.0007 p=0.4781 p=0.5087
vashigh log(mm) 0.12 ( 0.02, 0.22) -0.01 (-0.11,0.08) 0.10 ( 0.00, 0.19)
p=0.0168 p=0.7881 p=0.0474
1. The p-value represent the result of statistical comparison between the corresponding active treatment 
(i.e. azd6280 40 mg, azd6280 10 mg, or lorazepam 2 mg) and placebo for each pharmacodynamic parameter
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Figure 1 • Mean (standard error as error bars) concentration-time profiles of azd6280 10 mg, azd6280 
40 mg and lorazepam 
azd6280, a pharmacodynamically selective effect profile in healthy male volunteers | chapter 3
69
304_Connie_Proefschrift_19.indd   69 12-09-17   17:55
Figure 2 • Mean (standard error) profiles of objective pharmacodynamic parameters after the 
treatments of placebo, lorazepam 2 mg, azd6280 10 mg, and azd6280 40 mg 
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Figure 3 • Arithmetic mean (standard error) profiles of subjective pharmacodynamic paramters  
(i.e. visual analogue sub-scales) after the treatments of placebo, lorazepam 2 mg, azd6280 10 mg, 
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Figure 4 • Means (standard error) profiles of CogState parameters after the treatments of placebo, 
lorazepam 2 mg, azd6280 10 mg, and azd6280 40 mg 
islt=International Shopping List Task; ** represent ‘p<0.001’ compared to the placebo arm. 
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Figure 5 • The ∆log(Sway)-∆spv, ∆vasalertness-∆spv, ∆track-∆spv, ∆smooth-∆spv relations  
of azd6280 10 mg and 40 mg vs. lorazepam 2 mg. 
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Figure 6 • Normalized concentration-effect profiles of lorazepam and azd6280 on saccadic peak 
velocity (spv), body sway (sway), and adaptive tracking (track)
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abstract
ns11821 is a partial gaba-a agonist with relatively dominant α2,3 and α5 subtype 
efficacy but negligible α1 agonism. This first-in-human study was performed in 
healthy male subjects using a single-dose, parallel, double blind, placebo-con-
trolled, randomized, dose-escalation study design. In total six cohorts (n=48) were 
enrolled. The eight subjects of each cohort received ns11821 (10 mg, 30 mg, 75 mg, 
150 mg, 300 mg or 600 mg) or placebo in a 6:2 ratio. At low dose levels, ns11821 
had a relatively low exposure and a more-than-proportional increase of auc and 
cmax, probably due to poor solubility. Saccadic peak velocity (spv) decreased in a 
dose-related manner while limited impairments were seen on body sway and the 
visual analogue scale (vas) for alertness. The most common adverse events were 
somnolence and dizziness, which were more prominent with the higher doses. 
Although no positive control was used in this study, the results were compared 
post hoc to a chdr dataset for lorazepam 2 mg. The maximum spv effects seemed 
comparable to the typical effects lorazepam, whereas the other cns effects were 
smaller. These results support the pharmacological selectivity of ns11821 and show 
that pharmacodynamic effective doses of ns11821 were safe and well tolerated in 
healthy subjects.
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introduction 
Benzodiazepines (bzds) are one of the most commonly prescribed anxiolytic drugs, 
although therapeutic guidelines generally limit their use to several weeks. The 
use of bzds is restricted by tolerance and dependence, as well as concomitant psy-
chomotor impairments. In general, the effect profile of bzds is attributed to their 
non-selective agonism at the α1, α2, α3, and α5 subunit-containing gaba-a receptors. 
Preclinical studies have linked these subtypes to different pharmacological aspects 
of bzds: 1) α1-containing receptors are associated with sedative and motor effects 
(McKernan et al., 2000; Rowlett et al., 2005); 2) α2- and α3-containing receptors are 
related to anxiolysis and analgesia (Knabl et al., 2008; Knabl et al., 2009); and 3) 
α5-containing receptors are involved in amnesic effects (Atack et al., 2006; Ballard 
et al., 2009). In order to minimize the untoward depressive effects on the central 
nervous system (cns), several novel α2,3-subtype selective gabaergic compounds 
are being developed in preclinical and clinical phases and they are expected to 
deliver anxiolytic effects with less adverse effects.
According to the in vitro two-electrode voltage-clamp electrophysiological 
assessments performed on receptors expressed in oocytes, although the in vitro 
binding affinity is generally comparable (Ki [nM] = 1.6, 9.7, 3.8, 2.5 for α1, α2, α3 and 
α5 subunits, respectively, for different human gaba-a receptor subtypes expressed 
in hek cells), ns11821 has relatively higher maximum efficacy for gaba-a α2, α3 and 
α5 over gaba-a α1 receptors: compared to diazepam, ns11821 showed 17%, 40% and 
41% relative efficacy at the α2, α3 and α5 subunits, but 4% relative efficacy for the α1 
subunit, respectively (Neurosearch data on file). The ec50 of ns11821 was 59, 73 and 
44 nM for the in vitro pharmacological effects on human gaba-a α2ß2γ2s, α3ß2γ2s 
and α5ß2γ2s receptors, respectively. (Neurosearch data on file). Such a profile is 
translated to low propensity for sedative effects with retained anxiolytic activity: 
in both the rat conditioned emotional response (cer) test and the plus-maze task 
(Davis, 1990; Rodgers and Dalvi, 1997), ns11821 dose dependently reduced anxi-
ety-like behavior with a minimum effective dose (med) of 3 mg/kg, corresponding 
to a human equivalent dose (hed) of 29 mg. On the other hand, ns11821 was found 
to increase exploratory motility at doses between 3-30 mg/kg in mice, but signifi-
cantly reduce motor activity in rats at doses higher than 30 mg/kg. In the rotarod 
test, ns11821 had no significant effect on rotarod performance in rats up to 100 mg/
kg. In contrast, diazepam significantly reduced exploratory motility and rotarod 
performance at doses≤ 3 mg/kg. In addition, the passive avoidance memory test 
in mice has been shown sensitive to bzd-induced anterograde amnesia when 
the drug was administered prior to the learning session. Compared with a single 
dose of chlordiazepoxide, ns11821 demonstrated little effect on memory in mice 
with doses from 10 to 100 mg/kg, while chlodiazepoxide did impaire memory as 
measured by the test. With regard to safety, the no-observed adverse-effect level 
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(noael) in rats was 10 mg/kg after repeat doses, corresponding to a hed of 1.61 mg/
kg (97 mg) (Neurosearch data on file). Taken together, the above findings inferred 
potential anxiolytic effect of ns11821, with reduced sedative and memory-impair-
ing effects at its pharmacolocally active doses. 
Using the Food and Drug Administration guidelines for first-in-man studies, a 
starting dose of ns11821 10 mg was selected. In this study, ns11821 was orally admin-
istrated to healthy male volunteers in six single ascending doses (10 mg, 30 mg, 75 
mg, 150 mg, 300 mg and 600 mg) and compared to placebo. The objective was to 
evaluate the safety, tolerability and pharmacokinetic (pk) profile of the compound 
as well as to estimate the maximum tolerable dose. The study included a validated 
battery of cns measurements, including saccadic eye movement, smooth pursuit, 
body sway, adaptive tracking, tapping, visual analogue scales (vas) and memory 
tests, to evaluate the pharmacodynamic (pd) profile of ns11821. In previous stud-
ies conducted in healthy volunteers, bzds have demonstrated robust effects on 
vas-alertness, postural stability, memory and neurophysiological functions. These 
diverse effects across a wide range of different cns-regions are thought to account 
for the widespread distribution of gaba-a receptors throughout the brain, and the 
non-selective, full agonism of bzds on these receptors. 
Out of the many tests used to evaluate the cns effects of bzds, saccadic peak 
velocity (spv) and the visual analogue scale (vas) for alertness were identified as 
the most sensitive parameters for bzds (de Visser et al., 2003). Both tests showed 
consistent effects to various bzds at different doses. Studies with different α2,3 
subtype selective gaba-a agonists suggest that impairments of subjective alert-
ness and body sway have been primarily attributed to α1 stimulation, reduction of 
spv seems related to mainly reflect α2-3 stimulation (Chen et al., 2012), and mem-
ory effects could be related to α5 stimulation (Collinson et al., 2002). As a result, 
we employed this battery to measure the pharmacodynamic effects of ns11821 in 
healthy volunteers. In addition, a post hoc comparison was performed with a historic 
data set based on a considerable number of similar studies conducted at chdr with 
a therapeutic dose of the full benzodiazepine lorazepam.
methods
design
This was a single-dose, parallel, double blind, placebo-controlled, randomized, 
dose escalation study in healthy male subjects. There were 8 subjects per dose 
cohort. Decisions for dose escalation were based on investigator blinded interim 
assessments of pk, pd and safety results.
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subjects
Forty eight healthy male volunteers were recruited from the Centre for Human 
Drug Research (chdr) database. All volunteers gave written informed consent and 
were medically screened before entry into the study. Subjects were not allowed to 
smoke more than five cigarettes per day and had to refrain from smoking during 
the study days. In the 48 hours prior to the study days they were asked not to drink 
alcohol and to avoid xanthine- containing drinks until the end of the study days. 
The use of medication was not allowed during the study period (except occasion-
al use of paracetamol, up to 1.5 g per day). The study was approved by the Medical 
Ethics Review Board of Leiden University medical Centre, the Netherlands.
treatments
A total of six study cohorts (n=48) received capsules containing 10 mg, 30 mg, 75 
mg, 150 mg, 300 mg and 600 mg ns11821 or placebo with 250 mL of water. In each 
cohort, six subjects were randomized to receive a single dose of ns11821 and two 
subjects received placebo. A standard lunch was served 2 hr post-dose together 
with approximately 200 mL water.
safety
Adverse events, electrocardiogram (ecg), blood pressure and heart rate measure-
ments were collected throughout the study. Twelve lead ecg recordings were made 
using Electrocardiograph Marquette 5000/5500 (usa). Continuous real time telem-
etry (1 lead ecg) and pulse oxymetry were performed with ge Marquette (usa) and 
dash 4000 (usa) respectively. Blood pressure and heart rate were assessed using a 
Nihon Kohden bsm 1101K monitor (Japan) or a Dash 4000 (usa). All ecg, blood pres-
sure and heart rate measurements were made after the subject had been resting in 
a supine position for at least 5 minutes. In addition, for the evaluation of orthostatic 
blood pressure and heart rate, subjects were required to stand for 3 minutes prior to 
a second assessment.
pharmacokinetics
Whole blood samples and urine samples were taken for assay of the parent drug 
ns11821 and its metabolite ns14606. Blood samples were taken 1 hour pre-dose and 
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 22, 34 and 48 hours post-dose. The blood was 
drawn in 10 mL K2 edta tubes and then centrifuged (2000 G, 10 minutes, at 2-8° 
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C), transferred to 3.5 mL Sarsted tubes and stored at -80º C within 30 minutes after 
sampling. All urine voids were collected throughout the study days and combined 
in intervals: last 2 hours pre-dose, first 10 hours post-dose, 10-12 hours post-dose 
and 12-22 hours post-dose. Two 6 ml samples (duplicate) from each time interval 
were stored at -40° C. Analysis of the blood and urine samples was performed at pra 
International (Assen, the Netherlands), using lc ms/ms and validated bio analytical 
methods. The lower limit of quantification (lloq) for plasma ns11821 and ns14606 
was set to 0.1 ng/mL. 
pharmacodynamics
All subjects were trained to be familiarized with the psychometric tests during the 
screening sessions to minimize learning effects preceding the study. During the 
treatment period, pharmacodynamic measurements were performed twice pre-
dose and 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours post-dose. The cns tests were performed 
in a quiet room with subdued illumination with only one subject in the same room 
per session. Each session consisted of the following sequence of tests: saccadic eye 
movements; smooth pursuit; pharmaco-eeg, body sway with eyes closed; vas Bond 
and Lader; vas Bowdle; adaptive tracking and tapping. Cognitive function tests 
were performed at 2 and 6 h post-dose. 
saccadic eye movement
Measurements of saccadic eye movements were recorded as previously described 
(de Haas et al., 2008; de Haas et al., 2009). Average values of saccadic peak velocity 
(spv), latency (= reaction time) and inaccuracy were calculated for all artefact free 
saccades. spv is closely related to their anxiolytic properties (de Visser et al., 2003) 
and its measurement has been validated as the most sensitive biomarker for the 
effects of bzds (de Visser et al., 2003; van Steveninck et al., 1991; van Steveninck et 
al., 1992; van Steveninck et al., 1999).
smooth pursuit
Smooth pursuit was measured as previously described (de Haas et al., 2009). The 
time in which the eyes were in smooth pursuit of the target was calculated for each 
frequency and expressed as a percentage of stimulus duration. The average per-
centage of smooth pursuit for all stimulus frequencies was the target parameter.
body sway
Two minute body sway measurements were performed as previously described (de 
Haas et al., 2009). Body sway is a measure of postural stability that has previously 
been shown to be sensitive to bzds (van Steveninck et al., 1996).
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visual analogue scale
The visual analogue scales (vas) in this study were used as previously described by 
Norris (Norris, 1971). The Bond and Lader vas was performed to measure subjective 
alertness, mood and calmness (de Haas et al., 2009). The Bowdle vas evaluates psy-
chedelic effects clustered into three distinct total sum scores: internal perception 
(reflects inner feelings that do not correspond with reality, including mistrustful 
feelings), external perception (reflects a misperception of an external stimulus or a 
change in the awareness of the subject’s surroundings) and feeling high (Zuurman 
et al., 2008). 
adaptive tracking
The adaptive tracking test will be performed as originally described by Borland and 
Nicholson (Borland and Nicholson, 1975; Van Steveninck al, 1993), using custom-
ised equipment and software (based on Trackerusb hard-/software (Hobbs, 2004, 
Hertfordshire, uk)). The average performance and the standard deviation of scores 
over a 3.5-minute period will be used for analysis. This 3.5-minute period is includ-
ing a run in time of 0.5 minute, in this run in time the data is not recorded. Adaptive 
tracking is a pursuit-tracking task. A circle moves randomly about a screen. The sub-
ject must try to keep a dot inside the moving circle by operating a joystick. If this 
effort is successful, the speed of the moving circle increases. Conversely, the velocity 
is reduced if the test subject cannot maintain the dot inside the circle.
tapping
The test has been adapted from the Halstead Reitan Test Battery (Andrew, 1977), 
and evaluates motor activation and fluency. The volunteer is instructed to tap as 
quickly as possible with the index finger and to rest the wrist on the table. The space 
bar is used as tapping device and each session contains five performances of 10 sec-
onds. The mean tapping rate and the standard deviations for the dominant hand 
are used for statistical analysis.
pharmaco-eeg
Pharmacoelectroencephalography (pharmaco-eeg) recordings were performed as 
previously described (de Haas et al., 2010). eeg recordings were made at Fz, Cz, Pz 
and Oz. For each lead, fast Fourier transform analysis was performed to obtain the 
sum of amplitudes in the delta, theta, alpha and beta frequency ranges. The dura-
tion of eeg measurements was 64 s per session. Change in amplitudes in the beta 
frequency band of the eeg is found to be a relevant measure of the pharmacological 
effect intensity of bzds (Mandema et al., 1992).
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visual verbal learning tests (vvlt)
Short term and long term memory was similarly tested as recently described in 
another publication (de Haas et al., 2009). The 30 word memory learning test 
was performed at 2 h post-dose with ‘Immediate Recall’ immediately hereafter. 
Approximately 4 h after start of the Immediate Recall test, ‘Delayed Recall’ was per-
formed and followed by the ‘Delayed Recognition’.
statistical analysis
pharmacokinetics
The plasma pk parameter estimates were calculated in WinNonlin Version 5.2 
(Pharsight Corporation, usa) using non compartmental analysis of the individual 
plasma concentrations of ns11821 and ns14606. The area under the curve (auc) 
was calculated using the linear trapezoidal method. Terminal rate constants were 
estimated by fitting a linear regression of log concentration against time. Other 
parameters determined were: maximum plasma concentrations (cmax), time to 
maximum plasma concentration (tmax) and elimination half-life (t1/2).
pharmacodynamics
The pd parameters were analyzed by mixed model analyses of covariance (ancova) 
with treatment, time and treatment by time as fixed effects, with subject as ran-
dom effect, and with the baseline value as covariate, where baseline was defined 
as the average of the available values obtained prior to dosing. The six ns11821 
treatments (10 mg, 30 mg, 75 mg, 150 mg, 300 mg and 600 mg) were compared to 
placebo and used as contrasts within the ancova model. The cognitive function 
test resulted in single measured pharmacodynamic data for which the fixed fac-
tor treatment anova model was used. All variables were analyzed untransformed 
except for body sway and eeg results, which were log transformed prior to analysis 
to correct for the expected log normal distribution. Treatment effects were report-
ed as contrasts where the average of the measurements up to last time point, were 
calculated within the statistical model. Contrasts were reported along with 95% 
confidence intervals (cis) and analyses were two sided with a significance level of 
0.05. All calculations were performed using sas for windows V9.1.2 (sas Institute, 
Inc., Cary, nc, usa).
Pre-study power calculation based on previous studies conducted at chdr (de 
Haas et al., 2007; de Haas et al., 2008; de Haas et al., 2009) with lorazepam 2 mg, 
revealed that 6 subjects in each group, should provide 80% power, to detect a reduc-
tion in spv of at least 50.3 degrees per second after active treatment compared to 
placebo, assuming a common standard deviation of 15.0 degrees per second using 
a two group t-test with a 5% two sided significance level. Similarly, seven subjects 
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in each group should provide an 80% power to detect a difference of -11.2 mm in 
vas-alertness assuming that the common standard deviation is 6.5 mm using a two 
group t-test with a two-sided significance level of 5%.
post hoc comparison with historic lorazepam data set
No active control, e.g. benzodiazepine, was used in this first in man study for 
ns11821. Such a control might have complicated the blinded effect assessments 
and decisions on dose escalations. Recently, we reported a comparative study of 
several different subtype selective gaba-a partial agonists with lorazepam, which 
had been used as a positive control in a number of trials that basically employed 
the same methods that were also used in this first-in-man study of ns11821 (Chen 
et al., 2012). The combined lorazepam data from this historic data set were used 
for a post hoc comparison of the pharmacodynamic effects of ns11821 with those of 
lorazepam.
In the post hoc analysis the relationship of individual changes from baseline 
against the change from baseline of spv (∆spv) was done for: body sway (∆sway), 
tracking (∆tracking), vas-alertness (∆vas-alertness), and smooth pursuit (∆smooth). 
These data were then compared to the profile from a full, non-selective gaba-a ago-
nist (Lorazepam 2 mg). The slopes of these regression lines are thought to reflect the 
relation between the effect profile of anxiolysis and sedation (Chen et al., 2012). A 
mixed effect model was used, where the fixed factors were treatment and treatment 
by spv, whereas the random factors were subject slope and intercept. The estimate of 
the slopes of the regression lines of these ∆spv-relative effect profiles were compared 
between three high doses of ns11821 (150 mg, 300 mg, 600 mg) and lorazepam.
results
subjects 
Sixty seven male volunteers were medically screened after given written informed 
consent and forty eight were randomized. None of these subjects dropped out of 
the study; all randomized subjects completed all study days and had a follow up 
visit. On average (min-max) subjects were 23 (18-41) years old with a weight of 75 
(57-101) kg, and a body mass index of 22.9 (18.1-29.7) kg/m2. The mean body mea-
sures were generally comparable among the seven treatment groups, Table 1.
clinical observations / safety
All forty-eight subjects were included in the safety analysis. No serious adverse 
events occurred during the study. Neither did subjects withdraw from the study 
due to adverse events. No clinically significant changes in vital signs or ecg 
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characteristics were noted for any of the ns11821-treated groups. The highest dose 
of ns11821 (600 mg) caused the most gastrointestinal and neurological events, with 
≥50% subjects experiencing nausea, vomiting, fatigue, dizziness, and/or somno-
lence. The incidences of these aes were higher than those reported in the placebo 
group and were all judged ‘probably’ treatment-related by the investigator. None of 
the aes required medical intervention. Except for two aes occurring in one subject 
dosed with ns11821 600 mg, all aes were classified mild in intensity. This subject 
suffered from moderate dysphagia, nausea and subsequent vomiting, while trying 
to swallow the study medication (twelve capsules). 
pharmacokinetics
One subject in the 600 mg ns11821 dose group vomited shortly after taking the 
study medication and the pharmacokinetic data from this subject were exclud-
ed from the pk analysis. Figure 1 depicts the average plasma concentration-time 
curves for ns11821 and its metabolite ns14606 for all 6 doses. Table 2 summarizes 
the pharmacokinetic parameters of ns11821 and ns14606 by dose. The absorption 
time was dose dependent; tmax increase from 0.5 to 4.0 hr following doses of 10 
to 600 mg. A more than proportional increase in exposure was seen; aucinf/dose 
increase with a factor 10 from 0.9 at 10 mg to 9.7 at 600 mg. There was considerable 
variability between subjects was seen for all the pharmacokinetic parameters. 
pharmacodynamics
A total of three subjects, who were administered with ns11821 600 mg, vomited 
post-dose during performance of the pd tests. Their pharmacodynamics data were 
excluded from the pd datasets before the statistical analysis. 
Compared to placebo, ns11821 600 mg elicited statistically significant effects 
on a variety of pharmacodynamic parameters, Table 3. At a dose level of 150 mg 
ns11821 affected eeg ß-band power of the frontal-central leads statistically sig-
nificantly, a trend was seen at lower doses. ns11821 300 mg was associated with 
significant effects on spv, tracking, and eeg ß-band power of the frontal-central 
leads and the parietal-occipital leads. ns11821 300 mg also reduced the frequency 
of tapping, with an effect size similar to ns11821 600 mg. No significant effects were 
observed on body sway or smooth pursuit with any dose of ns11821. 
The effects of lorazepam 2 mg are also presented in Figure 2. These results were 
based on historic data for a number of studies with gaba-a subtype selective par-
tial agonists, in which lorazepam 2 mg was used as a positive control (Xia-Chen et 
al. 2012). Effects of 2 mg lorazepam on spv appear to be in line with the effects of 
higher doses of ns11821 (300-600 mg). Apart from the effect of 600 mg ns11821 on 
vas-alertness, lorazepam effects on body sway and vas-alertness clearly distinct 
from the effects observed from ns11821. 
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In addition to the above mentioned psychomotor effects, ns11821 reduced the 
response accuracy of immediate recall in a dose-dependent manner (600 mg: -7.2 
words [-10.7; -3.7], p=0.0001; 300 mg: -3.0 [-5.7, -0.3], p=0.0305). Doses of 75-600 mg 
ns11821 decreased the number of delayed recalled words in a dose dependent man-
ner without reaching statistical significance, while 75 and 300 mg of ns11821 impaired 
delayed recognition statistically significantly; 75mg: -5.6 [-9.7,-1.4], p=0.0095 and 
300mg -5.2 [-9.4,-1.1], p=0.0143; respectively (Figure 1, Panel D). A historic com-
parison between the memory effects of lorazepam 2 mg and ns11821 300 mg and 
600 mg was made with a previous study that used the same word memory test 
(De Haas et al. 2009). This analysis suggests that the average percentage decrease 
relative to placebo is in the same order of magnitude among lorazepam 2 mg, 
ns11821 300 mg and 600 mg, for immediate recall (-61%, -78% and -48%, resp.), de- 
layed recall (-46%,-67% and -48%) and delayed recognition (-76%,-79% and -82%).
discussion
This study investigated the pharmacokinetic, pharmacodynamics as well as safe-
ty and tolerability profiles of ns11821 after single oral doses. As a novel subtype 
selective gaba-a agonist, ns11821 was administered from a lower-than-med dose 
to a dose 6 times higher than its human equivalent dose of the noael with a dose 
escalation factor between 2 and 3. 
The systemic exposure of ns11821 (auc and cmax) increased approximately 
by a factor 10 following administration of 10 to 600 mg, a considerable variability 
between subjects was seen, Coefficient of Variation (cv) for the auc and cmax was 
more than 30%. The half-life increased with increasing dose levels. In addition, the 
time to maximum plasma concentration was dose dependent and increased with 
increasing dose levels. This complex absorption profile may be due to low solubility 
properties of the compound in gastric fluid.
ns14606, the hydroxyl metabolite of ns11821, accounts for 30-50% of the par-
ent compound. The ratios of active metabolite to parent compound are generally 
similar among the six doses. As is shown in Figure 1, the plasma concentration of 
ns11821 and ns14606 underwent multi-phase declines after tmax. Taken together, 
all these factors contribute to the complex non-linear pharmacokinetic profile of 
ns11821/ns14606 pharmacokinetics. Future studies of ns11821 should explore addi-
tional formulations, as for example acidic solutions of ns11821 to investigate how 
solubility affects the bioavailability of ns11821. 
The study did not show clear pharmacodynamic effects with the lower doses 
of ns11821 (i.e. 10 mg, 30 mg, and 75 mg). However, single doses of ns11821 150 mg 
and higher caused statistically significant effects on several pharmacodynamic 
parameters in a dose dependent manner. ns11821 600 mg demonstrated the most 
extensive and robust effects, with impairments on spv, vas-alertness, and adaptive 
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tracking, as well as increase on vas internal, vas feeling high and the spectrum 
power of eeg beta bands. However, this high dose required the administration of 
a large number of tablets, which was associated with nausea and vomiting in a 
substantial proportion of subjects. Consequently, the results were affected by low 
numbers of observations, and by adverse events. ns11821 300 mg showed smaller 
effects on spv and adaptive tracking and did not differ from placebo on vas internal 
perception or vas-alertness. Studies with other gaba-a subtype selective partial 
agonists have suggested that effects on vas-alertness and adaptive tracking are 
closely linked to gaba-a α1 subunit modulation (de Haas et al., 2010, Chen et al., 
2014, Chen et al., 2015), whereas spv is primarily sensitive to drug effects on the 
gaba-a α2,3 subunits (Chen et al., 2012). ns11821 300 mg and ns11821 600 mg are 
both effective on spv, indicating potential anxiolysis of the two doses. 
gaba-a α5-agonism is considered to be associated with the memory-impairing 
effects of lorazepam (Chen et al., 2014, Chen et al., 2015). ns11821 has comparable 
effect potency at the gaba-a α5-subunit and the gaba-a α2,3 subunits. This could 
cause memory deficits with clinically anxiolytic doses of ns11821. This seems to be 
corroborated by a historic comparison with lorazepam 2 mg, which suggests that 
the two highest doses cause roughly similar memory deficits. However, the memo-
ry effects need to be interpreted with caution. In particular, dose-relatedness wasn’t 
always very consistent. For instance, two doses (i.e. 75 mg and 300 mg) of ns11821 were 
linked to considerable reduction in delay word recall compared to placebo. The study 
also showed similar average responses between ns11821 10 mg and ns11821 300 mg 
in immediate recall, and demonstrated comparable responses among ns11821 10 
mg, 150 mg and placebo in delay recall (Figure 2, Panel D). These findings support 
the contribution of inter-subject variation to the observation of inter-treatment 
differences in this parallel-group study. Consequently, quantitative conclusions 
about memory effects of ns11821 are currently not warranted, and more dedicat-
ed studies with larger sample size are needed to further investigate these effects. 
        One limitation of this study is the lack of positive control to confirm the sen-
sitivity of the pharmacodynamic measurements and benchmark the effect size of 
ns11821 at different doses. To compensate this deficiency, we calculated the sample 
size on a power level of 80% based on previous studies with benzodiazepines (Chen 
et al., 2012, Chen et al., 2014, Chen et al., 2015) and compared the results of this 
study with those studies in the statistical analysis. Figure 3 provide further infor-
mation regarding the ∆spv-relative pharmacodynamic profiles. The three high 
doses of ns11821 (150 mg, 300 mg, 600 mg) showed similar flatness in the ∆spv-
Δlog(Sway) relation, the ∆spv-∆vas-alertness relation, and the ∆spv-∆smooth 
relation. A certain reduction of spv is accompanied with smaller change of body 
sway, vas-alertness or smooth pursuit, compared to the ∆spv-relative responses 
of these pd parameters after lorazepam 2 mg. For the relation between ∆spv and 
∆tracking, the slope of the regression line is marginally smaller with ns11821 300 
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mg versus lorazepam, but comparable between either 150 or 600 mg and lora-
zepam (Table 4). Normalized by the effect size on spv, the ∆pd-∆spv relations 
compare the anxiolytic potency of a treatment versus its effect potency on one of 
other cns regions. Based on the ∆pd-∆spv profiles of ns11821 at different doses, 
ns11821 300 mg showed the most prominent spv effect against the other cns-pd 
effects. As such, ns11821 300 mg is thought to be an effective anxiolytic dose with 
minimal off-target cns-effects. With ns11821 150 mg, the compound only had mar-
ginal effect on saccadic peak velocity, and adaptive tracking performance was even 
better than during placebo at some time points. These observations may provide 
some explanation for the lack of significant difference between ns11821 150 mg and 
lorazepam 2 mg. When subjects are dosed with ns11821 300 mg, both α1-contain-
ing receptors and α2,3,5-containing receptors are modulated, but pharmacological 
selectivity is preserved, causing minimal effects on body sway and vas-alertness. 
Such spv-relative pharmacodynamic effect profiles are distinct from those of a 
non-selective partial gaba-a agonist, where the slopes of the ∆pd-∆spv regression 
lines are theoretically comparable between the partial agonist and the full agonist. 
The effects of ns11821 600 mg seemed non-selective. These observations should be 
interpreted carefully since the occurrence of nausea and vomiting may have inter-
fered with the pharmacodynamic measurements.
In conclusion, the effects of ns11821 on the pharmacodynamic biomarkers indi-
cate entry of the compound into the central nervous system and a concentration 
dependent effect profile. The dose related effect of ns11821 on spv suggests poten-
tial anxiolytic effect; while the minimal effects of ns11821 150 mg, 300 mg and 600 
mg on subjective alertness, postural balance, psychomotor and cognitive functions 
imply reduced side effects of this compound. Pharmacological subtype selectivity 
is further confirmed by the response relation of various cns pharmacodynamic 
biomarkers versus spv as compared to lorazepam 2 mg. The absence of pharma-
codynamic effect and the placebo-like ae profile seen with ns11821 10 mg, 30 mg, 
and 75 mg may be caused by low exposure of this compound. Single oral doses of 
ns11821 10-600 mg were safe and well tolerated in the healthy male participants of 
this study. Modifying the formulations of ns11821 may result better bioavailability 
and dose-proportionality. 
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Table 1 • Summary of subject characteristics
Cohort n Age (yrs)* bmi (kg/m^2)* Height (m)* Weight (kg)*
Placebo 12 21.8 (18-29) 22.1 (18.1-28.1) 1.81 (1.72-1.93) 72.7 (59.2-88.2)
1: 10 mg ns11821 6 25.2 (20-41) 23.8 (21.5-28.7) 1.83 (1.78-1.88) 79.7 (68.6-101.4)
2: 30 mg ns11821 6 26.2 (19-39) 24.3 (21.1-29.7) 1.78 (1.71-1.85) 77.6 (61.7-98.1)
3: 75 mg ns11821 6 22.5 (18 -31) 22.9 (20.6-25.2) 1.80 (1.67 -1.89) 74.5 (57.5-89.0)
4:150 mg ns11821 6 20.0 (19-22) 23.3 (20.8-25.5) 1.81 (1.76-1.87) 76.2 (68.4-89.2)
5:300 mg ns11821 6 20.3 (18-24) 23.0 (19.6-25.6) 1.83 (1.73-1.90) 76.5 (65.0-87.5)
6:600 mg ns11821 6 22.7 (18-26) 22.1 (19.2-24.9) 1.84 (1.77-1.92) 74.5 (64.5-83.0)
*mean (min-max)
Table 2 • Summary of pharmacokinetic parameters of ns11821
















1: 10 mg 0.50 9.37 53 0.94 0.62 8.98 23 0.90 0.39 -
2: 30 mg 1.0 22.8 59 0.76 0.95 38.8 44 1.3 0.32 0.021
3: 75 mg 0.99 77.2 147 1.0 1.9 110 77 1.5 0.42 0.021
4:150 mg 0.75 236 111 1.6 3.2 419 90 2.8 0.31 0.0067
5:300 mg 2.5 477 49 1.6 5.0 1440 50 4.8 0.44 0.0061
6:600 mg 4.0 1430 83 2.4 4.4 5790 93 9.7 0.49 0.0046
For cmax, auc, clr the geometric mean values are presented, for tmax the median and for all other parameters 
the mean value is presented; * The half-life of the elimination phases; m/p ratio = aucns14606/aucns11821
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Table 4 • Results of the linear model for Saccadic Peak Velocity change from baseline and other 
pharmacodynamic parameter change from baseline by treatment 
Relation Slope of ns11821 ns11821 vs. Lorazepam P-value
ΔSmooth/Δspv
ns11821 150 mg 0.01118 -0.09867 0.0449
ns11821 300 mg 0.02222 -0.08764 0.0680
ns11821 600 mg 0.03822 -0.07164 0.1321
ΔSway/Δspv
ns11821 150 mg -0.00084 0.00221 0.0276
ns11821 300 mg 0.000347 0.0034 0.0004
ns11821 600 mg -0.00053 0.002525 0.0077
Δvas-alertness/Δspv
ns11821 150 mg 0.03906 -0.08692 0.1285
ns11821 300 mg -0.01465 -0.14062 0.0108
ns11821 600 mg 0.00655 -0.11942 0.0279
ΔTracking/Δspv
ns11821 150 mg 0.04592 -0.01128 0.6112
ns11821 300 mg 0.01835 -0.03885 0.0681
ns11821 600 mg 0.04672 -0.01049 0.6112
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Figure 1 • Mean (sd) drug concentrations profile of ns11821 (panel A) and ns14606 (panel B)  
following oral administration of 10-600 mg ns11821 (logarithmic scale).
304_Connie_Proefschrift_19.indd   92 12-09-17   17:55
Figure 2 • Pharmacodynamic profile for ns11821 with additional historic lorazepam 2 mg data 
for: saccadic peak velocity (panel a), body sway (panel b), vasalertness (panel c), and visual 
verbal learning test (panel d) (the y-axis presents the lsms change from baseline profile with 
95% ci error bars)
* p < 0.05 and # p = 0.001: comparing ns11821 to placebo. imr=Immediate Recall, dr= Delayed Recall  
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Figure 3. ∆pd-∆spv relative effect profile of ns11821 150 mg, ns11821 300 mg, and ns11821 600 mg 
vs. lorazepam 2 mg, respectively. 
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abstract
Various α2,3 subtype selective partial gaba-a agonists are in development to treat 
anxiety disorders. These compounds are expected to be anxiolytic with fewer 
undesirable side effects, compared to nonselective gaba-a agonists like benzo-
diazepines. Several α2,3 subtype selective and nonselective gaba-a agonists have 
been examined in healthy volunteers, using a battery addressing different brain 
domains. Data from five placebo-controlled double-blind studies were pooled. 
Lorazepam 2mg was the comparator in three studies. Three α2,3-selective gabaa 
agonists (i.e., tpa023, tpacmp2, sl65.1498), one α1-selective gabaa agonists (zol-
pidem), and another full agonist (alprazolam) were examined. Pharmacological 
selectivity was assessed by determination of regressionlines for the change from 
baseline of saccadic-peak-velocity-(∆spv-)relative effect,relative to changes in dif-
ferent pharmacodynamic endpoints (∆pd). spv was chosen for its sensitivity to the 
anxiolysis of benzodiazepines. Slopes of the ∆spv-∆pd relations were consistently 
lower with the α2,3 selective gaba-a agonists than with lorazepam, indicating that 
their pd effects are less than their spv-effects. The ∆spv-∆pd relations of lorazepam 
were comparable to alprazolam. Zolpidem showed relatively higher impairments 
in ∆pd relative to ∆spv, but did not significantly differ from lorazepam. These pd 
results support the pharmacological selectivity of the α2,3-selective gaba-a ago-
nists, implying an improved therapeutic window.
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introduction
Anxiety is a psychological and physiological state with somatic, emotional, cognitive, and 
behavioral components [1], which dominates thinking and leads to disturbance of 
daily functioning. Serotonergic antidepressants, either selective serotonin reuptake 
inhibitors (ssris) or serotonin-norepinephrine reuptake inhibitors (snris), are cur-
rently prescribed as the 1st-line treatment for several anxiety disorders. However, 
the slow onset of therapeutic effect and the presence of sexual side-effects prevent 
these drugs from more extensive use and lead to lack of treatment compliance [2]. 
Moreover, ssris/snris cause transient increase of anxiety during the first few weeks 
of administration. All these clinical experiences provide space for the use of benzo-
diazepines (bzds) in acute anxiety episodes. 
Benzodiazepines are the most commonly prescribed anxiolytic drugs, although 
treatment guidelines generally limit their use to several weeks to prevent the 
occurrence of tolerance and dependence. Benzodiazepines are allosteric modu-
lators of the gaba-a receptors that affect the central nervous system (cns) as full 
gabaergic agonists [3]. As a consequence, these drugs have detrimental effects on 
alertness, memory, postural stability and muscle tone. In loss-of-function studies 
conducted in point-mutated mice [4], different subtypes of gaba-a receptors have 
been found responsible for the specific aspects of benzodiazepine pharmacology: 
1) α1-containing receptors are associated with sedative effects of benzodiazepines 
[5,6]; 2) α2/α3-containing receptors are related to anxiolysis and analgesia [7,8]; and 
3) α5-receptors are associated with cognition [9,10]. bzds exert their cns actions in 
a concentration-related manner [11]. The anxiolytic, hypnotic, muscle relaxant, and 
amnesic effects of bzds generally appear concomitantly, and the onset and duration 
of action of the compounds correlates closely with their pharmacokinetic proper-
ties. The effect profile of bzds has been attributed to their non-selective agonism 
at the α1, α2, α3, and α5 subunit-containing gaba-a receptors. To improve the phar-
macological and functional selectivity, novel gabaergic anxioselective compounds 
are evaluated using recombinant human gaba-a receptors during preclinical 
development. The gabaergic effect profile of a compound is characterized by the 
affinity of the ligand for the receptor, and by the in vitro efficacy of the compound 
at each gaba-a receptor subtype. In the past years, several partial gaba-a-agonists 
have been developed, which have a relatively high in vitro efficacy at α2/α3 subtypes 
compared with α1 or α5 subtypes. Such α2/α3 subtype-selective partial gaba agonists 
are anticipated to have favorable therapeutic effect and to be less sedating or cog-
nition-impairing (Table 1).
Based on non-clinical investigations with in vitro assays and animal models 
of anxiety, the human pharmacology of novel gabaergic agents is approached 
through sequential clinical studies regarding pharmacokinetics, receptor occu-
pancy, and pharmacodynamics (pd) in healthy volunteers. Direct links have been 
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proposed between plasma drug concentration and receptor occupancy [4], as 
well as between plasma drug concentration and pharmacodynamic parameters 
[12,13,14,16]. Such pharmacokinetic/pharmacodynamic (pk/pd) relationships war-
rant the assessment of surrogate biomarkers in healthy volunteers treated with 
single doses of selective novel gabaergic compound(s). 
More than 170 pharmacodynamic tests or test variants have been developed 
to assess the cns effects of benzodiazepines [11]. De Visser et al analyzed the inter-
study consistence, sensitivity, and pharmacological specificity of the frequently 
used biomarkers. Saccadic peak velocity (spv) and visual analogue scale of alertness 
(vasalertness) were identified as the most sensitive parameters for benzodiazepines. 
Both tests showed consistent effects to a variety of benzodiazepines at different 
doses. 
During the past fifteen years, the Centre for Human Drug Research (chdr) has 
established a selection of computerized neuropsycho-pharmacodynamic tests 
called the Neurocart battery. The components of this battery target a variety of 
neurophysiological and/or neuropsychological domains (Table 2). Of this battery, 
adaptive tracking, saccadic eye movements and body sway was proved sensitive to 
the sedating effects of sleep deprivation [15], as well as benzodiazepines and other 
gabaergic drugs. In the recent years, the Neurocart battery was used in a series of 
phase I studies to assess cns pharmacodynamics of partial α2,3 subtype selective 
gaba-a agonists. Both non-selective and/or selective gaba-a agonists were admin-
istered as single oral dose to healthy volunteers. Clear distinctions of effect profile 
were observed in these trials [12,13,14]. The objective of this manuscript was to 
characterize the pharmacodynamic effect profiles of novel anxioselective gaba-a 
agonists and identify suitable biomarkers to distinguish α2,3 subtype-specific 
gaba-a agonists from full gaba-a -agonists like benzodiazepines. 
methods
Five clinical studies, all of which are published [12,13,14,16,31], were conducted at the 
chdr in healthy volunteers after approval from the Ethics Review Board of Leiden 
University Medical Centre. All subjects provided written inform consent for study 
participation. Each trial was designed as single-dose, cross-over or parallel-armed, 
randomized, double-blind, placebo- and/or positive-controlled study. The subjects 
took single oral doses of a selective gabaergic compound, placebo, and/or a non-se-
lective benzodiazepine. Three studies used lorazepam 2 mg as a positive control, 
whereas in the studies with zolpidem 10 mg and alprazolam 1 mg, these drugs 
were the only gabaergic study medications. Data of all studies came from the same 
research center and were pooled from the studies-specific electronic databases 
kept by the center. In vitro pharmacological parameters of novel compounds were 
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extracted from the Investigator’s Brochures and published articles. These parame-
ters provide reliable information about the subtype selectivity of each compound, 
but it is more difficult to compare the pharmacological properties between the 
drugs. Due to the diversity of cell types and gaba-a receptor homologies used in 
the whole-cell patch clamping assays, the links between in vitro pharmacology and 
human in vivo effects are considered less quantitative and semi-quantitative com-
parisons are preferred. 
treatments
Three novel drugs designed to be α2,3 subtype-selective were dosed in three of the 
abovementioned studies (for each dose group, the number of study participants is 
provided in parentheses): tpa023 0.5 mg, 1.5 mg (n=12)[12]; tpacpm2 (mk0343) 0.25 
mg, 0.75 mg (n=12)[13]; sl65.1498 2.5 mg, 7.5 mg, and 25 mg (n=20)[14]. Zolpidem 
is a hypnotic with a high affinity for α1-subtypes, and alprazolam is a nonselective 
gabaergic anxiolytic. Zolpidem 10 mg (N=14)[16] and alprazolam 1 mg (N=20) were 
administered in another two studies, respectively. 
pharmacodynamic assessments
saccadic eye movement
Saccadic eye movements are very sensitive to a variety of mostly cns-depressant 
drugs [17;18]. Saccadic peak velocity has been shown to be closely related to the 
anxiolytic properties of benzodiazepines [4]. Since partial α2,3 subtype selective 
gaba-a-agonists are developed to be anxiolytic, it was expected that these com-
pounds would reduce saccadic peak velocity, similar to what is typically observed 
with benzodiazepines. Therefore, saccadic peak velocity was used as a biomarker 
for the anxiolytic properties of the gaba-a agonists, to which all other pharmaco-
dynamics effects were compared in this meta-analysis. Recording and analysis of 
saccadic eye movements was conducted with a microcomputer-based system for 
sampling and analysis of eye movements. The program for signal collection and 
the ad-converter was from Cambridge Electronic Design (ced Ltd., Cambridge, uk), 
the amplifiers were supplied by either Nihon Kohden (Nihon Kohden, Life Scope 
ec, Tokyo, Japan) or Grass (Grass-Telefactor, An Astro-Med, Inc. Product Group, 
Braintree, usa) and the sampling and analysis scripts were developed at chdr 
(Leiden, the Netherlands).
smooth pursuit
The same systems as used for saccadic eye movements were also used for measuring 
smooth pursuit. For smooth pursuit eye movements, the target moves sinusoidally 
at frequencies ranging from 0.3 to 1.1 Hz, in steps of 0.1 Hz. The amplitude of target 
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displacement corresponds to 22.5 degrees eyeball rotation to both sides. Four cycles 
were recorded for each stimulus frequency. The method has been validated at chdr 
by van Steveninck based on the work of Bittencourt [19] and the original description 
of Baloh [20]. 
visual analogue scales (vas)
Visual analogue scales as originally described by Norris [21] were used previously 
to quantify subjective effects of benzodiazepines [18]. From the set of sixteen scales 
three composite factors were derived as described by Bond and Lader [22], corre-
sponding to alertness, mood and calmness. These factors were used to quantify 
subjective drug effects [23]. 
body sway
The body sway meter measures of body movements in a single plane, providing a 
measure of postural stability. Body sway was measured with an apparatus similar 
to the Wright ataxiameter, which integrates the amplitude of unidirectional body 
movement transferred through a string attached to the subject’s waist. Two min-
ute measurements were made in the antero-posterior direction with eyes open 
and closed, with the subject standing comfortably on a firm surface with their feet 
slightly apart. The method has been used before to demonstrate postural instabili-
ty due to benzodiazepines [24,25].
adaptive tracking
The adaptive tracking test as developed by Hobbs & Strutt was used, according 
to specifications of Borland and Nicholson [27]. The adaptive tracking test is a 
pursuit-tracking task. A circle of known dimensions moves randomly across a 
screen. The test subject must try to keep a dot inside the moving circle by operat-
ing a joystick. If this effort was successful, the speed of the moving circle increases. 
Conversely, the velocity was reduced if the test subject cannot maintain the dot 
inside the circle. The adaptive tracking test is a measure of visuomotor coordination 
that has proved to be very sensitive of various psychoactive drugs [26]. Table 3 sum-
marizes the pharmacodynamic tests used in the different studies. 
statistical analysis
Individual graphs are generated for each pharmacodynamic variable (y-axis) versus 
spv change from baseline (x-axis). Summary graphs are generated with Lorazepam 
and one other treatment per graph, for all gabaergic treatments. 
A regression analysis of change from baseline of body sway (∆sway), tracking 
(∆track), vas alertness (∆vasalertness), or vas calmness (∆vascalmness) against the 
change from baseline of spv (∆spv) was performed with a mixed effect model on 
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the available individual data. The fixed factor was the gabaergic treatment and 
treatment by saccadic peak velocity, while the random factors were subject slope 
and intercept. The values of body sway were analyzed after log-transformation, 
while the other parameters were taken without transformation. The estimate of 
the slopes of the linear relations of these ∆spv-relative effect profiles were com-
pared between each dose of subtype-selective gaba-a agonists and lorazepam. The 
estimates of slopes, their estimated difference and the p-values were tabulated. 
Thereafter, summary plots were generated, combined with the population regres-
sion line as calculated in the regression.
All statistical analyses were carried out with sas for Windows v9.1.3 (sas insti-
tute, inc., Cary, nc, usa). 
results 
∆spv-∆sway relation (∆=change from baseline)
Average changes from baseline of body sway against spv within the investigational 
time course (i.e. 6 hours post-dose) were plotted by study. Figure 1 demonstrates 
clear distinctions between the ∆spv-relative effect profile of lorazepam 2 mg and 
most doses of the α2,3-subtype selective compounds (i.e. tpa023 1.5 mg, tpacmp2 
0.75 mg). The full gaba-a agonist alprazolam is similar to lorazepam. The slope of 
the ∆spv-∆sway plots for zolpidem is slightly steeper than for lorazepam. 
As was revealed by the statistical analysis using the mixed linear model (Table 
4), the estimated differences of the slope of regression lines are statistically signifi-
cant between lorazepam and the α2,3 subtype selective partial gabaergic treatment 
of tpa023 1.5 mg, tpacmp2 0.75 mg, and sl65.1498 25 mg. There is no statistically 
significant difference between the slopes for lorazepam and alprazolam, and the 
difference with zolpidem suggested by the average plots (Figure 1) is not confirmed 
by the model (Table 4).
∆spv-∆vasalertness relation
Figure 2 plots the average values of ∆vasalertness vs. ∆spv obtained from individual 
subjects per study. As was found for the ∆spv-∆sway relations, a similar difference 
to lorazepam was observed with novel subtype selective gabaergic compounds. 
The slopes of the regression line of the ∆spv-∆sway relation for tpa023 1.5 mg, and 
sl65.1498 25 mg are statistically shallower than the slope for lorazepam, respective-
ly. No statistical differences can be demonstrated for tpacmp2 0.75 mg, alprazolam 
1 mg, or zolpidem 10 mg.
∆spv-∆smooth relation
Figure 3 and Table 4 provide the ∆spv-relative effect profiles and the slopes and 
intercept for smooth pursuit after alprazolam, zolpidem, and sl65.1498. Smooth 
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pursuit was not determined with the other partial agonists. Statistically significant 
differences is found in the slope of regression lines with sl65.2498 25 mg. Zolpidem 
and alprazolam show comparable slopes to lorazepam. 
∆spv-∆pd relations vs in vitro pharmacological properties
This analysis surmises that comparisons of ∆spv-∆pd profiles represent the 
underlying pharmacological characteristics of subtype selective and non-selective 
gaba-a agonists. A further corroboration of this approach could be provided by a 
comparison of ∆spv-∆pd profiles with the underlying pharmacological properties. 
This should be possible in principle, but the quantitative preclinical information 
provided in Table 1 was derived from different sources which in themselves were 
incomparable, despite the fact that all programs used oocyte-clamp assays to 
characterize the different gabaergic compounds. Some of these differences could 
be diminished by calculation of the ratio of relative efficacy on the α1 gaba-a sub-
unit to that on the α2 subunit, as a benchmark of α2-specificity of the gabaergic 
compounds. This calculated ratio is provided in Table 1. Although the number of 
compounds in this overview is too small for any meaningful statistical evaluation, 
it is interesting that the four compounds for which this could be calculated, showed 
a close relationship between α1/α2-efficacy ratio’s and ∆spv-∆vas alertness ratio’s 
with borderline statistical significance (r2=0.86, two-sided p=0.0727). Due to the 
absence of in vitro pharmacological data and the difference of experimental settings 
of the trail with alprazolam, alprazolam was not included into the present analysis.
discussion
This analysis was performed to explore the Central Nervous System (cns) effects of 
various gabaergic agents and characterize the pharmacodynamic effect profiles of 
these compounds in healthy volunteers and correlate such profiles to their phar-
macological properties. 
A battery of cns pharmacodynamic tests was administered to healthy volun-
teers who were dosed with gabaergic compound(s). The composition of the cns 
battery was based on the sensitivity of the measurements to non-selective gaba-
ergic treatments, and on the coverage of a wide range of different cns domains 
(Table 2). This approach enabled us to identify unique effect profiles for pharmaco-
logically distinct gabaergic treatments, including 1) traditional, pharmacologically 
non-selective, full gabaergic compounds at their clinical dose(s) (i.e. lorazepam 2 
mg and alprazolam 1 mg), 2) a marketed gabaergic compound with high α1-subtype 
affinity (i.e. zolpidem 10 mg), and 3) several novel, α2,3-subtype selective gabaergic 
compounds at different investigational doses. 
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The new class of partial subtype selective gaba agonists were expected to be anxio-
lytic but less sedating and cognition-impairing, as indicated by the preclinical in vitro 
and in vivo data. The anxiolytic effects of non-selective gabaergic agonists are accom-
panied by somnolence, impaired locomotion, and cognitive disturbance. These 
clinical side-effects are reflected by the pharmacodynamics effects of lorazepam or 
alprazolam on vasalertness (measure of subjective sedation), body sway (measure of 
postural instability) and adaptive tracking (measure of visuo-motor coordination). 
Memory testing was not performed frequently and consistently enough to allow a 
comparative analysis among the different compounds. However, the original pub-
lication of the tpa023-study provides indications that the partial subtype selective 
gaba agonist has fewer cognitive effects than the partial subtype selective gaba 
agonist. In this study, lorazepam 2 mg showed clear memory reductions, which did 
not occur with a dose of tpa023 1.5 mg that caused comparable spv reductions [12]. 
         Saccadic peak velocity (spv) has previously been shown to be closely related to the 
anxiolytic doses of benzodiazepines [11], and spv was therefore used as a reference 
parameter. As expected, spv showed significant responses to almost every gabaer-
gic compound investigated in these six studies [12,13,14]. In contrast to lorazepam or 
alprazolam, which influenced each output parameter of the saccadic eye movement 
test (i.e. spv, Saccadic reaction time, and inaccuracy), the α1-(zopidem) or α2,3-subtype 
selective gabaergic compounds (tpa023, tpacmp2, sl65.1498) only affected spv. 
At their highest investigational dose, the effect size of tpa023 and tpacmp2 on 
spv was comparable to the effects observed with lorazepam or alprazolam; where-
as the effect of sl65.1498 was only marginally significant on spv. In almost all these 
cases, the impact on other cns effects was lower. This by itself is an indication of 
pharmacological selectivity, but a comparison based merely on overall or maxi-
mum effects could obscure some of the more subtle pharmacological differences 
(like the findings of sl65.1498 study) when the pharmacodynamic biomarker is less 
sensitive to the drug or if the dose of a drug is subtherapeutic. The relationships 
between the ∆spv effects and other pharmacodynamic (∆pd) effects provide a 
complete profile of the differential effects, at each time point after drug adminis-
tration. These outputs reflect the degree of α2,3 selectivity, and may therefore also 
be indicators for anxioselectivity. Based on these perceptions, a gabaergic com-
pound with ‘flat’ regression lines in the ∆spv-relative plotting graphs would show 
anxiolysis with reduced off-target effects in clinical settings. For most of the novel 
compounds described in this overview, there are no clinical reports of anxiolytic 
effects or improved tolerability. However, a recent article on tpa023, the oldest com-
pound in this meta-analysis, reported reduced anxiety in a preliminary clinical trial 
at doses that were also used in our pharmacodynamic studies [4]. No detailed com-
parative information is available on the therapeutic window in these clinical trials. 
We found that the ∆spv-relative effect profiles of α2,3 subtype-specific gabaergic 
compounds are similar among each other, but different from lorazepam 2 mg. The 
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absolute slopes of the regression lines for the ∆spv-∆pd relations are generally 
lower with the selective gaba-a agonists than with the benzodiazepines. The results 
of alprazolam were comparable to lorazepam, which provides additional confi-
dence that the analyses reflect pharmacological differences as well as similarities. 
Zolpidem seemed to be the only major exception, since this α1 subtype-selective 
gabaergic compound produced considerably steeper average slopes for certain 
∆spv-relative profiles than lorazepam or alprazolam; whereas the statistical pop-
ulation model did not reveal statistically significant differences between zolpidem 
and the benzodiazepines. This could reflect a limitation of the population model 
for ∆spv-∆pd relationships, which was chosen to be simple and unbiased, but nec-
essarily had to ignore some rather complex individual response relationships. The 
analyses were based on linear slope estimates without a fixed intercept. In reality 
however, all individual data points started at a fixed intercept (at T=0, when ∆spv 
and ∆pd were both zero), and in many cases the ∆spv-∆pd relationships were not 
linear, and zolpidem even formed loops when the spv effect displayed a different 
time-course than the pd effect. In almost all other cases however, the statistical 
analyses and the graphical representations of the average relationships provide 
accurate representations of the individual plots.
This meta-analysis indicates that comparisons of ∆spv-∆pd profiles are able to 
identify pharmacological differences between subtype selective and non-selective 
gaba-a agonists. A comparison of ∆spv-∆pd profiles with the underlying pharma-
cological properties was refuted by the very small number of compounds for which 
this could be compared. Nonetheless, strong relationships (with an R-value of 0.93) 
between the α1/α2-ratio’s of the four compounds for which this could be determined, 
and their ∆spv-∆vasalertness ratios. Clearly this remains to be confirmed with larger 
numbers of compounds. Still, the consistent ∆spv-relative profiles of the selective 
gabaergic compounds suggest potential links between the preclinical profiles and 
the ∆spv-relative pharmacodynamics profiles of these compounds. Moreover, 
tpacmp2 showed a distinct ∆spv-∆vasalertness relation but shared a similar ∆spv-
∆sway relation with the other α2,3 subtype-selective gabaergic agonists. The 
relatively large amount of sedation with tpacmp2 could reflect the relatively high 
ratio of α1/α2-efficacy of tpmcmp2 compared to the other compounds. Similarly, the 
large efficacy of zolpidem is compatible with its steep ∆spv-∆vasalertness ratio and 
the strong hypnosedative effect of this z-hypnotic in the clinic.
conclusion
tpa023, tpacmp2, and sl65.1498 are members of the novel experimental drug 
family of α2,3-subtype selective receptor agonists. In vitro pharmacological prop-
erties of these compounds indicate higher binding affinity and relative efficacy 
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at the α2,3-subunits. In vivo preclinical studies with animal models translated such 
pharmacological properties into potential of anxiolysis and relatively reduced 
off-target effects in comparison with non-selective full gabaergic agonists like 
benzodiazepines. 
The Neurocart battery is a collection of validated tests amenable to the effects 
of various cns-acting drugs. Components of this battery were shown to be sensitive 
to different rapid-onset cns-effects of the benzodiazepines, in which reduction 
of saccadic peak velocity displays features of a gabaergic anxiolytic biomarker, 
whereas impairments of body sway, adaptive tracking, and memory are translated 
to effects that are less desirable for an anxiolytic drug. Most novel gabaergic com-
pounds showed dose-dependent responses to saccadic peak velocity, but did not 
affect the other cns-effects to the same extent, indicative of the pharmaco-selec-
tivity of these new compounds. Moreover, the ∆spv-relative effect profiles provide 
information about dose potency and effect specificity. This battery is suitable to not 
only present the general depressive effects of benzodiazepines but demonstrate 
the pharmacological selectivity and specificity of the novel gabaergic compounds. 
Comparative effect profiling as used in these studies can provide clear indications 
for the pharmacological selectivity and specificity of novel gabaergic compounds 
in healthy volunteers. This is a valuable approach for the early drug development 
of this new drug class, which will hopefully contribute novel anxiolytics with an 
improved therapeutic window to patients with anxiety disorders.
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Table 1 • In vitro pharmacological properties of the gabaergic compounds

















tpa023*[27] 0.27 0# 0.31 11 0.19 21 0.41 5 0
tpacmp2*[13] 0.22 18 0.40 23 0.21 45 0.23 18 0.78
SL65.1498#[28] 17 45 73 115 80 83 215 48 0.39
Zolpidem 20[30] 75§[29] 400[30] 78§[29] 400[30] 80§ 5000[30] 9§[29] 0.96
° Relative efficacy is defined as the extent of the potentiation of gaba-a ec20-equivalent current produced  
by the compound compared to that produced by a non-selective full-agonist (chlordiazepoxide/diazepam);  
* Mean values of 3 experiments in Xenopus oocytes with human recombinant αß3α2 receptors; efficacy relative  
to chlordiazepoxide; # Mean values of 3 experiments in hek293 cells with recombinant rat receptors αß2α2; 
efficacy relative to chlordiazepoxide; § Mean values of 3 experiments in Xenopus oocytes with human 
recombinant αß2α2 receptor; efficacy relative to diazepam 
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Table 2 • Component tests of the Neurocart battery and the related cns domains 
Neurocart test Targeted function Related cns areas
Saccadic eye movement Neurophysiologic function Superior colliculus, Substantia Nigra, amygdala
Smooth pursuit Neurophysiologic function Midbrain
Adaptive tracking Visuo-motor coordination Neocortex, basal nuclei, brain stem, cerebellum
Body sway Balance Cerebellum, brain stem
Visual verbal learning test (vvlt) Memory Hippocampus
vas Bond and Lader Alertness, mood, calmness Cortex, prefrontal cortex
vas Bowdle
Feeling high, internal and  
external perception Cortex, prefrontal cortex, amygdala
Table 3 • Use of pharmacodynamic tests in each study
Study chdr99112 chdr0102 chdr0105 chdr0614 chdr0407
Compound tpa023 tpacmp2 sl65.1498 Alprazolam Zolpidem
Comparator Lorazepam Lorazepam Lorazepam na na
sem Done Done Done Done Done
Sway Done Done Done Done Done
vasbl Done Done Done Done Done
Smooth nd nd Done Done Done
Track nd nd nd Done Done
nd=Not Done; na=Not Applicable; sem= Saccadic eye movement; Smooth=Smooth pursuit; Sway=Body sway; 
vas bl=vas Bond and Lader; Track= Adaptive tracking;
304_Connie_Proefschrift_19.indd   108 12-09-17   17:55
Table 4 • Results of the linear model for Saccadic Peak Velocity change from baseline and Log Body 
sway change from baseline by treatment with treatment by spv change from baseline as interaction
Treatment Δspv-relative  
relation
Item Estimate of  
treatment
Estimate of  
Lorazepam
P-value
tpa023 1.5 mg ΔSway-Δspv Slope -0.00048 -0.00305 <0.0001
Intercept -0.01316 0.1292 <0.0001
Δvasalertness-Δspv Slope 0.03312 0.126 0.0001
Intercept 0.4551 -4.4739 0.0021
tpacmp2 0.75 mg ΔSway-Δspv Slope -0.00027 -0.00305 <0.0001
Intercept 0.03784 0.1292 0.0009
Δvasalertness-Δspv Slope 0.09884 0.126 0.2525
Intercept -1.4465 -4.4739 0.0397
sl65.1498 25 mg ΔSway-ΔSPV Slope -0.00128 -0.00305 0.0003
Intercept 0.0222 0.1292 <0.0001
Δvasalertness-Δspv Slope 0.04193 0.126 0.0009
Intercept 0.2453 -4.4739 <0.0001
ΔSmooth-Δspv Slope 0.01554 0.1099 <0.0001
Intercept -1.4483 -6.2553 <0.0001
Alprazolam 1 mg ΔSway-Δspv Slope -0.00204 -0.00305 0.0667
Intercept 0.001788 0.1292 <0.0001
Δvasalertness-Δspv Slope 0.0734 0.126 0.0763
Intercept -0.628 -4.4739 0.0254
ΔTrack-Δspv Slope 0.0747 0.0572 0.1545
Intercept 0.3023 -4.0742 <0.0001
ΔSmooth-Δspv Slope 0.08077 0.1099 0.2808
Intercept -1.4025 -6.2553 0.0002
Zolpidem 10 mg ΔSway-Δspv Slope -0.0033 -0.00305 0.7336
Intercept 0.06014 0.1292 0.0127
Δvasalertness-Δspv Slope 0.1526 0.126 0.5231
Intercept -3.2697 -4.4739 0.5219
ΔTrack-Δspv Slope 0.0489 0.0572 0.6240
Intercept -0.9123 -4.0742 <0.0001
ΔSmooth-Δspv Slope 0.09771 0.1099 0.7412
Intercept -3.8439 -6.2553 0.0815
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Figure 1 • ∆logSway (log mm)-∆spv (deg/sec) relative effect profile of tpa023 1.5 mg, tpacmp2  
0.75 mg, sl65.1498 25 mg, zolpidem 10 mg, and alprazolam 1 mg vs. lorazepam 2 mg, respectively. 
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Figure 2 • ∆vasalertness-∆spv relative effect profile of tpa023 1.5 mg, tpacmp2 0.75 mg, sl65.1498 25 
mg, zolpidem 10 mg, and alprazolam 1 mg vs. lorazepam 2 mg, respectively. 
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Figure 3 • ∆smooth-∆spv relative effect profile of sl65.1498 25 mg, zolpidem 10 mg, and  
alprazolam 1 mg vs. lorazepam 2 mg, respectively.
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abstract
Compounds with selectivity for gaba-a receptor subtypes may differ significant-
ly from nonselective benzodiazepines in their dopaminergic effects in vivo. To 
explore the exact role of the gaba-a receptor subtypes in the regulation of prolactin 
secretion and the differential effects of selective and nonselective gaba receptor 
modulators, the effects of the nonselective benzodiazepine lorazepam, as well 
as two novel α2/α3 subunit-selective gaba-a receptor modulators azd7325 and 
azd6280, on prolactin levels were measured in healthy male volunteers. Following 
administration of lorazepam at 2 mg doses and azd6280 at 10 mg and 40 mg doses, 
prolactin levels increased significantly compared with placebo (difference 42.0%, 
19.8% and 32.8% respectively), suggesting that the α2 and/or α3 receptor subtypes 
are involved in gabaergic modulation of prolactin secretion, although possible 
roles of the α1 and α5 receptor subtypes are not excluded. The increases in prolactin 
levels after administration of azd7325 at 2 mg and 10 mg doses (difference 7.6% 
and 10.5% respectively) did not reach statistical significance, suggesting that doses 
of azd7325 or intrinsic efficacy at the α2 and α3 receptor subtypes may have been 
too low.
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introduction
A series of studies in animal models has indicated that certain effects of benzodi-
azepines may be attributable to efficacy at specific gaba-a receptor subtypes, such 
as sedation (α1 receptor subtype) [1, 2], anxiolysis (α2 and α3 receptor subtypes) [3-6] 
and learning and memory (α5 receptor subtype) [7, 8]. Accordingly, it has been sug-
gested that compounds with high efficacy at α2 and/or α3 receptor subtypes and low 
efficacy at α1 and α5 receptor subypes may exhibit significant anxiolysis, with less 
sedation than nonselective benzodiazepines [9]. In addition, because γ-aminobu-
tyric acid (gaba) is one of the major inhibitors of dopamine neurotransmission, it 
has also been suggested that compounds with selectivity for gaba-a receptor sub-
types may differ significantly from nonselective benzodiazepines in their effects 
on dopamine neurotransmission [9]. In the ventral tegmental area, dopaminergic 
neurons express α3 receptor subtypes, whereas gabaergic interneurons express 
α1 receptor subtypes [10]. Benzodiazepines inhibit the dopaminergic neurons 
through efficacy at α3 receptor subtypes, but simultaneous efficacy at α1 receptor 
subtypes on the gabaergic interneurons results in disinhibition of the dopami-
nergic neurons [9, 10]. Thus, compounds with high efficacy at α3 receptor subtypes 
and low efficacy at α1 receptor subtypes may attenuate dopamine neurotransmis-
sion without counteractive disinhibition. Such compounds may have therapautic 
potential in disorders such as schizophrenia [9].
To evaluate if compounds with selectivity for gaba-a receptor subtypes dif-
fer from nonselective benzodiazepines in their dopaminergic effects in vivo, we 
evaluated the effects of lorazepam and two novel selective modulators of α2 and 
α3 receptor subtypes on the activity of the tuberoinfundibular pathway, which rep-
resents the most readily available dopaminergic pathway for evaluation in vivo, 
by measuring circulating prolactin levels. The tuberoinfundibular dopaminergic 
pathway is the primary physiological inhibitory control mechanism of prolactin 
secretion [11, 12]. gaba may directly inhibit the activity of the hypothalamic tubero-
infundibular dopaminergic pathway, with a resulting increase in prolactin secretion 
[12-16]. It has also been reported that gaba exerts a dual control [17] and can also 
have an inhibitory effect on prolactin release by acting at gaba receptors in the ante-
rior pituitary gland [12, 16], but this effect is less clear in vivo [18] than in vitro. Only a 
few studies have evaluated the direct effects of gabaergic drugs on circulating basal 
prolactin levels in healthy subjects. Diazepam [19, 20] and bromazepam [21] did not 
significantly affect prolactin levels, while temazepam was found to increase prolac-
tin levels only to a small extent [22]. Alprazolam at high doses increased prolactin 
levels [23], while lower doses had no significant effect [24]. Zolpidem and breta-
zenil stimulated nocturnal secretion of prolactin [25, 26], while sodium valproate 
decreased prolactin levels [27]. The effect sizes in these studies, if any, were very 
small, especially compared with the potent prolactin-elevating effects of dopamine 
d2 receptor antagonists.
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To explore the exact role of the various gaba-a receptor subtypes in the regulation 
of prolactin secretion and the differential effects of selective and nonselective 
gaba receptor modulators, we report the effects of two novel α2/α3 subunit-se-
lective gaba-a receptor modulators, azd7325 [28, 29] and azd6280 [28, 30], and 
a therapeutic dose of lorazepam on prolactin secretion. These studies were part 
of larger phase i pharmacokinetic and pharmacodynamic studies of these com-
pounds, which will be reported elsewhere [31, 32].
methods
study design
In total, 32 healthy male volunteers were planned to participate in two parallel 
double-blind, placebo-controlled, randomized, cross-over studies. To be eligible 
for inclusion in both studies, subjects were required to be aged between 18 and 55 
years, with a body mass index (bmi) of 18 to 30 kg/m2 and refrain from alcoholic bev-
erages, smoking and caffeine-containing products during study days. Both studies 
were approved by the medical ethics review board of the Leiden University Medical 
Center. Prior to medical screening, all subjects gave written informed consent. Both 
studies had an identical design, except the administered drugs. In the first study, 16 
subjects were administered single oral doses of 2 mg lorazepam, 2 mg azd7325, 10 
mg azd7325 or placebo, during four separate study periods. In the second study, 16 
subjects were administered single oral doses of 2 mg lorazepam, 10 mg azd6280, 
40 mg azd6280 or placebo, during four separate study periods. Study periods 
were scheduled in randomized order using a Williams Latin square design and 
were separated by a washout time of at least 7 days. On study days, subjects fasted 
for minimally 2.5 hours after a light standard breakfast until dose administration 
(which generally occured between 11h00m and 12h00m am) and continued fasting 
until 4 hours after dose administration.
power calculation
A power calculation using data from a previous study [33] indicated that the present 
study (n = 32 subjects receiving lorazepam, power 80% and alpha 0.05) was pow-
ered to detect an increase of 12.5% or a decrease of 11% in prolactin concentration 
after administration of lorazepam, compared with placebo.
plasma concentration of prolactin
Venous blood samples for analysis of prolactin concentration were collected prior 
to study drug administration and at ½, 1, 1¼, 1½, 2, 2½, 3¼, 4, 4½, 6, 8, 12 and 21 hours 
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after study drug administration. Plasma concentrations of prolactin were deter-
mined using an electrochemiluminescence immunoassay (eclia) with a lower 
detection limit of 0.047 ng/mL (Elecsys Prolactin ii assay, Roche Diagnostics GmbH, 
Mannheim, Germany).
statistical analysis
Prolactin measurements up to 8 hours after administration of lorazepam or place-
bo were compared with a mixed model analysis of variance with treatment, period, 
time and treatment by time as fixed factors, and subject, subject by treatment and 
subject by time as random factors, and the pre-value (measurement prior to study 
drug administration) as covariate. Prolactin measurements were log-transformed 
prior to analysis to correct for the log-normal distribution of the data. Estimates of 
treatment differences and back-transformed estimates of the difference in per-
centage with corresponding 95% confidence intervals (95% ci) and p-values were 
calculated. All calculations were performed using sas for Windows version 9.1.3 
(sas Institute Inc., Cary, North Carolina, usa).
results
subjects
Subjects had a mean age of 28.1 years (range 18-54), weight of 76.1 kg (range 62.0-
89.5) and body mass index (bmi) of 23.0 kg/m2 (range 19.1-26.7). Two subjects 
withdrew informed consent after completion of study period 1 for reasons unre-
lated to study drug administration. Another subject tested positive for thc in 
study period 2 and was excluded from participation. Pharmacodynamic data from 
these subjects were not used for further analysis. All three subjects were replaced. 
Therefore, in total, 32 subjects completed the study. 
plasma concentration of prolactin
Plasma concentrations of prolactin after administration of lorazepam, azd7325 
and azd6280 are shown in Figure 1 and Table 1. Following administration of 2 mg 
lorazepam, prolactin levels increased with 42.0% compared with placebo (95% 
ci 31.4/53.5%, p < 0.001), which remained elevated until at least 8 hours after dose 
administration. Following administration of 2 mg and 10 mg azd7325, prolactin 
levels increased with 7.6% and 10.5%, respectively, compared with placebo. Both 
increases did not reach statistical significance, although the 10.5% increase after 
the 10 mg dose has a p-value of 0.0536. Following administration of 10 mg azd6280, 
prolactin levels increased significantly compared with placebo (difference 19.8% 
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versus placebo, 95% ci 8.2/32.6%, p = 0.0007). A larger increase was observed after 
administration of 40 mg of azd6280 (difference 32.8% versus placebo, 95% ci 
20.0/47.0%, p < 0.0001). Prolactin levels after administration of lorazepam were 
significantly higher than those after azd7325 at 2 and 10 mg doses and azd6280 
at 10 mg doses, but were not significantly different from those after azd6280 at 40 
mg doses.
discussion
Compounds with high efficacy at α2 subunit-containing gaba-a receptor subtypes 
and low efficacy at α1 receptor subtypes may differ significantly from nonselective 
benzodiazepines in their effects on dopaminergic circuits [9]. Such compounds 
may thus have therapeutic potential in disorders such as (certain aspects of) schizo-
phrenia [9]. The present study was performed to evaluate the effects of two novel 
α2/α3 subunit selective gabaergic drugs on the activity of the tuberoinfundibular 
dopaminergic pathway, by measuring circulating prolactin levels in healthy male 
volunteers, compared with lorazepam and placebo.
After administration of placebo, prolactin levels showed an initial decrease 
with a return to baseline values at the end of the study day, which is consistent with 
a normal circadian rhythm [12, 34]. Also, a peak in prolactin levels was observed 6 
hours after dose administration, which probably reflects normal prolactin release 
following food consumption [35, 36.]
After administration of a single oral dose of 2 mg lorazepam, an increase of 
42.0% in prolactin levels was observed. The magnitude of the effects of lorazepam 
on prolactin levels was rather small, especially in comparison to the much more 
potent prolactin-elevating effects of dopamine d2 receptor antagonists. Halope ri-
dol at 3 mg doses increases prolactin levels with 130.9% [37]. Thus, the effects of 
lorazepam administration on prolactin secretion are not likely to pro duce clinically 
relevant hyperprolactinaemia in men. However, our studies showed clear results in 
comparison with other studies that evaluated the effects of gabaergic drugs on 
basal prolactin levels in healthy subjects. The benzodiazepines diazepam and 
bromazepam showed no significant effects on prolactin levels under resting condi-
tions [19-21], whereas temazepam caused a small increase in prolactin levels of 
roughly 21.4 mU/L (which would correspond to roughly 1 ng/mL), but only at a single 
time point 1 hour after dose administration [22]. In contrast, our study de mon-
strates that lorazepam increases prolactin levels with roughly 5-6 ng/ml, which 
remain elevated until at least 8 hours after dose administration. The dose of loraze-
pam (2 mg) used in our study is roughly equipotent with the doses of diazepam (10 
mg), bromazepam (3 mg) and temazepam (20 mg) used in these earlies studies, 
although estimates of benzodiazepine dose equivalencies differ somewhat 
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between various authors [38-40]. Dose dependency of the effects on prolactin 
secretion has been demonstrated with the benzodiazepine alprazolam, which 
causes an increase of prolactin levels with roughly 9-10 ng/mL at relatively high 
doses (3 mg) [23], while doses in the lower therapeutic range (0.5 mg) demonstrat-
ed no effects [24]. The different findings might be explained by the small sample 
sizes used in the earlier studies (6-10 subjects in most studies) and statistical power 
may thus have been too small.
The increase in prolactin levels following administration of the gaba agonist 
lorazepam in our study suggests that the postulated stimulatory effect of gaba 
transmission (by suppressing the tuberoinfundibular dopaminergic neurons in 
the hypothalamus) exceeds the postulated inhibitory effect of gaba transmission 
(directly at the anterior pituitary gland). The preferential effect of lorazepam on the 
tuberoinfundibular dopaminergic neurons might result from differences in affinity 
for the pituitary and hypothalamic gaba binding sites, as has been shown for the 
gaba agonist muscimol and antagonist bicuculline [41], both of which have higher 
affinity for the binding sites in the mediobasal hypothalamus than for the binding 
sites in the anterior pituitary. However, effects of benzodiazepines on the activity of 
the tuberoinfundibular dopaminergic neurons have not been confirmed in vivo in 
man. A recent positron emission tomography (pet) study using the dopamine d2 
receptor ligand [11C]flb457 in healthy subjects has demonstrated that single oral 
doses of 2.5 mg lorazepam induce a statistically significant decrease in dopamine 
d2 receptor binding potential (bpnd) in the medial temporal and dorsolateral pre-
frontal cortex [42], but effects on the hypothalamus were not reported. Although 
a decrease in bpnd (i.e. suggesting dopamine release) in the cerebral cortex does 
not imply that lorazepam inhibits the tuberoinfundibular dopaminergic pathway 
in the hypothalamus, it does confirm that lorazepam can alter dopamine levels in 
extrastriatal areas in humans in vivo.
The present study evaluated the effects of two novel α2/α3 subunit-selec-
tive gaba-a receptor modulators, azd7325 and azd6280, on prolactin levels. 
Administration of 2 mg and 10 mg azd7325 produced small increases in prolactin 
levels, which did not reach statistical significance, although the 10.5% increase 
after the 10 mg dose is in line with the other effects and has a p-value of 0.0536. 
Administration of 10 mg and 40 mg azd6280 produced statistically significant 
increases in prolactin levels of 19.8% and 32.8%, respectively. These findings sug-
gest that the α2 and/or α3 receptor subtypes are involved in gabaergic modulation 
of the tuberoinfundibular dopaminergic pathway. Indeed, α2 and α3 subunit-con-
taining gaba-a recepors have been shown to be expressed in the arcuate nucleus 
and hypothalamus 43. However, it is not excluded that α1 or α5 receptor subtypes, 
which are also expressed in the arcuate nucleus and hypothalamus [43], are also 
involved in the control of prolactin secretion. The nonbenzodiazepine gaba ago-
nist zolpidem (10 mg), which has modest selectivity for α1 receptor subtypes [44], 
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increased nocturnal prolactin levels by two-fold 26. The effects of azd7325 on pro-
lactin secretion were less clear than those of azd6280. Similarly, in other studies [31, 
32], azd7325 also caused fewer effects than azd6280 on peak velocity of saccadic 
eye movements, which is one of the most consistent and sensitive biomarkers for 
the effects of nonselective benzodiazepines [45] and α2/α3 subtype-selective com-
pounds [46] in healthy volunteers. These differences may be related to the lower 
dosages of azd7325 used.
Comparison of the effects of 2 mg lorazepam with 40 mg azd6280 indicated no 
statistically significant difference. The lower prolactin levels after azd7325 at 2 and 
10 mg doses and azd6280 at 10 mg doses are likely related to dose. However, dose 
equivalencies of lorazepam, azd7325 and azd6280 are not known. Thus, these 
results do not fully exclude potential differences between nonselective benzodi-
azepines and selective α2/α3 subunit-containing gaba-a receptor modulators on 
prolactin secretion. In addition, our study measured prolactin levels only in healthy 
male volunteers. These results cannot readily be extrapolated to females, because 
the regulation of prolactin secretion in females is different, with the notable influ-
ence of estrogens.
In conclusion, the nonselective benzodiazepine lorazepam and the novel α2/
α3 subunit-selective gaba-a receptor modulator azd6280 at 40 mg doses both 
increase plasma prolactin levels in healthy male subjects. The increases in prolac-
tin levels after administration of the novel α2/α3 subunit-selective gaba-a receptor 
modulator azd7325 did not reach statistical significance, which may be related to 
the lower dosages used. These results indicate that the α2 and/or α3 receptor sub-
types are involved in gabaergic modulation of prolactin secretion.
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Table 1 • Comparison of prolactin levels after administration of lorazepam, azd7325 and azd6280 
compared with placebo. Treatment differences are expressed as percentages with 95% confidence 
intervals and p-values. 
Treatment comparisons Percentage difference (95% CI) p-value
Lorazepam versus placebo 42.0 (31.4/53.5) <0.0001
azd7325 2 mg versus placebo 7.6 (-2.8/19.1) 0.1566
azd7325 10 mg versus placebo 10.5 (-0.2/22.3) 0.0536
azd6280 10 mg versus placebo 19.8 (8.2/32.6) 0.0007
azd6280 40 mg versus placebo 32.8 (20.0/47.0) <0.0001
azd7325 2 mg versus lorazepam -24.2 (-31.6/-16.1) <0.0001
azd7325 10 mg versus lorazepam -22.2 (-29.7/-13.9) <0.0001
azd6280 10 mg versus lorazepam -15.7 (-23.8/-6.7) 0.0012
azd6280 40 mg versus lorazepam -6.4 (-15.5/3.6) 0.1957
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Figure 1 • Time course of plasma concentration of prolactin after administration of single oral doses 
of 2 mg lorazepam, 2 mg azd7325, 10 mg azd7325, 10 mg azd6280 and 40 mg azd6280  
(at t = 0 hours). Means are presented with standard errors of the mean (sem) as error bars.
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abstract
Introduction: Centrally-acting acutely anxiolytic drugs, like benzodiazepines, bar-
biturates and gabapentinoids, affect various central nervous system (cns) functions, 
which reflect not only their anxiolytic effects but also neuropsychological side-ef-
fects. To validate the pharmacodynamic biomarkers for gabaergic anxiolytics, this 
study determined the pharmacodynamics of two anxiolytics and a non-anxiolytic 
control and linked them to their anxiolytic and sedative effects, during an anxi-
ety-challenge study day. Methods: Twenty healthy volunteers were randomized in 
this placebo-controlled, double-blind, four-way cross-over study with single-dose 
alprazolam (1 mg), diphenhydramine (50 mg), pregabalin (200 mg) or placebo. The 
Neurocart® was used in-between repeated fear-potentiated-startle assessments. 
Thus the potential influence of anxiety on cns pharmacodynamic markers could be 
examined. Results: Compared to placebo, vascalmness increased with alprazolam 
(2.0 mm) and pregabalin (2.5 mm) but not with diphenhydramine. Saccadic-peak-
velocity (spv) declined after alprazolam (-57 deg/sec) and pregabalin (-28 deg/sec), 
more than with diphenhydramine (-14 deg/sec); so did smooth-pursuit. The aver-
age responses of spv and smooth-pursuit were significantly correlated with the 
drug-induced increases in vascalmness. The spv-relative responses of vasalertness, 
body-sway and adaptive-tracking also differed among alprazolam, pregabalin, and 
diphenhydramine. Conclusions: Compared with the antihistaminergic sedative 
diphenhydramine, alprazolam and pregabalin caused larger spv reduction, which 
was correlated with simultaneous improvement of subjective calmness, during 
a study day in which anxiety was stimulated repeatedly. The different effect pro-
files of the three drugs are in line with their pharmacological distinctions. These 
findings corroborate the profiling of cns effects to demonstrate pharmacological 
selectivity, and further support spv as biomarker for anxiolysis involving gabaergic 
neurons. The study also supports the use of prolonged mild threat to demonstrate 
anxiolytic effects in healthy volunteers.
304_Connie_Proefschrift_19.indd   126 12-09-17   17:55
pharmacodynamic response profiles of anxiolytic and sedative drugs | chapter 7
127
introduction
Centrally-acting acute anxiolytic drugs, like benzodiazepines, barbiturates and 
gabapentinoids, have an impact on a range of central nervous system (cns) 
functions, which reflect not only their anxiolytic effects but also side effects like 
sedation, postural instability and visuomotor and memory impairment [1]. It would 
be useful to identify the cns activities for those compounds that are more closely 
linked to reduction of anxiety than to general cns depression. 
Pharmacodynamic (pd) approaches have been increasingly employed in early 
human pharmacology studies to obtain in vivo pharmacological information of 
different drugs acting on the central nervous system and of the systems with which 
the drugs interact. The general aim of these methodology is to obtain information 
about the pharmacological characteristics of a drug (such as blood-brain barrier 
penetration, target engagement and mechanistically meaningful activity), which 
underlie its therapeutic effects [2-4]. The use of appropriate biomarkers may be 
especially useful for anxiety disorders, where therapeutic exploratory studies 
in patients can be difficult to achieve a clinically meaningful end-point due to 
the nature of subjective assessments, the relatively large size and probability of 
placebo effect, and other ethical or practical issues [5,6]. Of no doubt, a validated 
biomarker in early human pharmacology studies would serve as a useful tool for 
the development of new therapeutic anxiolytics. 
It has been well established that benzodiazepines (bzds) exert their pharma-
cological effects through positive allosteric modulation of the gaba-a receptors. 
Recent years, the experiments on gaba-a receptor subtype-gene knock-out 
mouse lines has greatly facilitated the identification of gaba-a receptor subtypes 
that mediates bzds-induced sedation (α1 gaba-a receptors), anxiolysis (α2 and α3 
gaba-a receptors), or memory impairment (α5 gaba-a receptors) [7-9]. To address 
the effects of bzds in human pharmacological studies, a collection of pharmaco-
dynamic measurements were employed and evaluated for their pharmacokinetic/
pharmacodynamic relationship with bzds, which include objective measures such 
as electroencephalography, semi-subjective measures such as psychomotor per-
formance, and subjective measures such as mood/sedation scales [10-13]. Despite 
of the acceptable sensitivity and the observed exposure-response relationship of 
these pd measurements for the effects of bzds, as well as the potential involvement 
of eye movement in anxiety disorder and related neuropsychiatric disturbance, 
increasing attention has been paid to evaluate the relevance of these pd param-
eters to the pharmacological effects of established or novel anxiolytic drugs. The 
exact clinical relevance of quantitative electroencephalogram (eeg), for example, to 
the anxiolytic, anticonvulsant, sedative and hypnotic actions of benzodiazepines, 
have not yet clearly been elucidated [14]. 
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The Centre for Human Drug Research (chdr) (Leiden, The Netherlands) has devel-
oped a Neurocart battery of validated computerized tests for the assessments 
of various cns functions. These tests have been shown to be sensitive to various 
aspects of sedation [15] and have been used in early studies of psychoactive drugs 
as pharmacodynamic biomarkers for postural (in)stability (body sway test), eye-
hand cooperation (adaptive tracking test), subjective feelings of alertness, mood 
and calmness (visual analogue scale [vas] Bond & Lader), and for neurophysiologic 
functions (saccadic eye movement and smooth pursuit eye movement tests) [6]. Our 
previous studies showed that the Neurocart battery presents distinct pharmaco-
dynamic response-patterns to different subtype-selective partial gaba-a agonists 
and non-selective benzodiazepine anxiolytics [16-19], which may imply potential 
gaba-a subtype specificity of these pd markers. Normally, this test battery does not 
provide any clear information about the specific anxiolytic properties of drugs, as 
measured by vascalmness. Benzodiazepines or selective serotonin reuptake inhibi-
tor (ssris), for instance, don’t cause consistently significant increases of subjective 
calmness in healthy volunteers, when the measurement was performed in stress-
free experimental settings [5,6]. Such findings can be true for ssris that have a slow 
onset of action and can even worsen anxiety symptoms during initial treatment 
[20], but is not expected for fast-acting anxiolytic drugs like benzodiazepines [21]. 
We therefore combined the Neurocart test battery with a modified fear-potenti-
ated-startle (fps) paradigm [22]. In this way, we could compare our more general 
cns test battery with a specific anxiety test, which in some studies [23-24], but not 
all [25], has been shown to be sensitive to anxiolytic drugs. To this end, we admin-
istered two sedating anxiolytic drugs (alprazolam and pregabalin) and a sedating 
non-anxiolytic (diphenhydramine) at therapeutic doses to healthy volunteers. 
methods
ethics
The study was approved by the Medical Ethics Review Board of Leiden University 
Medical Centre (lumc), and was conducted according to the principles of the 
Helsinki Declaration and the International Conference on Harmonization/Good 
Clinical Practice (ich/gcp). 
design
This was a single-center, randomized, placebo-controlled, four-way crossover, dou-
ble-blind study conducted in twenty healthy subjects. The scheme of this study 
included a screening period of maximally 14 days, four treatment periods separated 
by three washout periods of at least 3 days, and a telephone follow-up. 
304_Connie_Proefschrift_19.indd   128 12-09-17   17:55
pharmacodynamic response profiles of anxiolytic and sedative drugs | chapter 7
129
subjects
Ten men and ten women, aged between 18 and 40 years, with a bmi between 18 and 
30 kg/m2, without any clinically significant abnormalities, were recruited. All vol-
unteers provided written inform consent. Their eligibilities were evaluated before 
being randomized into the study. Subjects were instructed not to use alcoholic 
beverages from 24 hours before admission until the next morning of each study 
day. No xanthine or tobacco containing products were allowed from 22:00 in the 
evening before each study day and during stay in the research unit. They were asked 
to keep a normal day/night pattern from two weeks before the first study day until 
the last study day. 
sample size determination
As was shown in Grillon et al [23], the mean effect of the threat-safe difference 
between unpredictable threat and a neutral context seen under placebo was about 
15 μV ± 8.5 μV whereas the effect under 1 mg alprazolam was around 5 μV ± 8.5 μV 
(mean ± standard deviation). This leads to an alprazolam effect of 10 μV over pla-
cebo. Given that the within patient variability is normally not substantially greater 
than the between patient variability a residual standard deviation of 10 μV was 
assumed. Based on these assumptions, a sample size of 16 subjects was obtained to 
ensure a power of at least 80% with a two-sided alpha level of 5%. For the Neurocart 
end points, using data from previous studies [17-19], the same sample size of 16 
was determined to have equal to or greater than 80% power to detect the mean 
differences of 1.244 in vas alertness and 20.577 in saccadic peak velocity (spv), 
respectively assuming standard deviations of 1.663 (vas alertness) and 27.429 (spv) 
between placebo and lorazepam 2 mg using a paired t-test with a 0.050 two-sided 
significance level. Considering the possibility of drop-out and the sample should 
be a multiple of four (to keep the study design balanced the sample size), a total 
sample size of 20 subjects was finally decided for the study.
treatments
The study treatments were assigned according to a randomization schedule, which 
consisted of five blocks of the fully balanced 4*4 William Latin Squares. Each sub-
ject received single oral dose of over-capsulated pregabalin 200 mg, alprazolam 1 
mg, diphenhydramine 50 mg or matching placebo in a fasted state at about 8 to 9 
am on each treatment period. 
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safety
Adverse events, electrocardiograms (ecgs) and vital signs, as well as safety labora-
tory assays were frequently evaluated during the study. Twelve-Lead ecg recording 
was made using Nihon Kohden Cardiofax with Ecaps 12 software devices (Nihon 
Kohden, Tokyo, Japan). Vital signs (pulse rate and blood pressure) were taken using 
a Nihon-Kohden bsm-1101K monitor or a Colin Pressmate bp 8800. All blood pres-
sure, pulse rate, and ecg recordings were done after subject was resting in a supine 
position for at least 5 minutes. Safety laboratory tests on blood or urine samples 
were performed in the Central Clinical Laboratories of lumc.
pharmacokinetic measurements
For the determination of drug concentrations, two venous blood samples of 5 and 
2 ml were collected into ice-bathed Li-Hep tubes (Becton and Dickinson 367684 
& 368200, respectively) within 0.5 hour pre-dose and at 0.5, 1.25, 1.75, 2.25, 3, 4, 6, 
and 8 hours post-dose. The samples were centrifuged (2000G, 15 min, 4°C). The 
obtained plasma was transferred into two polypropylene Sarstedt 2 ml tubes and 
stored at -20°C until analysis.
Plasma pregabalin concentrations were determined at aai Pharma GmbH & Co 
kg, Neu-Ulm, Germany, using lc-ms/ms on a Finnigan lcq system. A Phenomenex 
Gemini (50 x 3.0 mm i.d., 5µm) was used as the hplc column. The quantification 
range was from 1.00 to 1000 µg/L. The intra- and inter-assay variability was 2.1-
10.5% and 0.9-6.6%, respectively. Plasma alprazolam and diphenhydramine 
concentrations were determined at the pharmacy of the Groningen University 
Medical Centre, Groningen, the Netherlands, using lc-ms/ms. All experiments were 
performed on a ThermoFisher (San Jose, usa) triple quadrupole lc-ms/ms with a 
Finnigan™ Surveyor® lc pump and a Finnigan™ Surveyor® autosampler which was 
set at 20 °C. Lower limit of Quantification (lloq) was 1.00 µg/L for alprazolam and 
5.00 µg/L for diphenhydramine, respectively. Intra- and inter- assay variability were 
2.1-7.2% and 0.0-3.3%, respectively, for alprazolam and 2.0-3.3% and 0.0-2.0%, 
respectively for diphenhydramine. 
pharmacodynamic measurements
A training session of the pharmacodynamic tests (i.e. the Neurocart battery 
and the fps paradigm) was performed during the screening. The purpose was 
to familiarize the subjects with the tests and prevent potential learning effect. 
In each study period, the fps paradigm was carried out around 1 hour after dos-
ing; while the Neurocart battery was assessed at pre-dose and 0.5, 1.25, 1.75, 2.25, 
3, 4, 6, and 8 hours post-dose in the following sequence of tests: body sway, vas 
Bond & Lader, saccadic eye movements, smooth pursuit eye movements, and 
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adaptive tracking. At each assessment, one subject was assigned to a quiet room with 
ambient illumination. 
Pharmaco- electroencephalograph (eeg) approach is currently widely used, 
and the empirical relation between this measure and other agonist effects of ben-
zodiazepines has been reported. However, the main purpose of this study was to 
compare the sensitivity and specificity of the Neurocart pd measurements versus 
those of the fps measurements to the effects of sedating, hypnotic, and anxiolytic 
drugs. As the flowcharts of the study days were already quite busy with the com-
bination of the non-eeg pd tests and the fps paradigm, and the device used for 
generation of electronic shocks in the fps paradigm may interfere with the pharma-
co-eeg measurements, the eeg measures were omitted from the study design for 
the sake of smooth operation.
body sway
Body sway was measured with an apparatus similar to the Wright ataxiameter [26], 
which integrates the amplitude of unidirectional body sway. The measurements 
were made in the antero-posterior direction with eyes closed for 2 minutes. The 
subject was asked to stand comfortably on a floor with his/her feet slightly apart. 
Body sway measures postural (in)stability. It has demonstrated considerable sensi-
tivity to the effect of benzodiazepines [27]. 
visual analogue scales of bond & lader (vas b&l)
Visual analogue scales, as originally described by Norris [28], were presented on a 
computer screen. Three composite factors were derived from the sixteen items, cor-
responding to alertness, mood and calmness, respectively. These factors quantify 
subjective feelings and have been extensively used to delineate subjective effects of 
a variety of sedative agents [6]. 
saccadic eye movements
Saccadic eye movements were evaluated using a computer-based system com-
posed of 1) stimulus display and signal collection (Nihon Kohden Corporation, 
Tokyo, Japan), 2) signal amplification (Grass-Telefactor, An Astro-Med, Inc. 
Product Group, Braintree, usa), 3) data recording (Cambridge Electronics Design, 
Cambridge, uk), 4) disposable silver-silver chloride electrodes (Medicotest N-oo-S, 
Olstykke, Denmark), as well as 5) the sampling and analysis scripts developed by 
chdr (Leiden, the Netherlands). The parameters of this test were the average values 
of saccadic peak velocity (spv, degree/msec), reaction time (msec) and inaccura-
cy (%) of all artefact-free saccades that were calculated on each session. Saccadic 
peak velocity appears to be the most sensitive measure for the sedative effect of 
benzodiazepines [6] and has been found to be a promising biomarker for the anxi-
olytic component of benzodiazepines and some newly developed compounds with 
potential anxiolytic effect [16-19].
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smooth pursuit eye movements
The same system as used for saccadic eye movements was also used for measure-
ment of smooth pursuit. For smooth pursuit eye movements, the target moved 
sinusoidally at frequencies ranging from 0.3 to 1.1 Hz, by step of 0.1 Hz. The ampli-
tude of target displacement corresponded to 22.5 degrees eyeball rotation to both 
sides. Four cycles were recorded for each stimulus frequency. The method has been 
validated at the chdr by van Steveninck et al. [29] based on the work of Bittencourt 
et al. [30] and the original description of Baloh et al. [31]. The time in which the 
eyes were in smooth pursuit of the target were calculated for each frequency and 
expressed as a percentage of stimulus duration. The average percentage of smooth 
pursuit for all stimulus frequencies were used as the parameter.
adaptive tracking
The adaptive tracking test was performed as originally described by Borland 
and Nicholson [32], using customised equipment and software (Hobbs, 2004, 
Hertfordshire, uk). After a 0.5-minute run-in time without data-recording, the 
average performance over the rest 3.0 minutes was scored and was used as the test 
parameter. Adaptive tracking is a pursuit-tracking task. The subject was required 
to operate a joystick and try to keep a dot inside a circle moving randomly on the 
computer screen. If he/she succeeded, the speed of the moving circle increases, and 
vice versa. 
fear potentiated startle (fps) paradigm
The fps paradigm is extensively described elsewhere [22]. In brief, the test con-
tained three contexts, which differed in the possibility of electronic shocks signaled 
by a computer displayed verbal instruction: ‘No shock’ for the Neutral (N) context, 
‘Shock only during cue’ for the Predictable (P) context, and ‘Shock at any time’ for 
the Unpredictable (U) context. Duration of each context was 90-100 sec, during 
which six startle probes were administered together with the assessment of startle 
response. Intervals between startle probes varied between 12 and 18 sec (16 sec on 
average). The fps session consisted of two blocks with the following orders of con-
texts: (1) p-n-u-n-u-n-p and (2) u-n-p-n-p-n-u. The order of these two blocks was 
counterbalanced across the subjects. A total of 12 shocks were administered during 
each fps test session. 
The shocks were delivered through two medal electrodes located on the inner 
side of one of the subjects’ forearms. Shock stimuli were delivered using a Digi-
timer ds7a constant current stimulator (Digitimer Ltd, Hertfordshire, England). 
Stimulation consists of short trains (total duration maximally 750 ms) of brief 
(2 ms) pulses. The maximum current intensity delivered during the study was 7 mA.
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The plasma concentrations of pregabalin, diphenhydramine and alprazolam were 
summarized by time points, and graphically presented as mean concentration-time 
profiles. The error bars represent the standard deviation (sd) at each time point. 
pharmacodynamics
Body sway values were log-transformed prior to analysis to correct for the expect-
ed log-normal distribution of the data [17-19]. The effects of the four treatments 
on the pharmacodynamic measurements were compared with a mixed model 
analysis of variance. In this statistic model, treatment, period, time and treatment 
by time were set as fixed factors; and the random factors were subject, subject 
by treatment and subject by time; the baseline value was included as covariate, 
where baseline is defined as the average of the available measures obtained 
prior to dosing. The following contrasts were requested to demonstrate the 
effects of the active treatments: placebo-pregabalin, placebo-alprazolam, and 
placebo-diphenhydramine.
A summary table of the analysis results was generated with estimates of the 
difference between each active treatment and placebo and a back-transformed 
estimate of the difference in percentage for Body Sway, 95% confidence intervals 
(in percentage for Body Sway) and Least Square Means (geometric means for Body 
Sway), and the p-value of the contrasts. Least Square Means graphs were gener-
ated, with the Least Square Means of the analysis of the data as change from 
baseline.
Previous studies suggested good sensitivity of spv to the effect of bzds [6] and 
α2,3 subtype-selective gaba-a receptor modulators [17-19,33-35]. There is a close 
association between the effect size of benzodiazepines for spv-reduction and their 
administered doses [6]. Based on the putative link between gaba-a α2,3 recep-
tors and anxiety [36,37], this supports the consideration of spv as a biomarker of 
clinical anxiolysis associated with gaba α2,3 activation [16], and the predictivity 
of spv was supported by the selective spv-reduction caused by tpa023 [17], com-
bined with early clinical findings of this partial gaba α2,3 agonist [36]. bzds also 
affected body sway, vasalertness, adaptive tracking, and vascalmness, suggesting 
impairment of postural balance, subjective alertness, eye-hand coordination, and 
subjective calmness, respectively [17-19,33,34]. Given the clinical relevance of these 
pharmacodynamic parameters, scatter plots of each pharmacodynamic measure-
ment against simultaneously obtained spv values were depicted to demonstrate 
spv-normalized effect profiles with the study treatments. Moreover, a regression 
analysis was performed using the mixed model with treatment as the fixed factor 
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and spv change from baseline and intercept as the random factors. Comparisons 
were made between each two active treatments with regards to the estimates of 
the slopes of the regression line obtained from each relative effect profile. The 
estimates of the slopes and their estimated difference were tabulated with the 
p-values. The slopes of these regression lines can be regarded as a measure of 
pharmacological selectivity of the drugs in respective of their anxiolytic effect [16].
results
subjects
Twelve men and ten women participated in the study. Ten subjects of each gender 
completed the study. The two drop-outs withdrew for personal reasons unrelated 
to the study, and were replaced by male subjects who received the same order of 
study treatments. Subjects had an average age of 22 years (range 18-36), and bmi of 
23.3 kg/m2 (range 18.1-29.6). Data from all treated subjects were used in the analy-
ses of safety and pharmacokinetics. Subjects who completed the study per protocol 
were included in the pharmacodynamic analysis.
safety
No serious adverse events were observed during the study. Neither were subjects 
discontinued their study due to aes. The most frequently reported adverse events 
were ‘somnolence’, ‘dizziness’, ‘fatigue’ and ‘headache’. Alprazolam was associated 
with the largest number of cns-related aes (n=21 in 14 out of 21 [66.7%] subjects), 
followed by diphenhydramine (n=19 in 16 out of 21 [76.2%] subjects), pregabalin 
(n=15 in 9 out of 20 [45.0%] subjects) and placebo (n=14 in 11 out of 20 [55.0%] 
subjects). Most aes were attributed to the cns-depressant effects of the study 
treatments. No ecg or laboratory abnormalities were judged clinically significant.
pharmacokinetics
Sixty-two concentration-time profiles were obtained (20 for pregabalin, 21 for 
diphenhydramine and 21 for alprazolam). Following single-dose oral administra-
tion, peak plasma concentrations of all three active treatments were reached at 2-3 
hours post-dose. Mean (standard deviation, sd) cmax was 4.87 (0.94), 91.47 (29.85) 
and 15.17 (2.10) mg/L for pregabalin, diphenhydramine and alprazolam, respec-
tively. Figure 1 showed the average concentration-time profiles of pregabalin, 
diphenhydramine and alprazolam.
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pharmacodynamics
The profiles of the cns pharmacodynamic parameters (Figure 2 and Figure 3) 
showed that peak effects of the study treatments were usually observed around the 
point of tmax. Table 1 summarized the results of statistical comparisons between 
each active drug and placebo. Compared to placebo, vascalmness increased statisti-
cally significantly with alprazolam (2.0 mm) and pregabalin (2.5 mm), but not with 
diphenhydramine (1.1 mm). In the meantime, saccadic peak velocity (spv) declined 
after alprazolam (-57 deg/sec) and pregabalin (-28 deg/sec), more than by diphen-
hydramine (-14 deg/sec); so did smooth pursuit. The average responses of spv were 
significantly correlated with the drug-induced increases in vascalmness.
To further characterize the pharmacodynamic profiles of these compounds, 
various cns pharmacodynamic effects were compared with the corresponding 
drug-induced spv reductions. According to the analyses about spv-relative effect 
profiles (Table 2), the spv-normalized impairment of adaptive tracking was higher 
after diphenhydramine and alprazolam, compared to that of pregabalin. The esti-
mated slope for the regression line ∆sway/∆spv was rather flat with pregabalin 
and significantly smaller than alprazolam and diphenhydramine. The slope for 
the ∆vasalertness/∆spv relation was larger with pregabalin and alprazolam than 
with diphenhydramine. No significant difference was found among alprazolam, 
diphenhydramine, and pregabalin in the relative effect profiles of ∆vascalmness ver-
sus ∆spv. The results of the fps paradigm were reported in a separate article [22]. 
discussion
In this study, a set of neuropsycho-pharmacodynamic tests (i.e., the Neurocart 
battery) was performed to characterize the cns profiles of three clinically anxio-
lytic and/or hypnotic drugs. Therapeutically relevant doses were administered as 
a single dose, because all drugs had a rapid onset of effects. The aim was to identify 
response patterns that are shared by fast-acting anxiolytics (alprazolam and prega-
balin) but differ from sedative effects (diphenhydramine). 
For the assessment of fear-potentiated startle, none of the treatments reliably 
reduced either fear- or anxiety-potentiated startle. Alprazolam and diphenhydr-
amine reduced overall baseline startle. Pregabalin did not significantly affect any 
of the physiological measures [22]. On the other hand, as a full gaba-a agonist, 
alprazolam induced robust effects on most cns parameters. Such generalized 
cns depressive pharmacodynamics is similar to that of other benzodiazepines 
[29,33,34] and can be explained by the non-selective modulation of alprazolam on 
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different gaba-a receptor subtypes, which constitute the most widely distributed 
inhibitory receptors in the cns. Pregabalin and its congener gabapentin are more 
selective and affect the α2 subunit of the voltage-dependent calcium channel. 
Contrary to benzodiazepines, ‘gabapentinoids’ don’t bind to gaba receptors, but 
both drug classes lead to a decrease of the stimulatory neurotransmitters that are 
involved in anxiety, such as glutamate and the monoamines [38]. In this study, pre-
gabalin was associated with moderate reduction of spv and smooth pursuit, as well 
as statistically significant increase of vascalmness. Diphenhydramine, acting as an 
antagonist at the histamine h1 receptors, slightly reduced spv, but it did not influ-
ence vascalmness. As an indication that the 50 mg dose was functionally relevant, 
diphenhydramine showed a prominent effect on adaptive tracking. 
An important finding of this study was the improvement of subjective calmness 
after a single dose of pregabalin and alprazolam. Moreover, the increase of vas-
calmness was significantly correlated with spv reductions. The literature is less clear 
about the subjective effects of anxiolytic drugs in healthy volunteers. In general, 
inconsistent changes of vascalmness have been reported for single doses of loraze-
pam (2 mg) and some α2,3-subtype selective gaba-a agonists [17-19,33,34], even at 
dosages that are clinically more anxiolytic than the relatively low doses of alprazol-
am 1 mg or pregabalin 200 mg employed in the current study. These inconsistencies 
suggest that vascalmness is a less reliable biomarker in studies where anxiety is not 
specifically stimulated. In such ‘normal’ drug studies, healthy subjects can expe-
rience different levels of anxiety, for instance depending on how familiar they are 
with these experiments, which may affect their sensitivity to anxiolytic drug effects. 
In the current study, subjects were repeatedly exposed to fear potentiated startle 
tests, which include unpleasant electrical shocks. We assume that this has induced 
a mild anticipatory anxiety in the study subjects [39], which was suppressed by the 
anxiolytic drugs but not by the sedative antihistamine. 
On the other hand, the partial effect profiles of diphenhydramine and prega-
balin and the more general cns depression caused by alprazolam seems to match 
their pharmacological characteristics. Strictly speaking, a reliable comparison of 
pharmacological effect profiles is only justified across a wider dose range or at least 
at roughly equipotent dosages. Although it is difficult to establish dose equivalence 
across different drugs classes, all doses were in their therapeutic range. We tried to 
solve this further by looking at relative effect profiles across the entire profile of the 
plasma concentrations of the investigated drugs [16]. With this approach, the con-
cern regarding dose equivalence in pd comparisons is overcome by transforming 
from dose-based pd-effect relationship to exposure-based pd effect relationship. 
spv is one of the most sensitive pharmacodynamic biomarkers for anxiolytic doses 
of benzodiazepines [6]. Therefore, spv was used to benchmark anxiolytic effects 
and was compared by linear regression with a second cns biomarker to depict a 
drug effect on another cns domain. 
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As can be seen in Table 1 and 2, alprazolam and diphenhydramine lead to compa-
rable impairments on body sway (measure of postural stability) relative to their 
effects on saccadic peak velocity. In contrast, the effect of pregabalin on body sway 
was less remarkable than spv. The differential effects of pregabalin on these two 
pharmacodynamic parameters seem to be consistent with the clinical behavior of 
this compound, which, compared to benzodiazepines, shows a larger therapeutic 
window between anxiolysis and ataxia [40]. The slopes of the ∆vasalertness/∆spv 
regression lines are comparable among the study treatments. This is different from 
our previous findings between selective and non-selective gaba-a receptor ago-
nists [16]. As subjects were physically and mentally stressed by electronic shocks 
of the fear-potentiated-startle paradigm [22], this challenge probably increased 
the baseline level of vasalertness and hence reduced the responses to the investi-
gated anxiolytic/hypnotic drugs. In addition, a distinct relationship was seen in the 
∆spv-relative effect profiles of ∆tracking among the three compounds. The steep-
er slope of the ∆tracking/∆spv regression line after diphenhydramine reflects its 
minimal effect on spv but substantial effect on tracking. Such a profile is linked to 
the clinical properties of diphenhydramine: it shows considerable hypnotic effects 
at the dose of 50 mg, but does not lead to anxiety relief. Known side-effects of this 
compound, including drowsiness and motor impairment, are attributed to its 
inverse agonism at the histamine h1-receptors distributed in the brain. 
Taken together, the results of present study supports the combination a phys-
ically stressful procedure to the subjective assessment of anxiolysis. Consistently, 
the simultaneous reduction of spv and the correlation between these two pd 
measurements provide further confirmation for the use of these biomarkers for 
clinically relevant anxiolytic effects. The sensitivity of the experiment appears to 
have been increased by the constant mild anticipation of shock during repeated fps 
testing. The different effect profiles of the three drugs are in line with their phar-
macological distinctions. These findings corroborate the profiling of cns effects 
to demonstrate pharmacological selectivity, optimize the previous use of eeg/
psychomotor/subjective pharmacological assessments [41] to a more pharmaco-
logical mechanism-based pd marker selection, and warrant the extension from 
a single, less reliable, subjective assessment to the combination of a stress-chal-
lenged subjective measurement and a neurophysiological test for the evaluation 
and extrapolation of clinical anxiolysis. 
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Table 1 • Summary of the analysis results for cns-pharmacodynamic parameters. (The results are 
presented as the estimated differences between each active treatment and placebo in the least 
square mean [lsm] change from baseline and the 95% confidence intervals [cis] of the differences. 
The results of body sway are presented as the differences of lsm proportional change from 
baseline and their 95% cis.)
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Table 2 • Summary of Relative Effect Profile Among The Three Active Treatments. (The results  
are presented as least square mean [lsm] estimates of the slope of regression line. The p-values are 




ΔSway/Δspv -0.00208 -0.00186 -0.00106 0.5733 0.0055 0.0716
ΔTracking/Δspv 0.07785 0.06189 0.03056 0.1526 <0.0001 0.0133
Δvas alertness/Δspv 0.07227 0.01491 0.06061 0.0008 0.4540 0.0156
Δvas calmness/Δspv -0.03626 -0.02776 -0.05070 0.6564 0.4123 0.2834
Figure 1 • Average plasma concentration-time profiles with standard deviation (sd) error bars  
of each compound after single oral administration (population estimates superimposed)
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Figure 2 • Graph of means of objective cns-pharmacodynamic parameters with standard deviation 
as error bars
2a. Body Sway; 2b. Saccadic Peak Velocity; 2c. Smooth Pursuit; 2d. Adaptive Tracking
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Figure 3 • Graph of means of subjective cns-pharmacodynamic parameters with standard deviation 
as error bars
3a. Visual Analogue Scale of Alertness; 3b. Visual Analogue Scale of Calmness
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For more than two decades, no mechanistically novel anxiolytic agents have been 
approved and launched into the market for the treatment of anxiety disorders. Such 
situation may be attributed to the lack of a solid understanding on the underlying 
pathophysiology of anxiety disorders, as well as the insufficiency in the develop-
ment and application of valid animal models and their inability to reliably predict 
clinical anxiolytic effects in humans [1]. In addition, the term ‘anxiety disorders’ 
actually represents a heterogeneous group of illnesses that share a core phenome-
nology of both excessive fear and anxiety in terms of apprehension and worry about 
future events. Psychiatrists are still struggling to define the appropriate nosolog-
ical classification of these disorders and current diagnostic classifications lack a 
robust neurobiological basis for clinical anxiety-related phenomena. The changing 
diagnostic landscape and uncertain boundaries between both the various anxiety 
disorders and mood disorders introduce further challenges for drug development 
[1]. Meanwhile, the search of novel pharmacotherapies for various anxiety disor-
ders is driven by the growing medical need derived from clinically available drugs 
for the improvement of their effectiveness and/or for the reduction of their side-ef-
fect profiles [2]. 
The pharmacotherapeutic pipeline of anxiolytic treatments in development can 
be outlined into three major trends: 1) exploration of compounds acting on novel 
targets that address the underlying neural circuits of anxiety disorders, in which 
the glutamate, various neuropeptides and the endocannabinoid systems show 
particular promise as the targets of future drug development [4-6]; 2) design of 
compounds with established mechanism of action for anxiety but have modified 
or additional pharmacological properties than the traditional drugs: the devel-
opment of subtype-selective gaba(a)-ergic partial agonists is an example of this 
approach; likewise, the recently marketed multi-target serotoninergic compounds, 
such as vortioxetine, vilazodone, and agomelatine [1], have been proved effective as 
antidepressant agents, and their efficacy on anxiety disorders has been shown in 
small population of patients; 3) repositioning of registered drugs for other indica-
tions in the treatment of anxiety disorders, such as clinical trials investigating the 
effects of antipsychotic drugs on anxiety disorders, and the approval of pregaba-
lin by the European Medicines Agency for treatment of gad in 2006 is a successful 
example of this approach [1,3]. 
Benzodiazepines were discovered by serendipity in the 1950s. Thereafter, due to the 
widespread therapeutic use of gabaergic agents on anxiolysis, sedation, seizure 
suppression, muscle relaxation, etc., as well as the cumulating understanding about 
gaba(a) receptor subunit neurophysiology and subtype-specific pharmacology, 
gaba(a) receptors have become a highly appreciated target in preclinical-to-clin-
ical translational strategies. In the area of anxiety disorders, increasing evidence 
304_Connie_Proefschrift_19.indd   146 12-09-17   17:55
discussion and conclusion | chapter 8
147
from neuroscience indicates that anxiety disorders result from a functional imbal-
ance in the modulation of brain circuits that regulate the emotional response to 
potentially threatening stimuli. In this context, the inhibitory network of gabaergic 
neurotransmission system is proposed to contribute to the pathogenesis of anxi-
ety and hence serves as a promising therapeutic target for the treatment of human 
anxiety disorders [7].
In addition to anxiolytic effects, benzodiazepines also display potent seda-
tive-hypnotic properties. For anxiety-related symptomatology like insomnia, these 
properties are useful. However, for the management of daytime anxiety, such 
effects are undesirable. The sedative effects and their ensuing cognition impair-
ment and the potential for tolerance development and abuse liability are the major 
obstacles against wide and long-term use of benzodiazepines in the treatment of 
anxiety disorders. Previous research suggested these untoward effects are asso-
ciated with the off-target pharmacological activities of benzodiazepines on the 
gaba(a) receptors containing α1 and α5 subunits [8-11]. As a result, novel gaba(a)- 
ergic α1- and α5-subtype sparing partial agonists, with either disproportional bind-
ing affinity or disproportional in vitro efficacy at the benzodiazepine-targeted 
gaba(a)-ergic receptor subtypes, are expected to separate anxiolytic effects from 
the bzds-induced sedative and cognition-impairing effects. 
Across the industry, the most common reason for developmental failure in Phase 
2 in was lack of efficacy [12]. There are many areas of uncertainty regarding the 
translation of preclinical pharmacology data to human. These questions cannot 
be readily answered unless we know whether the drug actually expressed the 
intended pharmacology by modulating its target(s). In the entire process of clinical 
drug development, the demonstration of pharmacological effects with clinically 
tolerable doses is termed as proof-of-mechanism (pom) study. Generally speaking, 
these types of studies should comprise three goals: 1) observing drug exposure at 
the target site of action; 2) detecting drug interaction with the intended drug tar-
get; and 3) exploring effect of the drug on human biology using biomarker(s). Such 
investigational approach may be especially useful for anxiety disorders, in which 
therapeutic exploratory studies in patients can be difficult to achieve a clinically 
meaningful end-point due to the nature of subjective assessments, the relatively 
large sample size, the high probability of placebo effect, and other ethical or prac-
tical issues [13,14].
This thesis presents the early-phase proof-of-mechanism studies evaluating the 
pharmacokinetics and pharmacodynamics of three α2,3-subunit-selective gaba(a) 
agonists (i.e., azd7325, azd6280 and ns11821), in at least two dose levels, compared 
with active control (lorazepam), in its therapeutic dose, and placebo control. Most 
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of the studies were single-dose, double-blind, randomized, cross-over trials in 
healthy volunteers. A number of validated pharmacodynamic measurements were 
taken to address the effects of these novel drugs on psychomotor, neurophysiologi-
cal, and neuroendocrine functions. 
The results of each study provided a comprehensive picture about the pharma-
cological ‘fingerprint’ of the investigated compounds on a variety of cns domains 
[15-17]. The concept of pharmacological selectivity was demonstrated by the rel-
atively dominant effects of these novel compounds on saccadic eye movements, 
which measure the α2,3-subtype gaba(a) receptor related pharmacodynamic 
responses, in comparison with their minimal or none effects on postural stability, 
subjective alertness (i.e., measurements reflecting gaba(a) receptor α1-subtype 
modulation) and cognition (i.e., gaba(a) α5-subtype specific effects) [18]. In con-
trast, lorazepam-induced spv reduction was generally consistent with its effect 
size on the other non-spv neurophysiologic biomarkers. Considering the potential 
relation between spv decline and clinical anxiolysis [19], the similarity in the effect 
size of these gaba(a) subtype-selective agonists on spv implied the possibility of 
comparable anxiolytic effect between the novel compounds at certain dose levels 
and the active control, and was therefore taken as supportive evidence for future 
dose selection and the decision of further clinical development. Meanwhile, the 
flat concentration-effect curves of the novel gaba(a)-ergic compounds on subjec-
tive alertness, visuo-motor coordination, postural balance, and cognition indicate 
relatively favorable clinical side-effect profiles of these drugs versus the traditional 
non-subtype-selective full gaba(a) agonists, such as lorazepam. However, since the 
dose potency of the novel gaba(a)-ergic drugs might not be equivalent to that of 
lorazepam 2 mg, the lack of effects on the abovementioned cns domains cannot 
be directly interpreted as improvement of adverse effects. In order to resolve this 
problem, we incorporate these pharmacodynamic (pd) measurements into an 
spv-normalized regression model. 
As is indicated in the previous chapters, the abovementioned repeat pharmacody-
namic measurements all presented a clear dose/exposure-response relationship 
in healthy volunteers administered with benzodiazepines and subtype-selective 
gaba ergic compounds. The pd-spv regression models established on simultane-
ously measured pharmacodynamic endpoints actually reflect the relative effect 
profiles of the investigated drug across a wide range of plasma drug concentrations. 
The effect size on spv was used as the normalizer because spv has been shown asso-
ciated with α2,3 gaba(a) receptor subtype modulation [20]. Interestingly, recent 
studies [21] reported quantitative correlation between disturbed performance in 
saccadic eye movement paradigm and the severity of various anxiety disorders. 
These results suggested measurements of saccadic eye movements might also 
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serve as neuropathophysiological biomarkers for the status or severity of anx-
iety. Moreover, two additional findings suggested performance of saccadic eye 
movement may be a predictive biomarker for clinical anxiolytic effect: 1) tpa023, 
a previously developed gaba(a) receptor α2,3 subtype-selective agonist, induced 
significant spv reduction and minimal sway impairment and no memory change 
in single-dose study performed in healthy volunteers [22], has demonstrated a bet-
ter-than-placebo anxiolytic effect in its phase 2 proof-of-efficacy studies [19]; 2) our 
study with both gaba(a)-ergic and non-gaba anxiolytic compounds showed simi-
lar spv-depressive effects by alprazolam and pregabalin with single doses of these 
drugs at their clinically anxiolytic doses [23]. 
The pooled data analysis on the studies of this gaba(a) modulator family was 
performed to not only summarize the common pharmacological characteristics 
of these compounds but also evaluate the sensitivity and specificity of the select-
ed cns-pharmacodynamic measures. Three α2,3-selective gaba(a) agonists (i.e., 
tpa023, tpacmp2, sl65.1498), one α1-selective gaba(a) agonists (zolpidem), and 
another full gaba(a) agonist (alprazolam) were examined through this approach. 
Pharmacological selectivity was assessed by determination of regression lines for 
the change of a pharmacodynamic endpoint (∆pd) versus the change from base-
line of spv (∆spv). The absolute slopes of the ∆pd-∆spv relations were consistently 
lower with the α2,3 selective gaba(a) agonists than with lorazepam, indicating 
that their effects on non-spv pharmacodynamic measurements are less than their 
effects on spv. The ∆spv-∆pd relations of lorazepam were comparable to those of 
alprazolam. In contrast, zolpidem, an α1 selective gaba(a) agonist, showed relative-
ly higher impairments in the α1-relevant pd parameters relative to the effect on spv, 
although its ∆pd-∆spv profiles did not statistically significantly differ from those 
of lorazepam. These ∆pd-∆spv findings support the pharmacological selectivity 
of the α2,3-selective gaba(a) agonists, implying that the clinical anxiolytic effect of 
these drugs might be accompanied with fewer untoward side effects on psychomo-
tor and cognitive function.
In summary, the development of novel gabaergic compounds can be structured, 
step-by-step, as the preclinical-to-clinical translation process depicted in Figure 1. 
First of all, the neurobiological investigation about anxiety and the clinical expe-
rience with benzodiazepines both cast light on the gabaergic neurotransmission 
system as a potential pathway for new drug development. Further knock-in ani-
mal studies suggest that the pharmacological selectivity of a ligand for a certain 
gaba(a) receptor subtype can be achieved either by affinity differentiation (i.e., 
forming or not forming a receptor-ligand complex) or by efficacy differentiation 
(i.e., eliciting or not eliciting a biological response after binding to the receptor) 
[24]. Using 18f-flumazenil as the tracer, a positron emission computed tomography 
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(pet) study provides information on the dose-dependency or exposure-dependen-
cy of the drug’s in vivo gaba(a) receptor occupancy, and thereby helps to determine 
the dose range to be administered in future clinical development. In a clinical 
pharmacology study, the compound is assessed for its pharmacological effects and 
pharmacokinetic exposures within the tolerated dose range, at which considerable 
receptor occupancy can be reached based on the findings of previous neuroimag-
ing study. The observed effects indicate biological interactions between the ligand 
and the targeted receptors. More specifically, in the case of gaba(a)-ergic novel 
compounds, the subtype-specific pharmacodynamic biomarkers, in conjunction 
with the simultaneously measured plasma drug concentrations, allows addressing 
the effect amplitude and effect potency of gaba(a) receptor subtype modulation 
elicited by the investigated drug and the active control, and demonstrates the pk/
pd profile distinctions that one would expect between full agonist and partial ago-
nist [25]. Also, the relationship of these effects builds up a bridge that connects the 
in vitro pharmacological activity to the in vivo physiological responses and supports 
the concept of pharmacological selectivity for α2,3-subtype selective gaba-a ago-
nists in general and, in the case of this thesis, azd7325, azd6280 and ns11821. 
The results of our research were informative and affected the decision of further 
clinical development of each specific novel compound: 1) since 10 mg azd7235 was 
associated with 80-90% receptor occupancy, the small effect size of 2 mg and 10 
mg azd7325 indicated insufficient receptor modulation of the compound at the 
investigated dose [26]; 2) for ns11821, the pharmacodynamic effects observed at 
the moderate-to-high dose levels in the first-in-human study helped to identify 
and select the pharmacologically active doses for future clinical trials [27]; 3) for 
azd6280, the pharmacodynamic effect size on spv was similar to that of lorazepam, 
suggesting potentially comparative clinical anxiolytic effect, while the ignorable 
effects of this compound on body sway and vasalertness were thought to predict a 
reduced profile of cns side-effects [25]. Such clinical pharmacological profile was 
considered promising for further development and future clinical doses were prob-
ably limited to the range of 10 to 40 mg. 
In order to link the neurophysiological and neuropsychological biomarkers to the 
pathophysiological alteration of anxiety patients in fear extinction, we integrated 
a fear-potentiated-startle (fps) paradigm with the Neurocart pharmacodynam-
ic set, and, in particular, with the repeated assessments of subjective calmness 
(vascalmness). The fps paradigm is a procedure that mimics the fear extinction 
experiment in rodents [28] and aims to induce stressfulness in human. To evalu-
ate the feasibility and utility of this approach, a validation study was conducted in 
healthy vopunteers. The pd effects of three marketed comparator drugs (i.e. two 
anxiolytic drugs and one hypnotic drug) were characterized by applying them as 
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pharmacological probes in the fps study. The findings of this study corroborated 
the sensitivity and specificity of the cns-pd measures to single therapeutic dose of 
gabaergic (alprazolam) and non-gabaergic (pregabalin) anxiolytic compounds, 
and reinforced the clinical relevance of saccadic eye movement measurements to 
clinical anxiolysis. In conjunction with the fps paradigm, significant increase of 
subjective calmness was observed with the two anxiolytic drugs, which warrants 
the use of stress-challenged subjective measurements and neurophysiological 
tests for the prediction of clinical anxiolytic drug effect [24]. 
Last but not least, the exploration of potential endocrine biomarkers regarding 
the differential effects of selective and nonselective gaba receptor modulators 
suggested a compensatory approach for the pharmacodynamic evaluation of 
novel anxiolytic agents. The overall effects of the nonselective benzodiazepine 
lorazepam, as well as two novel α2,3 subunit-selective gaba(a) receptor modulators 
azd7325 and azd6280, on prolactin levels were measured within 8 hours post-dose 
in healthy male volunteers. Following administration of lorazepam at 2 mg and 
azd6280 at 10 mg and 40 mg, prolactin levels increased significantly compared 
with placebo (difference 42.0%, 19.8%, and 32.8%, respectively), suggesting that 
the α2 and/or α3 receptor subtypes are involved in gabaergic modulation of prolac-
tin secretion, although possible roles of the α1 and α5 receptor subtypes cannot be 
excluded. The increases in prolactin levels after administration of azd7325 at 2 mg 
and 10 mg doses (difference 7.6% and 10.5%, respectively) did not reach statisti-
cal significance. Such results were consistent with the non-significant responses 
observed on the other neurophysiological and neuropsychological measurements 
with azd7325 [15], reinforcing the conclusion that the investigated doses of 
azd7325 or the intrinsic efficacy of azd7325 at the α2 and α3 receptor subtypes may 
have been too low [29].
conclusion
The gabaergic system has been implicated in the pathogenesis of various anxiety 
disorders. Pharmacological treatments, like benzodiazepines, have been proven 
to target the gaba(a) receptors and exert quick-onset anxiolytic effect in anxiety 
patients. However, the side effects of these non-selective gaba(a)ergic compounds, 
such as sedation, postural imbalance, or potential abuse, limit their use for clinical 
anxiolysis. Based on the understanding of benzodiazepines’ mechanism of action, 
the emergence of α2,3 subtype-selective gaba(a) modulator is expected to provide 
a novel pharmacological approach that alleviates anxiety symptoms but spares the 
common undesired side effects. Most of these compounds are still in early clinical 
development, in which stage proof-of-mechanism studies are usually performed 
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in healthy volunteers. The findings from our studies consistently present a similar 
pattern in the pharmacodynamic effect profiles of the α2,3 subtype-selective gab-
a(a) modulators versus those of the non-selective full gaba(a) agonist, lorazepam. 
Future application of anxiogenic symptom provocation models that combine 
subjective measurements and/or neuroendocrine biomarker assays may provide 
further construct validity for clinical anxiolytic effects of α2,3 subtype-selective 
gaba(a) modulators. Also, such findings are expected to provide insights into the 
translation of preclinical pharmacological properties of α2,3 subtype-selective gab-
a(a)-ergic compounds to clinical effects in patients with anxiety disorders through 
human pharmacology studies. 
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Figure 1 • Schematic graph about the developmental steps of gabaergic novel compounds from 
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Anxiety disorders are highly prevalent psychiatric disorders that are associated 
with significant personal and societal costs. The transition from adaptive nega-
tive affect such as fear and anxiety to an anxiety disorder in humans is mediated 
by an interplay between psychosocial factors and a wide array of neurobiological 
alterations. 
The introduction of this thesis (chapter 1) provides a detailed overview of 
the definition, classification, neurobiology and current psychopharmacological 
treatment of anxiety disorders. On a conceptual level, anxiety disorders result 
from disruptions of highly interconnected neuronal circuits that normally serve 
to process the stream of potentially threatening stimuli detected by the human 
brain from the outside world. Perturbations in any of these circuits cause imbal-
ance in the entire system, resulting in a fundamental misinterpretation of sensory 
information as threatening and leading to inappropriate emotional hyperarousal, 
physical symptoms and behavioral responses that are characteristic of anxiety 
disorders. Although monoamine modulating drugs such as the selective serotonin 
reuptake inhibitors (SSRI’s) and gamma-aminobutyric acid (gaba) agonists are 
widely applied to modulate central emotional processing centers in patients with 
anxiety disorders, their effectiveness is limited in a large proportion of patients 
due to either inefficacy or untoward effects. This obviously unmet clinical need in 
the treatment of anxiety disorders opens an opportunity for novel pharmacologi-
cal approaches. 
As the predominant inhibitory neurotransmitter system in the human brain, 
the gabaergic system has been implicated in the pathophysiology of anxiety dis-
orders. Evidence from preclinical studies suggests distinct physiological effects 
of the benzodiazepines-targeted α1, α2, α3, and α5 gaba(a) receptor subunits: 
α2/α3-subunits predominantly mediate analgesia and anxiolysis, while α1- and 
α5-subunits are associated with sedation and cognition, respectively. The relatively 
high affinity or in vitro efficacy of novel α2,3 subtype-selective gabaergic receptor 
modulators therefore represents a potentially useful innovative pharmacological 
approach for the treatment of anxiety disorders. This thesis is largely devoted to 
the early development of these innovative compounds, and to methods to show 
their effects in humans.
In the subsequent chapters, we report three first-in-human (fih) clinical pharma-
cology studies which evaluated the pharmacokinetics and pharmacodynamics of the 
α2,3-subunit-selective gaba(a) agonists azd7325 (chapter 2), azd6280 (chapter 3) 
and ns11821 (chapter 4), respectively. Because of their pharmacological selectivity 
at the α2,3 gaba(a) receptor subtypes, these compounds are expected to elicit clin-
ical anxiolysis without inducing unwanted sedative effects in humans. Therefore, 
these studies aimed to characterize the pharmacodynamic effects and evaluate 
the pharmacologically active doses/exposure levels of these compounds by apply-
ing Neurocart, a battery of previously validated pharmacodynamic measurements 
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that assess different functional central nervous system (cns) domains. In all stud-
ies, at least two dose levels were explored and were compared with placebo and 
the non-selective gaba-a receptor agonist lorazepam as active control. The results 
of these studies demonstrate compound-specific effect profiles on the neurophys-
iological functions postural balance, visuo-motor coordination, cognition and 
subjective feelings for most compounds. Moreover, the concept of pharmacolog-
ical selectivity is demonstrated by the relatively dominant effects of these novel 
compounds on saccadic eye movements, which reflects the gaba(a) α2,3-subtype 
receptor related pharmacodynamic responses, in comparison with their minimal 
or absent effects on postural stability and subjective alertness (i.e., α1-subtype 
receptor modulation) and cognition (i.e., α5-subtype-specific effects). In contrast, 
lorazepam-induced spv reduction is generally similar to its effect size on the 
other non-spv neurophysiologic biomarkers, indicating a comparable interaction 
with different gaba(a) receptor subtypes. These findings are corroborated by the 
α2,3-subtype-selective gaba(a) partial agonist tpa023, which previously demon-
strated spv reduction in healthy volunteers that translated to a clinical anxiolytic 
effect in patients with generalized anxiety disorder. Therefore, similar effect sizes 
of the evaluated α2,3 gaba(a) subtype-selective agonists on spv suggest poten-
tially efficacious anxiolytic effects comparable to the clinically effective dose of 
non-subtype-selective gaba(a) modulator, lorazepam. On the other hand, the 
flat concentration-effect curves of the α2,3-selective gaba(a)-ergic compounds on 
subjective alertness, visuo-motor coordination, postural balance and cognition, 
indicate a relatively favorable clinical side-effect profile of these drugs versus the 
traditional non-subtype-selective full gaba(a) agonists, such as lorazepam. Taken 
together, the demonstration of an equipotent α2,3 gaba(a) effect in the absence of 
either α1 or α5 effects provides support to further pursue clinical development and 
can potentially guide future dose selection for studies in both healthy volunteers 
and patients with anxiety disorders.
In chapter 5, we present a pooled data analysis based on studies with the 
α2,3 subtype-selective gaba(a) modulator family that were previously published 
by our group. The pharmacological selectivity of three α2,3-selective gaba(a) 
agonists (i.e., tpa023, tpacmp2, sl65.1498), one α1-selective gaba(a) agonist (zolp-
idem), and another non-selective gaba(a) agonist (alprazolam) were examined 
by modeling their regression lines for the effect on one of the (unwanted) phar-
macodynamic endpoints (Δpd) versus the simultaneous (desired) effect on spv 
(Δspv). The absolute slope of the relation between the unwanted and desired 
pharmacodynamics effect (Δpd-Δspv) was consistently lower with the α2,3 selec-
tive gaba(a) agonists than with lorazepam. Moreover, the Δspv-Δpd relations 
of lorazepam were comparable to those of alprazolam, but slightly lower than 
zolpidem. Together, these Δpd-Δspv findings further support the pharmacologi-
cal selectivity of the α2,3-selective gaba(a) agonists, and as a consequence, imply 
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that the clinical anxiolytic effect of these drugs might be accompanied with fewer 
untoward side effects on psychomotor and cognitive function compared to the 
non-selective benzodiazepines.
Next to the neurophysiological, emotional and cognitive effects that were 
investigated in previous chapters, anxiety responses are also characterized by 
neuroendocrine reactions. This was explored further in chapter 6, which focused 
on potential potential peripheral neuroendocrine biomarkers for the effects of 
selective and non-selective gaba receptor modulators. The effects of two novel 
α2,3 subunit-selective gaba(a) receptor modulators, azd7325 and azd6280, on 
serum prolactin levels were evaluated in healthy male volunteers, compared 
with the non-selective gaba(a) modulator lorazepam. Prolactin levels increased 
significantly after administration of azd6280 and lorazepam, whereas increases 
in prolactin levels after administration of azd7325 did not reach statistical signifi-
cance, probably because the dosages were too low. These findings suggest that the 
α2 and/or α3 receptor subtypes are involved in gabaergic modulation of prolactin 
secretion, although possible roles of the α1 and α5 receptor subtypes cannot be 
excluded. The observed drug effects on serum prolactin levels support the use of 
serum prolactin level as a neuroendocrine biomarker complementary to the vali-
dated pharmacodynamic measurements in clinical pharmacology study of novel 
anxiolytic agents.
The previous chapters mainly describe the pharmacological effects of gaba-er-
gic compounds on the cns. To get an impression of their potential anxiolytic 
effects, anxiety and fear can be examined in healthy volunteers. Finally in chapter 
7, the fear-potentiated-startle (fps) paradigm is used to experimentally simulate 
conditioned and unconditioned threat in healthy volunteers. Conceptually the 
former scenario represents fear whereas the latter relates to anxiety. In this 
study, fps is combined with saccadic and smooth pursuit eye-movement tests, 
visual analogue scales measuring subjective alertness, visuo-motor coordination 
and postural balance to evaluate anxiolytic drug effect on the fps-stimulated 
neurophysiological and neuropsychological responses. The pd effects of two 
anxiolytic drugs (alprazolam and pregabalin) and one hypnotic drug (diphen-
hydramine) were characterized in the presented study. None of the treatments 
reliably reduced either fear or anxiety-potentiated startle responses, probably due 
to methodological complexity and the variability of startle responses between and 
within study participants. However, decrease of subjective calmness from base-
line was evident after the stressful fps procedure during the placebo treatment, 
while alprazolam and pregabalin maintained subjective calmness to its baseline 
level following fps. Such findings corroborate the sensitivity and specificity of 
the cns-pd measures to a single therapeutic dose of gabaergic (alprazolam) and 
non-gabaergic (pregabalin) anxiolytic compounds. In fact, clinically available 
anxiolytic drugs, such as benzodiazepines or ssris also do not consistently induce 
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significant increases of subjective calmness in healthy volunteers under stress-free 
experimental conditions. Therefore, the measurable effects on subjective calm-
ness, as well as the test procedure modification with fps integration, may warrant 
the use of stress-challenged subjective measurements and neurophysiological 
tests for the simulation of clinical anxiolytic drug effect. 
conclusion
The gabaergic system has been implicated in the pathogenesis of various anxiety 
disorders. Clinically effective pharmacological treatments like benzodiazepines 
have been demonstrated to target the gaba(a) receptors, by which they exert acute 
anxiolytic effects in patients with anxiety disorders. However, the side effects of 
these non-selective gaba(a)-ergic compounds, such as sedation, postural imbal-
ance, cognitive effects and potential abuse limit their use in clinical practice. Based 
on the understanding of benzodiazepines’ mechanism of action, the emergence 
of α2,3 subtype-selective gaba(a) modulators is expected to provide a novel phar-
macological approach that alleviates anxiety symptoms but spares the common 
undesired side-effects. Most of these compounds are still in early clinical develop-
ment, in which stage proof-of-mechanism studies are usually performed in healthy 
volunteers. The findings from our studies consistently present a similar pattern in 
the pharmacodynamic effect profiles of the α2,3 subtype-selective gaba(a) mod-
ulators versus those of the non-selective full gaba(a) agonist, lorazepam. Future 
application of anxiogenic symptom provocation models that combine subjective 
measurements and/or neuroendocrine biomarker assays may provide further 
construct validity for clinical anxiolytic effects of α2,3 subtype-selective gaba(a) 
modulators. Also, such findings are expected to provide insights into the translation 
of preclinical pharmacological properties of α2,3 subtype-selective gaba(a)-ergic 
compounds to clinical effects in patients with anxiety disorders through human 
pharmacology studies. 
Overall, the work in this thesis illustrates an important step in a structured 
translational process of novel subtype-selective gabaergic compounds from pre-
clinical development to early phase clinical trials : 1) pathway identification of the 
gabaergic neurotransmission system informed by the neurobiology of anxiety and 
clinical efficacy of benzodiazepines; 2) novel drug design and discovery based on 
knock-in animal studies that suggest the distinct pharmacological activities of var-
ious gaba(a) receptor subtypes; 3) proof-of-target study using neuroimaging tools 
to demonstrate the drug’s in vivo gaba(a) receptor occupancy; 4) proof-of-mecha-
nism study assessing the drug’s pharmacodynamic effects and pharmacokinetic 
exposures within the tolerated dose range; 5) proof-of-efficacy study exploring 
the drug’s clinical efficacy in the target patient population; 6) proof-of-therapy 
study confirming the drug’s clinical utility and effectiveness in in clinical practice. 
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Angststoornissen zijn veel voorkomende psychiatrische aandoeningen die persoon-
lijk lijden en hoge maatschappelijke kosten met zich meebrengen. De overgang van 
adaptieve negatieve emoties zoals vrees en angst naar een angststoornis wordt bij 
mensen medebepaald door psychosociale factoren en een breed scala aan neuro-
biologische veranderingen.
Het inleidende hoofdstuk van dit proefschrift (hoofdstuk 1) geeft een ge-
detailleerd overzicht van de definitie, classificatie, neurobiologie en de actuele 
farmacotherapie van angststoornissen. Op conceptueel niveau zijn angststoor-
nissen het gevolg van een verstoring van onderling sterk verbonden hersencircuits 
die onder normale omstandigheden potentieel bedreigende stimuli uit de bui-
tenwereld verwerken. Verstoringen in één of meer van deze circuits kunnen ertoe 
leiden dat het gehele systeem uit balans raakt. Sensorische informatie wordt dan 
ten onrechte als bedreigend geïnterpreteerd, wat leidt tot de extreme emotionele 
en lichamelijke reacties en de bijbehorende gedragingsveranderingen die ken-
merkend zijn voor angststoornissen. Gamma-aminoboterzuur (gaba)-agonisten 
en monoaminerge geneesmiddelen zoals de selectieve serotonine heropname-
remmers (ssri’s), worden frequent toegepast om de centrale emotieverwerkende 
centra in patiënten met angststoornissen te beïnvloeden. De toepasbaarheid van 
dergelijke behandelingen is echter bij veel patiënten beperkt als gevolg van onvol-
doende werkzaamheid en/of ongewenste bijwerkingen. Er bestaat dus duidelijk 
een behoefte aan betere geneesmiddelen voor de behandeling van angststoor-
nissen en geeft aanleiding tot innovatieve farmacologische benaderingen in de 
ontwikkeling van nieuwe anxiolytica.
Het gaba-erge systeem is het belangrijkste inhibitoire systeem in de menselijke 
hersenen. gaba is in verband gebracht met de pathofysiologie van angststoornis-
sen en vormt daarmee een belangrijk aangrijpingspunt voor farmacologische 
behandelingen. Preklinisch onderzoek suggereert duidelijk te onderscheiden 
fysiologische functies voor de verschillende gaba(a) receptor subtypes, namelijk 
α1, α2, α3, en α5, die aangrijpingspunten zijn voor de benzodiazepines. Hierbij 
lijken de α2/α3-subtypes vooral betrokken te zijn bij pijnstilling en anxiolyse, 
terwijl de α1- en α5-subtypes samenhangen met respectievelijk de sederende en 
cognitieve effecten van benzodiazepines. Een groep nieuwe α2,3 subtype-selec-
tieve gaba-agonisten hebben een relatief hoge receptoraffiniteit dan wel in vitro 
werkzaamheid voor gaba(a) α2,3, waarmee zij een innovatieve en potentieel 
nuttige aanvulling kunnen zijn in de farmacotherapie van angststoornissen. Dit 
proefschrift is grotendeels gewijd aan de vroege ontwikkeling van dergelijke in-
novatieve middelen, en aan manieren om hun effecten bij mensen aan te tonen. 
    In de volgende drie hoofdstukken worden klinisch farmacologische studies 
beschreven waarin drie verschillende α2,3-subtype selectieve gaba(a) agonis-
ten voor het eerst worden toegediend aan menselijke vrijwilligers. In deze first 
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in human (fih) studies werden de farmacokinetiek en de farmacodynamiek van 
de α2,3-subtype selectieve gaba(a) agonisten azd7325 (hoofdstuk 2), azd6280 
(hoofdstuk 3) and ns11821 (hoofdstuk 4) onderzocht. Vanwege hun farmaco-
logische selectiviteit voor de α2,3 gaba(a) receptorsubtypes, verwacht men een 
klinisch anxiolytische werking zonder de ongewenste sederende effecten van de 
benzodiazepines. In het bijzonder waren deze studies gericht op het karakterise-
ren van de farmacodynamische effecten en het vaststellen van de farmacologisch 
actieve doses en plasmaconcentraties van deze middelen. Voor dit doel werd de 
NeuroCart toegepast, een testbatterij bestaande uit eerder gevalideerde farma-
codynamische metingen die verschillende functionele domeinen van het centraal 
zenuwstelsel (czs) kwantificeren. In deze studies werden tenminste twee verschil-
lende doseringen van de nieuwe geneesmiddelen onderzocht en werden deze 
doorgaans vergeleken met placebo enerzijds en met de niet-selectieve gaba-a 
receptoragonist lorazepam als ‘actieve controle’ anderzijds. De resultaten van deze 
studies tonen voor de meeste stoffen een duidelijke farmacologische selectiviteit. 
Vergeleken met benzodiazepines, zijn er relatief sterke effecten op de saccadische 
oogbewegingen (saccadic peak velocity, spv), die vooral een maat zijn voor gaba(a) 
α2,3-subtype activiteit. Daarentegen worden nauwelijks tot geen effecten gevon-
den op houdingsstabiliteit en subjectieve alertheid (α1-subtype effect) en cognitie 
(α5-subtype effect). Bij lorazepam is de afname van de spv in het algemeen van de-
zelfde orde van grootte als het effect op de andere genoemde neurofysiologische 
biomarkers, wat erop wijst dat lorazepam de verschillende gaba(a) receptorsub-
types in ongeveer dezelfde mate beïnvloedt. Deze bevindingen zijn in lijn met 
de eerder onderzochte effecten van de α2,3-subtype-selectieve gaba(a) partiële 
agonist tpa023, waarbij een vermindering van de spv bij gezonde proefpersonen 
werd gevonden en bij patiënten met een gegeneraliseerde angststoornis klinisch 
relevante anxiolyse werd aangetoond. Vergelijkbare effectgroottes van de drie on-
derzochte α2,3 gaba(a) subtype-selectieve agonisten op spv suggereren dat deze 
stoffen potentieel een even krachtige anxiolytische werking zouden kunnen heb-
ben als een klinisch effectieve dosis van de niet-subtype selectieve gaba(a) agonist 
lorazepam. Met betrekking tot de bijwerkingen, wijzen de relatief vlakke concen-
tratie-effect curves van de α2,3 gaba(a) -erge middelen voor subjectieve alertheid, 
visuo-motorische coördinatie, houdingsbalans en cognitie op een gunstig klinisch 
bijwerkingenprofiel in vergelijking met traditionele niet-subtypeselectieve ga-
ba(a) agonisten zoals lorazepam. Al met al vormen de gerapporteerde studies 
een goede basis voor de verdere klinische ontwikkeling van deze middelen, 
waarbij de α2,3 gaba(a) effecten even krachtig zijn als de niet-selectieve gaba(a) 
agonisten terwijl er geen sprake is α1 of α5 effecten. Overigens kunnen deze re-
sultaten ook worden toegepast bij het selecteren van de optimale dosering in 
toekomstige studies met gezonde vrijwilligers en patiënten met angststoornissen. 
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In hoofdstuk 5 wordt een gecombineerde analyse gepresenteerd, gebaseerd op 
data afkomstig uit studies met α2,3 subtype-selectieve gaba(a)  modulatoren die 
eerder door onze onderzoeksgroep zijn gepubliceerd. De farmacologische selec-
tiviteit van drie α2,3 subtype-selectieve gaba(a) agonisten (tpa023, tpacmp2 en 
sl65.1498), een α1-selectieve gaba(a) agonist (zolpidem) en een niet-selectieve 
gaba(a) agonist (alprazolam), werd onderzocht door de regressielijn te modelle-
ren voor een van de (ongewenste) farmacodynamische eindpunten (Δpd) versus 
het gelijktijdige (gewenste) effect op spv (Δspv). De absolute helling van de ver-
houding tussen de ongewenste en ongewenste farmacodynamische effecten 
(Δpd/Δspv) was lager voor α2,3 subtype-selectieve gaba(a) agonisten dan voor 
lorazepam. Verder waren de Δpd/Δspv verhoudingen van lorazepam vergelijkbaar 
met die van alprazolam, maar iets lager dan voor zolpidem. Deze bevindingen 
bieden verdere steun aan de hypothese dat α2,3 subtype-selectieve gaba(a) ago-
nisten inderdaad farmacologisch selectief zijn en dat het klinische anxiolytische 
effect van deze middelen gepaard zou kunnen gaan met minder ongewenste bij-
werkingen op de psychomotorische en cognitieve functies dan de niet-selectieve 
benzodiazepines.
Naast de neurofysiologische, emotionele en cognitieve reacties die in voor-
gaande hoofdstukken werden bestudeerd, vormen neuro-endocriene responsies 
een belangrijk onderdeel van angstreacties. Derhalve werden potentiële perifere 
neuro-endocriene biomarkers voor de effecten van selectieve en niet-selectieve 
gaba receptormodulatoren in hoofdstuk 6 verkend. Het effect van twee α2,3 sub-
type-selectieve gaba(a) receptormodulatoren, azd7325 en azd6280, op de serum 
prolactineconcentraties werd bij gezonde proefpersonen vergeleken met de 
niet-selectieve gaba(a) receptormodulator lorazepam. azd6280 en lorazepam 
leidden tot een significante stijging van de prolactineconcentratie terwijl de stij-
ging van de prolactineconcentratie na toediening van azd7325 geen statistische 
significantie bereikte mogelijk vanwege een te lage dosering. Deze resultaten 
suggereren dat het gaba(a) α2 en/of α3 receptorsubtype betrokken is bij prolactine-
secretie, al kan eventuele betrokkenheid van de receptorsubtypes α1 en α5 niet met 
zekerheid worden uitgesloten. Deze effecten op serum prolactine ondersteunen 
het integreren van prolactine als neuro-endocriene biomarker met gevalideerde 
farmacodynamische metingen bij de klinisch farmacologische evaluatie van nieu-
we anxiolytica.
In de voorafgaande hoofdstukken zijn vooral de farmacologische effecten 
van gaba-erge stoffen op het czs bestudeerd. Om een indruk te krijgen van 
hun potentiële anxiolytische effecten, kunnen tevens de effecten op angstre-
acties bij gezonde vrijwilligers worden onderzocht. In hoofdstuk 7 wordt het 
fear-potentiated-startle (fps) paradigma toegepast om geconditioneerde en on-
geconditioneerde bedreigende stimuli experimenteel bij gezonde vrijwilligers 
te simuleren. Geconditioneerde bedreiging komt conceptueel overeen met vrees 
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(Engels: fear), terwijl ongeconditioneerde bedreiging meer overeenkomsten heeft 
met angst (Engels: anxiety). In deze studie worden de farmacodynamische effec-
ten van twee klinisch effectieve anxiolytica (alprazolam en pregabaline) en een 
slaapmiddel (difenhydramine) onderzocht door fps te combineren met neurofy-
siologische en neuropsychologische metingen, zoals saccadische oogbewegingen 
(spv), subjectieve alertheid, houdingstabiliteit en oog-handcoördinatie. Geen van 
deze middelen verminderden de vrees of angst-gerelateerde schrikreactie (Engels: 
startle response), vermoedelijk als gevolg van de methodologische complexiteit en 
de grote intra-individuele en interindividuele variatie in schrikreacties. Wel er-
voeren deelnemers die placebo hadden gekregen een duidelijke afname van de 
subjectief ervaren kalmte na de stressvolle fps procedure, terwijl na toediening 
van alprazolam of pregabaline de subjectieve kalmte vergelijkbaar bleef met de 
uitgangswaarde. Deze bevindingen bevestigen de sensitiviteit en specificiteit van 
farmacodynamische czs-metingen na toediening van een therapeutische dosis 
van een gaba-erg anxiolyticum (alprazolam) en een anxiolyticum met een ander 
werkingsmechanisme (pregabaline). Daarnaast is bekend dat klinisch effectie-
ve anxiolytica zoals de benzodiazepines of ssri’s bij gezonde vrijwilligers onder 
stressvrije experimentele condities evenmin de subjectieve kalmte consistent 
vergroten. Bij het evalueren van anxiolytische geneesmiddeleffecten onder stress- 
volle omstandigheden valt daarom te overwegen om subjectieve metingen en 
neurofysiologische tests te combineren met fps.
conclusie
Het gaba-erge systeem speelt een rol in de pathogenese van angststoornissen. 
Klinisch effectieve geneesmiddelen zoals de benzodiazepines hebben hun anxi-
olytische werking te danken aan een interactie met de gaba(a) receptoren. De 
toepassing van deze niet-selectieve gaba-erge middelen in de klinische praktijk 
wordt echter beperkt door bijwerkingen zoals sedatie, verstoorde lichaamsba-
lans en cognitieve effecten, en potentieel misbruik en verslaving. Huidige 
inzichten in het werkingsmechanisme van de benzodiazepines maken een nieuwe 
farmacologische benadering mogelijk, waarbij de α2,3 subtype-selectieve gaba(a) 
receptormodulatoren angst zouden kunnen reduceren zonder de ongewenste 
bijwerkingen van de benzodiazepines te hebben. De meeste van deze nieuwe 
middelen bevinden zich in de vroege klinische geneesmiddelontwikkeling, waarin 
overwegend mechanistische studies worden uitgevoerd bij gezonde vrijwilligers. 
De resultaten van onze studies laten consequent eenzelfde patroon zien in de 
farmacodynamische effecten van α2,3 subtype-selectieve gaba(a) receptormo-
dulatoren vergeleken met de niet-selectieve gaba(a) agonist lorazepam. In de 
toekomst kunnen provocatiemodellen voor het induceren van angstsymptomen 
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bijdragen aan de constructvaliditeit en klinische toepasbaarheid van deze vroege 
bevindingen bij gezonde vrijwilligers. Bovendien kunnen dergelijke bevindingen 
inzichten opleveren voor de vertaalslag van de preklinische farmacologie van α2,3 
subtype-selectieve gaba-erge middelen naar klinische effecten in patiënten met 
angststoornissen.
De beschreven studies illustreren een belangrijke stap in een gestructureerd 
translationeel proces van preklinische geneesmiddelontwikkeling naar vroege kli-
nische studies voor nieuwe subtype selectieve gaba-erge middelen: 1) identificatie 
van de betrokken signaalroutes (Engels: pathway identification) van het gaba-erge 
neurotransmittersysteem vanuit de neurobiologie van angst en de klinische effec-
ten van benzodiazepines; 2) geneesmiddelontdekking en ontwerp op basis van 
knock-in dierstudies die laten zien dat de verschillende gaba(a) receptor subtypes 
een te onderscheiden farmacologische activiteit vertonen; 3) proof-of-target stu-
dies waarin met behulp van beeldvormende technieken (Engels: neuro-imaging) 
wordt aangetoond met welke gaba(a) receptorsubtypen het middel in vivo daad-
werkelijk bindt; 4) proof-of-mechanism studies waarin de farmacodynamische 
effecten en de farmacokinetische blootstelling binnen de bandbreedte van ver-
schillende doseringen wordt vastgesteld; 5) proof-of-efficacy studies waarin de 
klinische werkzaamheid van het middel wordt verkend binnen de groep patiënten 
voor wie het middel uiteindelijk bedoeld is; 6) proof-of-therapy studies die beves-
tigen dat het middel inderdaad bruikbaar en effectief is in de klinische praktijk. 
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